[
  {
    "query": "Answer this question: Does Corning have positive working capital based on FY2022 data? If working capital is not a useful or relevant metric for this company, then please state that and explain why. \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Table of Contents\n \nConsolidated Balance Sheets\nCorning Incorporated and Subsidiary Companies\n \n \n \nDecember 31,\n \n(in millions, except share and per share amounts)\n \n2022\n \n2021\n \n \n \n \n \nAssets\n \n \n \n \n \n \n \nCurrent assets:\n \n \n \nCash and cash equivalents\n $\n1,671 $\n2,148 \nTrade accounts receivable, net of doubtful accounts - $40 and $42\n \n1,721 \n2,004 \nInventories (Note 5)\n \n2,904 \n2,481 \nOther current assets (Notes 10 and 14)\n \n1,157 \n1,026 \nTotal current assets\n \n7,453 \n7,659 \n \n \n \n \nProperty, plant and equipment, net of accumulated depreciation - $14,147 and $13,969 (Note 8)\n \n15,371 \n15,804 \nGoodwill, net (Note 9)\n \n2,394 \n2,421 \nOther intangible assets, net (Note 9)\n \n1,029 \n1,148 \nDeferred income taxes (Note 7)\n \n1,073 \n1,066 \nOther assets (Notes 10 and 14)\n \n2,179 \n2,056 \n \n \n \n \nTotal Assets\n $\n29,499 $\n30,154 \n \n \n \n \nLiabilities and Equity\n \n \n \n \n \n \n \nCurrent liabilities:\n \n \n \nCurrent portion of long-term debt and short-term borrowings (Note 11)\n $\n224 $\n55 \nAccounts payable\n \n1,804 \n1,612 \nOther accrued liabilities (Notes 10 and 13)\n \n3,147 \n3,139 \nTotal current liabilities\n \n5,175 \n4,806 \n \n \n \n \nLong-term debt (Note 11)\n \n6,687 \n6,989 \nPostretirement benefits other than pensions (Note 12)\n \n407 \n622 \nOther liabilities (Notes 10 and 13)\n \n4,955 \n5,192 \nTotal liabilities\n \n17,224 \n17,609 \n \n \n \n \nCommitments and contingencies (Note 13)\n \n \n \nShareholders equity (Note 16):\n \n \n \nCommon stock Par value $0.50 per share; Shares authorized 3.8 billion; Shares issued: 1.8 billion and 1.8\nbillion\n \n910 \n907 \nAdditional paid-in capital common stock\n \n16,682 \n16,475 \nRetained earnings\n \n16,778 \n16,389 \nTreasury stock, at cost; Shares held: 977 million and 970 million\n \n(20,532) \n(20,263)\nAccumulated other comprehensive loss\n \n(1,830) \n(1,175)\nTotal Corning Incorporated shareholders equity\n \n12,008 \n12,333 \nNon-controlling interest\n \n267 \n212 \nTotal equity\n \n12,275 \n12,545 \n \n \n \n \nTotal Liabilities and Equity\n $\n29,499 $\n30,154 \n \nThe accompanying notes are an integral part of these consolidated financial statements.\n60\n [END OF FILING]",
    "gt": "Yes. Corning had a positive working capital amount of $831 million by FY 2022 close. This answer considers only operating current assets and current liabilities that were clearly shown in the balance sheet.",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: What is the amount of the gain accruing to JnJ as a result of the separation of its Consumer Health business segment, as of August 30, 2023? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Exhibit 99.1\nJohnson & Johnson Announces Updated Financials and 2023 Guidance Following Completion of the Kenvue\nSeparation\n\nCompany expects increased 2023 Reported Sales Growth of 7.0% - 8.0%, Operational Sales Growth of 7.5% - 8.5%, and\nAdjusted Operational Sales Growth of 6.2% - 7.2%; Figures exclude the COVID-19 Vaccine\n\nCompany expects 2023 Adjusted Reported Earnings Per Share (EPS) of $10.00 - $10.10, reflecting increased growth of\n12.5% at the mid-point and Adjusted Operational EPS of $9.90 - $10.00, reflecting increased growth of 11.5% at the mid-\npoint\n\nCompany reduced outstanding share count by approximately 191 million; 2023 guidance reflects only a partial-year benefit\nof approximately 73.5 million shares or $0.28 benefit to EPS\n\nCompany secured $13.2 billion in cash proceeds from the Kenvue debt offering and initial public offering and maintains 9.5%\nof equity stake in Kenvue\n\nCompany maintains its quarterly dividend of $1.19 per share\nNew Brunswick, N.J. (August 30, 2023) Johnson & Johnson (NYSE: JNJ) (the Company) today announced updates to its financials and\n2023 guidance which reflect its operations as a company focused on transformational innovation in Pharmaceutical and MedTech. The\nCompany has published a recorded webinar for investors to provide additional context behind the updated financials and 2023 guidance\nfound in this release, which may be accessed by visiting the Investors section of the Company's website at webcasts & presentations.\nThe completion of this transaction uniquely positions Johnson & Johnson as a Pharmaceutical and MedTech company focused on delivering\ntransformative healthcare solutions to patients, said Joaquin Duato, Chairman of the Board and Chief Executive Officer. We are incredibly\nproud of the focus and dedication of our employees worldwide to achieve this milestone, which we are confident will unlock near- and long-\nterm value for all of our stakeholders.\nAs previously announced, the Company recently completed an exchange offer to finalize the separation of Kenvue Inc., formerly Johnson &\nJohnsons Consumer Health business. As a result of the completion of the exchange offer, Johnson & Johnson will now present its\nConsumer Health business financial results as discontinued operations, including a gain of approximately $20 billion in the third quarter of\n2023.\n [END OF FILING]",
    "gt": "JnJ will make a gain of approximately $20 billion from the separation of its Consumer Health business segment.",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: Considering the data in the balance sheet, what is Block's (formerly known as Square) FY2016 working capital ratio? Define working capital ratio as total current assets divided by total current liabilities. Round your answer to two decimal places. \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] \nSQUARE,INC.\nCONSOLIDATEDBALANCESHEETS\n(In thousands, except share and per share data)\n\nDecember31,\n\n2016\n\n2015\nAssets\n\n \nCurrentassets:\n\n \nCashandcashequivalents\n$\n452,030 $\n461,329\nShort-terminvestments\n59,901 \n\nRestrictedcash\n22,131 \n13,537\nSettlementsreceivable\n321,102 \n142,727\nCustomerfundsheld\n43,574 \n9,446\nLoansheldforsale\n42,144 \n604\nMerchantcashadvancereceivable,net\n4,212 \n36,473\nOthercurrentassets\n56,331 \n41,447\nTotalcurrentassets\n1,001,425 \n705,563\nPropertyandequipment,net\n88,328 \n87,222\nGoodwill\n57,173 \n56,699\nAcquiredintangibleassets,net\n19,292 \n26,776\nLong-terminvestments\n27,366 \n\nRestrictedcash\n14,584 \n14,686\nOtherassets\n3,194 \n3,826\nTotalassets\n$\n1,211,362 $\n894,772\nLiabilitiesandStockholdersEquity\n\n \nCurrentliabilities:\n\n \nAccountspayable\n$\n12,602 $\n18,869\nCustomerspayable\n388,058 \n215,365\nCustomerfundsobligation\n43,574 \n9,446\nAccruedtransactionlosses\n20,064 \n17,176\nAccruedexpenses\n39,543 \n44,401\nOthercurrentliabilities\n73,623 \n28,945\nTotalcurrentliabilities\n577,464 \n334,202\nDebt(Note11)\n \n\nOtherliabilities\n57,745 \n52,522\nTotalliabilities\n635,209 \n386,724\nCommitmentsandcontingencies(Note16)\n\nStockholdersequity:\n \nPreferredstock,$0.0000001parvalue:100,000,000sharesauthorizedatDecember31,2016andDecember31,2015.None\nissuedandoutstandingatDecember31,2016andDecember31,2015.\n \n\nClassAcommonstock,$0.0000001parvalue:1,000,000,000sharesauthorizedatDecember31,2016andDecember31,2015;\n198,746,620and31,717,133issuedandoutstandingatDecember31,2016andDecember31,2015,respectively.\n \n\nClassBcommonstock,$0.0000001parvalue:500,000,000sharesauthorizedatDecember31,2016andDecember31,2015;\n165,800,756and303,232,312issuedandoutstandingatDecember31,2016andDecember31,2015,respectively.\n \n\nAdditionalpaid-incapital\n1,357,381 \n1,116,882\nAccumulatedothercomprehensiveloss\n(1,989) \n(1,185)\nAccumulateddeficit\n(779,239) \n(607,649)\nTotalstockholdersequity\n576,153 \n508,048\nTotalliabilitiesandstockholdersequity\n$\n1,211,362 $\n894,772\nSeeaccompanyingnotestoconsolidatedfinancialstatements.\n68\n [END OF FILING]",
    "gt": "1.73",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: Which of JPM's business segments had the lowest net revenue in 2021 Q1? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Segment results managed basis\nThe following tables summarize the Firms results by segment for the periods indicated.\nThree months ended March 31,\nConsumer & Community Banking\nCorporate & Investment Bank\nCommercial Banking\n(in millions, except ratios)\n2021\n2020\nChange\n2021\n2020\nChange\n2021\n2020\nChange\nTotal net revenue\n$ 12,517 \n$ 13,287 \n (6) %\n$ 14,605 \n$ 10,003 \n 46 %\n$ \n2,393 \n$ \n2,165 \n 11 %\nTotal noninterest expense\n \n7,202 \n \n7,269 \n (1) \n \n7,104 \n \n5,955 \n 19 \n \n969 \n \n986 \n (2) \nPre-provision profit/(loss)\n \n5,315 \n \n6,018 \n (12) \n \n7,501 \n \n4,048 \n 85 \n \n1,424 \n \n1,179 \n 21 \nProvision for credit losses\n \n(3,602) \n \n5,772 \nNM\n \n(331) \n \n1,401 \nNM\n \n(118) \n \n1,010 \nNM\nNet income/(loss)\n \n6,728 \n \n197 \nNM\n \n5,740 \n \n1,985 \n 189 \n \n1,168 \n \n139 \nNM\nReturn on equity (ROE)\n \n54 % \n1 %\n 27 %\n 9 %\n 19 %\n 2 %\nThree months ended March 31,\nAsset & Wealth Management\nCorporate\nTotal\n(in millions, except ratios)\n2021\n2020\nChange\n2021\n2020\nChange\n2021\n2020\nChange\nTotal net revenue\n$ \n4,077 \n$ \n3,389 \n 20 %\n$ \n(473) $ \n166 \nNM\n$ 33,119 \n$ 29,010 \n 14 %\nTotal noninterest expense\n \n2,574 \n \n2,435 \n 6 \n \n876 \n146 \n 500 \n \n18,725 \n \n16,791 \n 12 \nPre-provision profit/(loss)\n \n1,503 \n \n954 \n 58 \n \n(1,349) \n20 \nNM\n \n14,394 \n \n12,219 \n 18 \nProvision for credit losses\n \n(121) \n \n94 \nNM\n \n16 \n8 \n 100 \n \n(4,156) \n \n8,285 \nNM\nNet income/(loss)\n \n1,244 \n \n669 \n 86 \n \n(580) \n(125) \n (364) \n \n14,300 \n \n2,865 \n 399 \nROE\n \n35 % \n25 %\nNM\nNM\n 23 %\n 4 %\nThe following sections provide a comparative discussion of the Firms results by segment as of or for the three months ended \nMarch31, 2021 versus the corresponding periods in the prior year, unless otherwise specified.\n19\n [END OF FILING]",
    "gt": "Corporate. Its net revenue was -$473 million.",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: What are the major products and services that AMD sells as of FY22? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Table of Contents\nPART I\nITEM 1. BUSINESS\nCautionary Statement Regarding Forward-Looking Statements\nThe statements in this report include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-\nlooking statements are based on current expectations and beliefs and involve numerous risks and uncertainties that could cause actual results to differ\nmaterially from expectations. These forward-looking statements speak only as of the date hereof or as of the dates indicated in the statements and should not\nbe relied upon as predictions of future events, as we cannot assure you that the events or circumstances reflected in these statements will be achieved or will\noccur. You can identify forward-looking statements by the use of forward-looking terminology including believes, expects, may, will, should, seeks,\nintends, plans, pro forma, estimates, anticipates, or the negative of these words and phrases, other variations of these words and phrases or\ncomparable terminology. The forward-looking statements relate to, among other things: possible impact of future accounting rules on AMDs consolidated\nfinancial statements; demand for AMDs products; the growth, change and competitive landscape of the markets in which AMD participates; international sales\nwill continue to be a significant portion of total sales in the foreseeable future; that AMDs cash, cash equivalents and short-term investment balances together\nwith the availability under that certain revolving credit facility (the Revolving Credit Agreement) made available to AMD and certain of its subsidiaries, our\ncommercial paper program, and our cash flows from operations will be sufficient to fund AMDs operations including capital expenditures and purchase\ncommitments over the next 12 months and beyond; AMDs ability to obtain sufficient external financing on favorable terms, or at all; AMDs expectation that\nbased on managements current knowledge, the potential liability related to AMDs current litigation will not have a material adverse effect on its financial\nposition, results of operation or cash flows; anticipated ongoing and increased costs related to enhancing and implementing information security controls; all\nunbilled accounts receivables are expected to be billed and collected within 12 months; revenue allocated to remaining performance obligations that are\nunsatisfied which will be recognized in the next 12 months; and a small number of customers will continue to account for a substantial part of AMDs revenue in\nthe future. For a discussion of the factors that could cause actual results to differ materially from the forward-looking statements, see Part I, Item 1A-Risk\nFactors and the Financial Condition section set forth in Part II, Item 7-Managements Discussion and Analysis of Financial Condition and Results of\nOperations, or MD&A, and such other risks and uncertainties as set forth below in this report or detailed in our other Securities and Exchange Commission\n(SEC) reports and filings. We assume no obligation to update forward-looking statements.\nReferences in this Annual Report on Form 10-K to AMD, we, us, management, our or the Company mean Advanced Micro Devices, Inc. and our\nconsolidated subsidiaries.\nOverview\nWe are a global semiconductor company primarily offering:\n\nserver microprocessors (CPUs) and graphics processing units (GPUs), data processing units (DPUs), Field Programmable Gate Arrays (FPGAs), and\nAdaptive System-on-Chip (SoC) products for data centers;\n\nCPUs, accelerated processing units (APUs) that integrate CPUs and GPUs, and chipsets for desktop and notebook personal computers;\n\ndiscrete GPUs, and semi-custom SoC products and development services; and\n\nembedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products.\nFrom time to time, we may also sell or license portions of our intellectual property (IP) portfolio.\n1\n [END OF FILING]",
    "gt": "AMD sells server microprocessors (CPUs) and graphics processing units (GPUs), data processing units (DPUs), Field Programmable Gate Arrays (FPGAs), and Adaptive System-on-Chip (SoC) products for data centers; CPUs, accelerated processing units (APUs) that integrate CPUs and GPUs, and chipsets for desktop and notebook personal computers; discrete GPUs, and semi-custom SoC products and development services; and embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products.",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: By drawing conclusions from the information stated only in the income statement, what is Amazon's FY2019 net income attributable to shareholders (in USD millions)? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Table of Contents\nAMAZON.COM, INC.\nCONSOLIDATED STATEMENTS OF OPERATIONS\n(in millions, except per share data)\n \n \nYear Ended December 31,\n \n2017\n \n2018\n \n2019\nNet product sales\n$\n118,573 $\n141,915 $\n160,408\nNet service sales\n59,293 \n90,972 \n120,114\nTotal net sales\n177,866 \n232,887 \n280,522\nOperating expenses:\n \n \n \nCost of sales\n111,934 \n139,156 \n165,536\nFulfillment\n25,249 \n34,027 \n40,232\nTechnology and content\n22,620 \n28,837 \n35,931\nMarketing\n10,069 \n13,814 \n18,878\nGeneral and administrative\n3,674 \n4,336 \n5,203\nOther operating expense (income), net\n214 \n296 \n201\nTotal operating expenses\n173,760 \n220,466 \n265,981\nOperating income\n4,106 \n12,421 \n14,541\nInterest income\n202 \n440 \n832\nInterest expense\n(848) \n(1,417) \n(1,600)\nOther income (expense), net\n346 \n(183) \n203\nTotal non-operating income (expense)\n(300) \n(1,160) \n(565)\nIncome before income taxes\n3,806 \n11,261 \n13,976\nProvision for income taxes\n(769) \n(1,197) \n(2,374)\nEquity-method investment activity, net of tax\n(4) \n9 \n(14)\nNet income\n$\n3,033 $\n10,073 $\n11,588\nBasic earnings per share\n$\n6.32 $\n20.68 $\n23.46\nDiluted earnings per share\n$\n6.15 $\n20.14 $\n23.01\nWeighted-average shares used in computation of earnings per share:\n \n \n \nBasic\n480 \n487 \n494\nDiluted\n493 \n500 \n504\nSee accompanying notes to consolidated financial statements.\n38\n [END OF FILING]",
    "gt": "$11588.00",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: Based on the information provided primarily in the balance sheet and the statement of income, what is FY2020 days payable outstanding (DPO) for Corning? DPO is defined as: 365 * (average accounts payable between FY2019 and FY2020) / (FY2020 COGS + change in inventory between FY2019 and FY2020). Round your answer to two decimal places. \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Index\n\n\n\n\n\n\nConsolidated Statements of Income\nCorning Incorporated and Subsidiary Companies\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nYearendedDecember31,\n(Inmillions,exceptpershareamounts)\n2020\n\n2019\n\n2018\nNetsales\n$\n 11,303 \n$\n11,503 $\n11,290\nCostofsales\n\n 7,772 \n\n7,468 \n6,829\n\n\n\n\n\n\n \nGrossmargin\n\n 3,531 \n\n4,035 \n4,461\n\n\n\n\n\n\n \nOperatingexpenses:\n\n\n\n\n\n \nSelling,generalandadministrativeexpenses\n\n 1,747 \n\n1,585 \n1,799\nResearch,developmentandengineeringexpenses\n\n 1,154 \n\n1,031 \n993\nAmortizationofpurchasedintangibles\n\n 121 \n\n113 \n94\n\n\n\n\n\n\n \nOperatingincome\n\n 509 \n\n1,306 \n1,575\n\n\n\n\n\n\n \nEquityin(losses)earningsofaffiliatedcompanies(Note3)\n\n (25)\n\n17 \n390\nInterestincome\n\n 15 \n\n21 \n38\nInterestexpense\n\n (276)\n\n(221) \n(191)\nTranslatedearningscontract(loss)gain,net(Note15)\n\n (38)\n\n248 \n(93)\nTransaction-relatedgain,net(Note4)\n\n 498 \n\n\n \nOtherexpense,net\n\n (60)\n\n(155) \n(216)\n\n\n\n\n\n\n \nIncomebeforeincometaxes\n\n 623 \n\n1,216 \n1,503\nProvisionforincometaxes(Note8)\n\n (111)\n\n(256) \n(437)\n\n\n\n\n\n\n \nNetincomeattributabletoCorningIncorporated\n$\n 512 \n$\n960 $\n1,066\n\n\n\n\n\n\n \nEarningspercommonshareattributableto\nCorningIncorporated:\n\n\n\n\n\n \nBasic(Note18)\n$\n 0.54 \n$\n1.11 $\n1.19\nDiluted(Note18)\n$\n 0.54 \n$\n1.07 $\n1.13\n\nTheaccompanyingnotesareanintegralpartoftheseconsolidatedfinancialstatements.\n\n70\n\n\nIndex\n\n\n\n\nConsolidated Balance Sheets\nCorning Incorporated and Subsidiary Companies\n\n\n\n\n\n\n\n\n\n\n\n\n\nDecember31,\n(Inmillions,exceptshareandpershareamounts)\n2020\n\n2019\n\n\n\n\n\n\nAssets\n\n\n \n\n\n\n \nCurrentassets:\n\n\n \nCashandcashequivalents\n$\n 2,672 $\n2,434\nTradeaccountsreceivable,netofdoubtfulaccounts-$46and$41\n\n 2,133 \n1,836\nInventories,net(Note6)\n\n 2,438 \n2,320\nOthercurrentassets(Note11and15)\n\n 761 \n873\nTotalcurrentassets\n\n 8,004 \n7,463\n\n\n\n \nProperty,plantandequipment,netofaccumulateddepreciation-\n$13,663and$12,995(Note9)\n\n 15,742 \n15,337\nGoodwill,net(Note10)\n\n 2,460 \n1,935\nOtherintangibleassets,net(Note10)\n\n 1,308 \n1,185\nDeferredincometaxes(Note8)\n\n 1,121 \n1,157\nOtherassets(Note11and15)\n\n 2,140 \n1,821\n\n\n\n \nTotal Assets \n$\n 30,775 $\n28,898\n\n\n\n \nLiabilities and Equity\n\n\n \n\n\n\n \nCurrentliabilities:\n\n\n \nCurrentportionoflong-termdebtandshort-termborrowings(Note12)\n$\n 156 $\n11\nAccountspayable\n\n 1,174 \n1,587\nOtheraccruedliabilities(Note11and14)\n\n 2,437 \n1,923\nTotalcurrentliabilities\n\n 3,767 \n3,521\n\n\n\n \nLong-termdebt(Note12)\n\n 7,816 \n7,729\nPostretirementbenefitsotherthanpensions(Note13)\n\n 727 \n671\nOtherliabilities(Note11and14)\n\n 5,017 \n3,980\nTotalliabilities\n\n 17,327 \n15,901\n\n\n\n \nCommitments,contingenciesandguarantees(Note14)\n \n \nShareholdersequity(Note17):\n\n\n \nConvertiblepreferredstock,SeriesAParvalue$100pershare;\nSharesauthorized3,100;Sharesissued:2,300\n\n 2,300 \n2,300\nCommonstockParvalue$0.50pershare;Sharesauthorized:3.8billion;\nSharesissued:1,726millionand1,718million\n\n 863 \n859\nAdditionalpaid-incapitalcommonstock\n\n 14,642 \n14,323\nRetainedearnings\n\n 16,120 \n16,408\nTreasurystock,atcost;sharesheld:961millionand956million\n\n (19,928) \n(19,812)\nAccumulatedothercomprehensiveloss\n\n (740) \n(1,171)\nTotalCorningIncorporatedshareholdersequity\n\n 13,257 \n12,907\nNoncontrollinginterests\n\n 191 \n90\nTotalequity\n\n 13,448 \n12,997\n\n\n\n \nTotal Liabilities and Equity\n$\n 30,775 $\n28,898\n\nTheaccompanyingnotesareanintegralpartoftheseconsolidatedfinancialstatements.\n72\n [END OF FILING]",
    "gt": "63.86",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: Has AMCOR's quick ratio improved or declined between FY2023 and FY2022? If the quick ratio is not something that a financial analyst would ask about a company like this, then state that and explain why. \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Amcor plc and Subsidiaries\nConsolidated Balance Sheets\n($ in millions, except share and per share data)\nAs of June 30,\n2023\n2022\nAssets\nCurrent assets:\nCash and cash equivalents\n$\n689 \n$\n775 \nTrade receivables, net of allowance for credit losses of $21 and $25, respectively\n1,875 \n1,935 \nInventories, net\nRaw materials and supplies\n992 \n1,114 \nWork in process and finished goods\n1,221 \n1,325 \nPrepaid expenses and other current assets\n531 \n512 \nAssets held for sale, net\n \n192 \nTotal current assets\n5,308 \n5,853 \nNon-current assets:\nProperty, plant, and equipment, net\n3,762 \n3,646 \nOperating lease assets\n533 \n560 \nDeferred tax assets\n134 \n130 \nOther intangible assets, net\n1,524 \n1,657 \nGoodwill\n5,366 \n5,285 \nEmployee benefit assets\n67 \n89 \nOther non-current assets\n309 \n206 \nTotal non-current assets\n11,695 \n11,573 \nTotal assets\n$\n17,003 \n$\n17,426 \nLiabilities\nCurrent liabilities:\nCurrent portion of long-term debt\n$\n13 \n$\n14 \nShort-term debt\n80 \n136 \nTrade payables\n2,690 \n3,073 \nAccrued employee costs\n396 \n471 \nOther current liabilities\n1,297 \n1,344 \nLiabilities held for sale\n \n65 \nTotal current liabilities\n4,476 \n5,103 \nNon-current liabilities:\nLong-term debt, less current portion\n6,653 \n6,340 \nOperating lease liabilities\n463 \n493 \nDeferred tax liabilities\n616 \n677 \nEmployee benefit obligations\n224 \n201 \nOther non-current liabilities\n481 \n471 \nTotal non-current liabilities\n8,437 \n8,182 \nTotal liabilities\n$\n12,913 \n$\n13,285 \nCommitments and contingencies (See Note 20)\nShareholders' Equity\nAmcor plc shareholders equity:\nOrdinary shares ($0.01 par value):\nAuthorized (9,000 million shares)\nIssued (1,448 and 1,489 million shares, respectively)\n$\n14 \n$\n15 \nAdditional paid-in capital\n4,021 \n4,431 \nRetained earnings\n865 \n534 \nAccumulated other comprehensive loss\n(862)\n(880)\nTreasury shares (1 and 2 million shares, respectively)\n(12)\n(18)\nTotal Amcor plc shareholders' equity\n4,026 \n4,082 \nNon-controlling interests\n64 \n59 \nTotal shareholders' equity\n4,090 \n4,141 \nTotal liabilities and shareholders' equity\n$\n17,003 \n$\n17,426 \nSee accompanying notes to consolidated financial statements.\n52\n [END OF FILING]",
    "gt": "The quick ratio has slightly improved from 0.67 times to 0.69 times between FY 2023 and FY 2022.(3.4% jump)",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: By drawing conclusions from the information stated only in the statement of financial position, what is General Mills's FY2020 working capital ratio? Define working capital ratio as total current assets divided by total current liabilities. Round your answer to two decimal places. \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING]  \n50 \n \nConsolidated Balance Sheets \nGENERAL MILLS, INC. AND SUBSIDIARIES \n(In Millions, Except Par Value) \n \nMay 31, 2020 \nMay 26, 2019 \nASSETS \n \n \n \n \nCurrent assets: \n \n \n \n \nCash and cash equivalents \n$ \n1,677.8 $ \n450.0 \nReceivables \n \n1,615.1 \n1,679.7 \nInventories \n \n1,426.3 \n1,559.3 \nPrepaid expenses and other current assets \n \n402.1 \n497.5 \nTotal current assets \n \n5,121.3 \n4,186.5 \nLand, buildings, and equipment \n \n3,580.6 \n3,787.2 \nGoodwill \n \n13,923.2 \n13,995.8 \nOther intangible assets \n \n7,095.8 \n7,166.8 \nOther assets \n \n1,085.8 \n974.9 \nTotal assets \n$ \n30,806.7 $ \n30,111.2 \n \n \n \n \n \nLIABILITIES AND EQUITY \n \n \n \n \nCurrent liabilities: \n \n \n \n \nAccounts payable \n$ \n3,247.7 $ \n2,854.1 \nCurrent portion of long-term debt \n \n2,331.5 \n1,396.5 \nNotes payable \n \n279.0 \n1,468.7 \nOther current liabilities \n \n1,633.3 \n1,367.8 \nTotal current liabilities \n \n7,491.5 \n7,087.1 \nLong-term debt \n \n10,929.0 \n11,624.8 \nDeferred income taxes \n \n1,947.1 \n2,031.0 \nOther liabilities \n \n1,545.0 \n1,448.9 \nTotal liabilities \n \n21,912.6 \n22,191.8 \nRedeemable interest \n \n544.6 \n551.7 \nStockholders' equity: \n \n \n \n \nCommon stock, 754.6 shares issued, $0.10 par value \n \n75.5 \n75.5 \nAdditional paid-in capital \n \n1,348.6 \n1,386.7 \nRetained earnings \n \n15,982.1 \n14,996.7 \nCommon stock in treasury, at cost, shares of 144.8 and 152.7 \n \n(6,433.3) \n(6,779.0)\nAccumulated other comprehensive loss \n \n(2,914.4) \n(2,625.4)\nTotal stockholders' equity \n \n8,058.5 \n7,054.5 \nNoncontrolling interests \n \n291.0 \n313.2 \nTotal equity \n \n8,349.5 \n7,367.7 \nTotal liabilities and equity \n$ \n30,806.7 $ \n30,111.2 \nSee accompanying notes to consolidated financial statements. \n \n \n \n \n [END OF FILING]",
    "gt": "0.68",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: What drove operating margin change as of FY2022 for 3M? If operating margin is not a useful metric for a company like this, then please state that and explain why. \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Table of Contents\nRESULTS OF OPERATIONS\nNet Sales:\nRefer to the preceding Overview section and the Performance by Business Segment section later in MD&A for additional discussion of sales change.\nOperating Expenses:\n(Percent of net sales)\n2022\n2021\nChange\nCost of sales\n56.2 %\n53.2 %\n3.0 %\nSelling, general and administrative expenses (SG&A)\n26.5 \n20.4 \n6.1 \nResearch, development and related expenses (R&D)\n5.4 \n5.6 \n(0.2)\nGain on business divestitures\n(8.0)\n \n(8.0)\nGoodwill impairment expense\n0.8 \n \n0.8 \nOperating income margin\n19.1 %\n20.8 %\n(1.7)%\nThe Company is continuing the ongoing deployment of an enterprise resource planning (ERP) system on a worldwide basis, with these investments impacting cost of sales,\nSG&A, and R&D.\nCost of Sales:\nCost of sales, measured as a percent of sales, increased in 2022 when compared to the same period last year. Increases were primarily due to 2022 special item costs for\nsignificant litigation from additional commitments to address PFAS-related matters at 3M's Zwijndrecht, Belgium site (discussed in Note 16), higher raw materials and logistics\ncosts, manufacturing productivity headwinds which were further magnified by the shutdown of certain operations in Belgium and progress on restarting previously-idled\noperations, and investments in growth, productivity and sustainability. On a percent of sales basis, these increases were partially offset by increases in selling prices.\nSelling, General and Administrative Expenses:\nSG&A, measured as a percent of sales, increased in 2022 when compared to the same period last year. SG&A was impacted by increased special item costs for significant\nlitigation primarily related to steps toward resolving Combat Arms Earplugs litigation (discussed in Note 16) resulting in a 2022 second quarter pre-tax charge of approximately\n$1.2 billion, certain impairment costs related to exiting PFAS manufacturing (see Note 15), costs related to exiting Russia (see Note 15), divestiture-related restructuring\ncharges (see Note 5), and continued investment in key growth initiatives. These increases were partially offset by restructuring benefits and ongoing general 3M cost\nmanagement.\nResearch, Development and Related Expenses:\nR&D, measured as a percent of sales, decreased in 2022 when compared to the same period last year. 3M continues to invest in a range of R&D activities from application\ndevelopment, product and manufacturing support, product development and technology development aimed at disruptive innovations.\nGain on Business Divestitures:\nIn the third quarter of 2022, 3M recorded a pre-tax gain of $2.7 billion ($2.7 billion after tax) related to the split-off and combination of its Food Safety business with Neogen\nCorporation. Refer to Note 3 for further details.\nGoodwill Impairment Expense:\nAs a result of 3M's commitment to exit per- and polyfluoroalkyl substance (PFAS) manufacturing, 3M recorded a goodwill impairment charge related to the Advanced\nMaterials reporting unit (within the Transportation and Electronics business). Refer to Note 15 for further details.\n27\n [END OF FILING]",
    "gt": "Operating Margin for 3M in FY2022 has decreased by 1.7% primarily due to: \n-Decrease in gross Margin\n-mostly one-off charges including Combat Arms Earplugs litigation, impairment related to exiting PFAS manufacturing, costs related to exiting Russia and divestiture-related restructuring\ncharges",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: By how much did Pepsico increase its unsecured five year revolving credit agreement on May 26, 2023? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] \n\nItem 8.01.\nOther Events.\n\nEffective May 26, 2023, PepsiCo, Inc. (PepsiCo) terminated the $3,800,000,000 364 day unsecured revolving credit agreement, dated as of\nMay 27, 2022, among PepsiCo, as borrower, the lenders party thereto, and Citibank, N.A., as administrative agent (the 2022 364 Day Credit\nAgreement). There were no outstanding borrowings under the 2022 364 Day Credit Agreement at the time of its termination.\n\nOn May 26, 2023, PepsiCo entered into a new $4,200,000,000 364 day unsecured revolving credit agreement (the 2023 364 Day Credit\nAgreement) among PepsiCo, as borrower, the lenders party thereto, and Citibank, N.A., as administrative agent. The 2023 364 Day Credit Agreement\nenables PepsiCo and its borrowing subsidiaries to borrow up to $4,200,000,000 in U.S. Dollars and/or Euros, subject to customary terms and conditions,\nand expires on May 24, 2024. PepsiCo may also, upon the agreement of either the then existing lenders or of additional banks not currently party to the\n2023 364 Day Credit Agreement, increase the commitments under the 2023 364 Day Credit Agreement to up to $4,950,000,000 in U.S. Dollars and/or\nEuros. PepsiCo may request renewal of the 2023 364 Day Credit Agreement for an additional 364 day period or convert any amounts outstanding into a\nterm loan for a period of up to one year, which term loan would mature no later than the anniversary of the then effective termination date. Subject to\ncertain conditions stated in the 2023 364 Day Credit Agreement, PepsiCo and its borrowing subsidiaries may borrow, prepay and reborrow amounts under\nthe 2023 364 Day Credit Agreement at any time during the term of the 2023 364 Day Credit Agreement. Funds borrowed under the 2023 364 Day Credit\nAgreement may be used for general corporate purposes of PepsiCo and its subsidiaries. The 2023 364 Day Credit Agreement contains customary\nrepresentations and warranties and events of default. In the ordinary course of their respective businesses, the lenders under the 2023 364 Day Credit\nAgreement and their affiliates have engaged, and may in the future engage, in commercial banking and/or investment banking transactions with PepsiCo\nand its affiliates.\n\nEffective May 26, 2023, PepsiCo terminated the $3,800,000,000 five year unsecured revolving credit agreement, dated as of May 27, 2022, among\nPepsiCo, as borrower, the lenders party thereto, and Citibank, N.A., as administrative agent (the 2022 Five Year Credit Agreement). There were no\noutstanding borrowings under the 2022 Five Year Credit Agreement at the time of its termination.\n\nOn May 26, 2023, PepsiCo entered into a new $4,200,000,000 five year unsecured revolving credit agreement (the 2023 Five Year Credit\nAgreement) among PepsiCo, as borrower, the lenders party thereto, and Citibank, N.A., as administrative agent. The 2023 Five Year Credit Agreement\nenables PepsiCo and its borrowing subsidiaries to borrow up to $4,200,000,000 in U.S. Dollars and/or Euros, including a $750,000,000 swing line\nsubfacility for Euro-denominated borrowings permitted to be borrowed on a same day basis, subject to customary terms and conditions, and expires on\nMay 26, 2028. PepsiCo may also, upon the agreement of either the then existing lenders or of additional banks not currently party to the 2023 Five Year\nCredit Agreement, increase the commitments under the 2023 Five Year Credit Agreement to up to $4,950,000,000 in U.S. Dollars and/or Euros. PepsiCo\nmay, once a year, request renewal of the 2023 Five Year Credit Agreement for an additional one year period. Subject to certain conditions stated in the 2023\nFive Year Credit Agreement, PepsiCo and its borrowing subsidiaries may borrow, prepay and reborrow amounts under the 2023 Five Year Credit\nAgreement at any time during the term of the 2023 Five Year Credit Agreement. Funds borrowed under the 2023 Five Year Credit Agreement may be used\nfor general corporate purposes of PepsiCo and its subsidiaries. The 2023 Five Year Credit Agreement contains customary representations and warranties\nand events of default. In the ordinary course of their respective businesses, the lenders under the 2023 Five Year Credit Agreement and their affiliates have\nengaged, and may in the future engage, in commercial banking and/or investment banking transactions with PepsiCo and its affiliates.\n\nThe foregoing descriptions of the 2023 364 Day Credit Agreement and 2023 Five Year Credit Agreement do not purport to be complete and are\nqualified in their entirety by reference to the full text of the 2023 364 Day Credit Agreement and the 2023 Five Year Credit Agreement, as applicable,\nwhich are filed as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and incorporated by reference herein.\n\n1\n [END OF FILING]",
    "gt": "$400,000,000 increase.",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: Are Best Buy's gross margins historically consistent (not fluctuating more than roughly 2% each year)? If gross margins are not a relevant metric for a company like this, then please state that and explain why. \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING]  \nConsolidated Statements of Earnings\n$ and shares in millions, except per share amounts\n \n \n \n \n \n \n \n \n \n \n \n \n \nFiscal Years Ended\nJanuary 28, 2023\n \nJanuary 29, 2022\n \nJanuary 30, 2021\nRevenue\n$\n 46,298 \n \n$\n 51,761 \n \n$\n 47,262 \nCost of sales\n \n 36,386 \n \n \n 40,121 \n \n \n 36,689 \nGross profit\n \n 9,912 \n \n \n 11,640 \n \n \n 10,573 \nSelling, general and administrative expenses\n \n 7,970 \n \n \n 8,635 \n \n \n 7,928 \nRestructuring charges\n \n 147 \n \n \n (34) \n \n \n 254 \nOperating income\n \n 1,795 \n \n \n 3,039 \n \n \n 2,391 \nOther income (expense):\n \n \n \n \n \n \n \n \n \n \n \nInvestment income and other\n \n 28 \n \n \n 10 \n \n \n 38 \nInterest expense\n \n (35) \n \n \n (25) \n \n \n (52) \nEarnings before income tax expense and equity in income of affiliates\n \n 1,788 \n \n \n 3,024 \n \n \n 2,377 \nIncome tax expense\n \n 370 \n \n \n 574 \n \n \n 579 \nEquity in income of affiliates\n \n 1 \n \n \n 4 \n \n \n - \nNet earnings\n$\n 1,419 \n \n$\n 2,454 \n \n$\n 1,798 \n \n \n \n \n \n \n \n \n \n \n \n \nBasic earnings per share\n$\n 6.31 \n \n$\n 9.94 \n \n$\n 6.93 \nDiluted earnings per share\n$\n 6.29 \n \n$\n 9.84 \n \n$\n 6.84 \n \n \n \n \n \n \n \n \n \n \n \n \nWeighted-average common shares outstanding:\n \n \n \n \n \n \n \n \n \n \n \nBasic\n \n 224.8 \n \n \n 246.8 \n \n \n 259.6 \nDiluted\n \n 225.7 \n \n \n 249.3 \n \n \n 263.0 \n \nSee Notes to Consolidated Financial Statements.\n \n \n40\n [END OF FILING]",
    "gt": "Yes, the margins have been consistent, there has been a minor decline of 1.1% in gross margins between FY2022 and FY2023.",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: Assume that you are a public equities analyst. Answer the following question by primarily using information that is shown in the balance sheet: what is the year end FY2018 net PPNE for 3M? Answer in USD billions. \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Table of Contents \n3M Company and Subsidiaries\nConsolidated Balance Shee t\nAt December 31\n \n \n \nDecember 31,\n \nDecember 31,\n \n(Dollars in millions, except per share amount)\n \n2018\n \n2017\n \nAssets\n \n \n \n \n \nCurrent assets\n \n \n \n \n \nCash and cash equivalents\n \n$\n2,853 \n$\n3,053 \nMarketable securities current\n \n \n380 \n \n1,076 \nAccounts receivable net of allowances of $95 and $103\n \n \n5,020 \n \n4,911 \nInventories\n \n \n \n \n \nFinished goods\n \n \n2,120 \n \n1,915 \nWork in process\n \n \n1,292 \n \n1,218 \nRaw materials and supplies\n \n \n954 \n \n901 \nTotal inventories\n \n \n4,366 \n \n4,034 \nPrepaids\n \n \n741 \n \n937 \nOther current assets\n \n \n349 \n \n266 \nTotal current assets\n \n \n13,709 \n \n14,277 \nProperty, plant and equipment\n \n \n24,873 \n \n24,914 \nLess: Accumulated depreciation\n \n \n(16,135) \n \n(16,048) \nProperty, plant and equipment net\n \n \n8,738 \n \n8,866 \nGoodwill\n \n \n10,051 \n \n10,513 \nIntangible assets net\n \n \n2,657 \n \n2,936 \nOther assets\n \n \n1,345 \n \n1,395 \nTotal assets\n \n$\n36,500 \n$\n37,987 \nLiabilities\n \n \n \n \n \nCurrent liabilities\n \n \n \n \n \nShort-term borrowings and current portion of long-term debt\n \n$\n1,211 \n$\n1,853 \nAccounts payable\n \n \n2,266 \n \n1,945 \nAccrued payroll\n \n \n749 \n \n870 \nAccrued income taxes\n \n \n243 \n \n310 \nOther current liabilities\n \n \n2,775 \n \n2,709 \nTotal current liabilities\n \n \n7,244 \n \n7,687 \n \n \n \n \n \n \nLong-term debt\n \n \n13,411 \n \n12,096 \nPension and postretirement benefits\n \n \n2,987 \n \n3,620 \nOther liabilities\n \n \n3,010 \n \n2,962 \nTotal liabilities\n \n$\n26,652 \n$\n26,365 \nCommitments and contingencies (Note 16)\n \n \n \n \n \nEquity\n \n \n \n \n \n3M Company shareholders equity:\n \n \n \n \n \nCommon stock par value, $.01 par value\n \n$\n 9 \n$\n 9 \nShares outstanding - 2018: 576,575,168\n \n \n \n \n \nShares outstanding - 2017: 594,884,237\n \n \n \n \n \nAdditional paid-in capital\n \n \n5,643 \n \n5,352 \nRetained earnings\n \n \n40,636 \n \n39,115 \nTreasury stock\n \n \n(29,626) \n \n(25,887) \nAccumulated other comprehensive income (loss)\n \n \n(6,866) \n \n(7,026) \nTotal 3M Company shareholders equity\n \n \n9,796 \n \n11,563 \nNoncontrolling interest\n \n \n52 \n \n59 \nTotal equity\n \n$\n9,848 \n$\n11,622 \nTotal liabilities and equity\n \n$\n36,500 \n$\n37,987 \n \nThe accompanying Notes to Consolidated Financial Statements are an integral part of this statement.\n58\n \n [END OF FILING]",
    "gt": "$8.70",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: Among operations, investing, and financing activities, which brought in the most (or lost the least) cash flow for AMD in FY22? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Table of Contents\nAdvanced Micro Devices, Inc.\nConsolidated Statements of Cash Flows\nYear Ended\nDecember 31,\n2022\nDecember 25,\n2021\nDecember 26,\n2020\n(In millions)\nCash flows from operating activities:\nNet income\n$\n1,320 \n$\n3,162 \n$\n2,490 \nAdjustments to reconcile net income to net cash provided by operating activities:\nDepreciation and amortization\n4,174 \n407 \n312 \nStock-based compensation\n1,081 \n379 \n274 \nAmortization of debt discount and issuance costs\n \n5 \n14 \nAmortization of operating lease right-of-use assets\n88 \n56 \n42 \nAmortization of inventory fair value adjustment\n189 \n \n \nLoss on debt redemption, repurchase and conversion\n \n7 \n54 \nLoss on sale or disposal of property and equipment\n16 \n34 \n33 \nDeferred income taxes\n(1,505)\n308 \n(1,223)\n(Gains) losses on equity investments, net\n62 \n(56)\n(2)\nOther\n(14)\n(7)\n8 \nChanges in operating assets and liabilities:\nAccounts receivable, net\n(1,091)\n(640)\n(219)\nInventories\n(1,401)\n(556)\n(417)\nReceivables from related parties\n(13)\n8 \n10 \nPrepaid expenses and other assets\n(1,197)\n(920)\n(231)\nPayables to related parties\n379 \n7 \n(135)\nAccounts payable\n931 \n801 \n(513)\nAccrued liabilities and other\n546 \n526 \n574 \nNet cash provided by operating activities\n3,565 \n3,521 \n1,071 \nCash flows from investing activities:\nPurchases of property and equipment\n(450)\n(301)\n(294)\nPurchases of short-term investments\n(2,667)\n(2,056)\n(850)\nProceeds from maturity of short-term investments\n4,310 \n1,678 \n192 \nCash received from acquisition of Xilinx\n2,366 \n \n \nAcquisition of Pensando, net of cash acquired\n(1,544)\n \n \nOther\n(16)\n(7)\n \nNet cash provided by (used in) investing activities\n1,999 \n(686)\n(952)\nCash flows from financing activities:\nProceeds from debt, net of issuance costs\n991 \n \n200 \nRepayment of debt\n(312)\n \n(200)\nProceeds from sales of common stock through employee equity plans\n167 \n104 \n85 \nRepurchases of common stock\n(3,702)\n(1,762)\n \nCommon stock repurchases for tax withholding on employee equity plans\n(406)\n(237)\n(78)\nOther\n(2)\n \n(1)\nNet cash (used in) provided by financing activities\n(3,264)\n(1,895)\n6 \nNet increase in cash and cash equivalents\n2,300 \n940 \n125 \nCash and cash equivalents at beginning of year\n2,535 \n1,595 \n1,470 \nCash and cash equivalents at end of year\n$\n4,835 \n$\n2,535 \n$\n1,595 \n55\n [END OF FILING]",
    "gt": "In 2022, AMD brought in the most cashflow from Operations",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: What is the FY2022 unadjusted EBITDA % margin for PepsiCo? Calculate unadjusted EBITDA using unadjusted operating income and D&A (from cash flow statement). Give a response to the question by relying on the details shown in the statement of cash flows and the P&L statement. \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Table of Contents\nConsolidated Statement of Income\nPepsiCo, Inc. and Subsidiaries\nFiscal years ended December 31, 2022, December 25, 2021 and December 26, 2020\n(in millions except per share amounts)\n2022\n2021\n2020\nNet Revenue\n$\n86,392 $\n79,474 $\n70,372 \nCost of sales\n40,576 \n37,075 \n31,797 \nGross profit\n45,816 \n42,399 \n38,575 \nSelling, general and administrative expenses\n34,459 \n31,237 \n28,453 \nGain associated with the Juice Transaction (see Note 13)\n(3,321)\n \n \nImpairment of intangible assets (see Notes 1 and 4)\n3,166 \n \n42 \nOperating Profit\n11,512 \n11,162 \n10,080 \nOther pension and retiree medical benefits income\n132 \n522 \n117 \nNet interest expense and other\n(939)\n(1,863)\n(1,128)\nIncome before income taxes\n10,705 \n9,821 \n9,069 \nProvision for income taxes\n1,727 \n2,142 \n1,894 \nNet income\n8,978 \n7,679 \n7,175 \nLess: Net income attributable to noncontrolling interests\n68 \n61 \n55 \nNet Income Attributable to PepsiCo\n$\n8,910 $\n7,618 $\n7,120 \nNet Income Attributable to PepsiCo per Common Share\nBasic\n$\n6.45 $\n5.51 $\n5.14 \nDiluted\n$\n6.42 $\n5.49 $\n5.12 \nWeighted-average common shares outstanding\nBasic\n1,380 \n1,382 \n1,385 \nDiluted\n1,387 \n1,389 \n1,392 \nSee accompanying notes to the consolidated financial statements.\n60\n\n\nTable of Contents\nConsolidated Statement of Cash Flows\nPepsiCo, Inc. and Subsidiaries\nFiscal years ended December 31, 2022, December 25, 2021 and December 26, 2020\n(in millions)\n2022\n2021\n2020\nOperating Activities\nNet income\n$\n8,978 $\n7,679 $\n7,175 \nDepreciation and amortization\n2,763 \n2,710 \n2,548 \nGain associated with the Juice Transaction\n(3,321)\n \n \nImpairment and other charges\n3,618 \n \n \nOperating lease right-of-use asset amortization\n517 \n505 \n478 \nShare-based compensation expense\n343 \n301 \n264 \nRestructuring and impairment charges\n411 \n247 \n289 \nCash payments for restructuring charges\n(224)\n(256)\n(255)\nAcquisition and divestiture-related charges\n80 \n(4)\n255 \nCash payments for acquisition and divestiture-related charges\n(46)\n(176)\n(131)\nPension and retiree medical plan expenses\n419 \n123 \n408 \nPension and retiree medical plan contributions\n(384)\n(785)\n(562)\nDeferred income taxes and other tax charges and credits\n(873)\n298 \n361 \nTax expense related to the TCJ Act\n86 \n190 \n \nTax payments related to the TCJ Act\n(309)\n(309)\n(78)\nChange in assets and liabilities:\nAccounts and notes receivable\n(1,763)\n(651)\n(420)\nInventories\n(1,142)\n(582)\n(516)\nPrepaid expenses and other current assets\n118 \n159 \n26 \nAccounts payable and other current liabilities\n1,842 \n1,762 \n766 \nIncome taxes payable\n57 \n30 \n(159)\nOther, net\n(359)\n375 \n164 \nNet Cash Provided by Operating Activities\n10,811 \n11,616 \n10,613 \nInvesting Activities\nCapital spending\n(5,207)\n(4,625)\n(4,240)\nSales of property, plant and equipment\n251 \n166 \n55 \nAcquisitions, net of cash acquired, investments in noncontrolled affiliates and purchases of\nintangible and other assets\n(873)\n(61)\n(6,372)\nProceeds associated with the Juice Transaction\n3,456 \n \n \nOther divestitures, sales of investments in noncontrolled affiliates and other assets\n49 \n169 \n6 \nShort-term investments, by original maturity:\nMore than three months - purchases\n(291)\n \n(1,135)\nMore than three months - maturities\n150 \n1,135 \n \nThree months or less, net\n24 \n(58)\n27 \nOther investing, net\n11 \n5 \n40 \nNet Cash Used for Investing Activities\n(2,430)\n(3,269)\n(11,619)\n(Continued on following page)\n62\n [END OF FILING]",
    "gt": "16.5%",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: Are there any product categories / service categories that represent more than 20% of Boeing's revenue for FY2022? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Table of Contents\nThe Boeing Company and Subsidiaries\nNotes to the Consolidated Financial Statements\nSummary of Business Segment Data\n(Dollars in millions)\n \nYears ended December 31,\n2022\n2021\n2020\nRevenues:\nCommercial Airplanes\n$25,867 \n$19,493 \n$16,162 \nDefense, Space & Security\n23,162 \n26,540 \n26,257 \nGlobal Services\n17,611 \n16,328 \n15,543 \nBoeing Capital\n199 \n272 \n261 \nUnallocated items, eliminations and other\n(231)\n(347)\n(65)\nTotal revenues\n$66,608 \n$62,286 \n$58,158 \n(Loss)/earnings from operations:\nCommercial Airplanes\n($2,370)\n($6,475)\n($13,847)\nDefense, Space & Security\n(3,544)\n1,544 \n1,539 \nGlobal Services\n2,727 \n2,017 \n450 \nBoeing Capital\n29 \n106 \n63 \nSegment operating loss\n(3,158)\n(2,808)\n(11,795)\nUnallocated items, eliminations and other\n(1,532)\n(1,267)\n(2,355)\nFAS/CAS service cost adjustment\n1,143 \n1,173 \n1,383 \nLoss from operations\n(3,547)\n(2,902)\n(12,767)\nOther income, net\n1,058 \n551 \n447 \nInterest and debt expense\n(2,533)\n(2,682)\n(2,156)\nLoss before income taxes\n(5,022)\n(5,033)\n(14,476)\nIncome tax (expense)/benefit\n(31)\n743 \n2,535 \nNet loss\n(5,053)\n(4,290)\n(11,941)\nLess: net loss attributable to noncontrolling interest\n(118)\n(88)\n(68)\nNet loss attributable to Boeing Shareholders\n($4,935)\n($4,202)\n($11,873)\nThis information is an integral part of the Notes to the Consolidated Financial Statements. See Note 22 for further segment results.\n58\n [END OF FILING]",
    "gt": "Yes. Boeing has product and service categories that represent more than 20% of Boeing's revenue for FY2022. These categories are Commercial Airplanes which comprises 39% of total revenue, Defence which comprises 35% of total revenue and Services which comprises 26% of total revenue.",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: Does Adobe have an improving operating margin profile as of FY2022? If operating margin is not a useful metric for a company like this, then state that and explain why. \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] ADOBE INC.\nCONSOLIDATED STATEMENTS OF INCOME\n(In millions, except per share data)\n \nYears Ended\n \nDecember 2,\n2022\nDecember 3,\n2021\nNovember 27,\n2020\nRevenue:\n \nSubscription\n$ \n16,388 $ \n14,573 $ \n11,626 \nProduct\n \n532 \n555 \n507 \nServices and other\n \n686 \n657 \n735 \nTotal revenue\n \n17,606 \n15,785 \n12,868 \n \nCost of revenue:\nSubscription\n \n1,646 \n1,374 \n1,108 \nProduct\n \n35 \n41 \n36 \nServices and other\n \n484 \n450 \n578 \nTotal cost of revenue\n \n2,165 \n1,865 \n1,722 \n \nGross profit\n \n15,441 \n13,920 \n11,146 \n \nOperating expenses:\nResearch and development\n \n2,987 \n2,540 \n2,188 \nSales and marketing\n \n4,968 \n4,321 \n3,591 \nGeneral and administrative\n \n1,219 \n1,085 \n968 \nAmortization of intangibles\n \n169 \n172 \n162 \nTotal operating expenses\n \n9,343 \n8,118 \n6,909 \n \nOperating income\n \n6,098 \n5,802 \n4,237 \n \nNon-operating income (expense):\nInterest expense\n \n(112) \n(113) \n(116) \nInvestment gains (losses), net\n \n(19) \n16 \n13 \nOther income (expense), net\n \n41 \n \n42 \nTotal non-operating income (expense), net\n \n(90) \n(97) \n(61) \nIncome before income taxes\n \n6,008 \n5,705 \n4,176 \nProvision for (benefit from) income taxes\n \n1,252 \n883 \n(1,084) \nNet income\n$ \n4,756 $ \n4,822 $ \n5,260 \nBasic net income per share\n$ \n10.13 $ \n10.10 $ \n10.94 \nShares used to compute basic net income per share\n \n470 \n477 \n481 \nDiluted net income per share\n$ \n10.10 $ \n10.02 $ \n10.83 \nShares used to compute diluted net income per share\n \n471 \n481 \n485 \nSee accompanying Notes to Consolidated Financial Statements.\nTable of Contents\n54\n [END OF FILING]",
    "gt": "No the operating margins of Adobe have recently declined from 36.8% in FY 2021 to 34.6% in FY2022. A drop by 2.2% in a year.",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: Which debt securities are registered to trade on a national securities exchange under 3M's name as of Q2 of 2023? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Table of Contents\nUNITED STATES\nSECURITIES AND EXCHANGE COMMISSION\nWASHINGTON, D.C. 20549\nFORM 10-Q\n QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\nFor the quarterly period ended June 30, 2023\nor\no TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\nFor the transition period from __________ to __________\nCommission file number: 1-3285\n3M COMPANY\n(Exact name of registrant as specified in its charter)\nDelaware\n41-0417775\n(State or other jurisdiction of incorporation)\n(IRS Employer Identification No.)\n3M Center, St. Paul, Minnesota\n55144-1000\n(Address of Principal Executive Offices)\n(Zip Code)\n(Registrants Telephone Number, Including Area Code) (651) 733-1110\nNot Applicable\n(Former Name or Former Address, if Changed Since Last Report)\nSecurities registered pursuant to Section 12(b) of the Act:\nTitle of each class\nTrading Symbol(s)\nName of each exchange on which registered\nCommon Stock, Par Value $.01 Per Share\nMMM\nNew York Stock Exchange\nMMM\nChicago Stock Exchange, Inc.\n1.500% Notes due 2026\nMMM26\nNew York Stock Exchange\n1.750% Notes due 2030\nMMM30\nNew York Stock Exchange\n1.500% Notes due 2031\nMMM31\nNew York Stock Exchange\nNote: The common stock of the Registrant is also traded on the SIX Swiss Exchange.\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or\nfor such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No \nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (232.405 of this\nchapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No \nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the\ndefinitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.:\nLarge accelerated filer\n\nAccelerated filer\n\nNon-accelerated filer\n\nSmaller reporting company\n\nEmerging growth company\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting\nstandards provided pursuant to Section 13(a) of the Exchange Act. \nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No \nIndicate the number of shares outstanding of each of the issuers classes of common stock, as of the latest practicable date.\nClass\nOutstanding at June 30, 2023\nCommon Stock, $0.01 par value per share\n551,992,430 shares\n1\n [END OF FILING]",
    "gt": "Following debt securities registered under 3M's name are listed to trade on the New York Stock Exchange:\n-1.500% Notes due 2026 (Trading Symbol: MMM26)\n-1.750% Notes due 2030 (Trading Symbol: MMM30)\n-1.500% Notes due 2031 (Trading Symbol: MMM31)",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: Taking into account the information outlined in the income statement, what is the FY2019 - FY2021 3 year average unadjusted operating income % margin for Corning? Answer in units of percents and round to one decimal place. \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] TableofContents\n\n\nConsolidated Statements of Income \nCorning Incorporated and Subsidiary Companies\n\n\n\n\nYearendedDecember31,\n\n(Inmillions,exceptpershareamounts)\n\n2021\n \n2020\n \n2019\n\nNetsales\n $\n14,082 $\n11,303 $\n11,503\nCostofsales\n \n9,019 \n7,772 \n7,468\n\n \n \n \n\nGrossmargin\n \n5,063 \n3,531 \n4,035\n\n \n \n \n\nOperatingexpenses:\n \n \n \n\nSelling,generalandadministrativeexpenses\n \n1,827 \n1,747 \n1,585\nResearch,developmentandengineeringexpenses\n \n995 \n1,154 \n1,031\nAmortizationofpurchasedintangibles\n \n129 \n121 \n113\n\n \n \n \n\nOperatingincome\n \n2,112 \n509 \n1,306\n\n \n \n \n\nEquityinearnings(losses)ofaffiliatedcompanies(Note3)\n \n35 \n(25) \n17\nInterestincome\n \n11 \n15 \n21\nInterestexpense\n \n(300) \n(276) \n(221)\nTranslatedearningscontractgain(loss),net(Note15)\n \n354 \n(38) \n248\nTransaction-relatedgain,net(Note4)\n \n \n498 \n\nOtherincome(expense),net\n \n185 \n(60) \n(155)\n\n \n \n \n\nIncomebeforeincometaxes\n \n2,397 \n623 \n1,216\nProvisionforincometaxes(Note8)\n \n(491) \n(111) \n(256)\n\n \n \n \n\nNetincomeattributabletoCorningIncorporated\n $\n1,906 $\n512 $\n960\n\n \n \n \n\nEarningspercommonshareattributabletoCorningIncorporated:\n \n \n \n\nBasic(Note18)\n $\n1.30 $\n0.54 $\n1.11\nDiluted(Note18)\n $\n1.28 $\n0.54 $\n1.07\n\n \n \n \n\nReconciliationofnetincomeattributabletoCorningIncorporatedversusnetincomeavailabletocommon\nshareholders:\n \n \n \n\n\n \n \n \n\nNetincomeattributabletoCorningIncorporated\n $\n1,906 $\n512 $\n960\n\n \n \n \n\nSeriesAconvertiblepreferredstockdividend\n \n(24) \n(98) \n(98)\nExcessconsiderationpaidforredemptionofpreferredstock(1)\n \n(803) \n \n \n\n \n \n \n\nNetincomeavailabletocommonshareholders\n $\n1,079 $\n414 $\n862\n\n\n(1)\nRefertoNote17(Shareholders'Equity)andNote18(EarningsperCommonShare)totheconsolidatedfinancialstatementsforadditionalinformation.\n\nTheaccompanyingnotesareanintegralpartoftheseconsolidatedfinancialstatements.\n\n65\n [END OF FILING]",
    "gt": "10.3%",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: If we exclude the impact of M&A, which segment has dragged down 3M's overall growth in 2022? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Table of Contents\nSales and operating income (loss) by business segment:\nThe following tables contain sales and operating income (loss) results by business segment for the years ended December 31, 2022 and 2021. Refer to the section entitled\nPerformance by Business Segment later in MD&A for additional discussion concerning 2022 versus 2021 results, including Corporate and Unallocated. Refer to Note 19 for\nadditional information on business segments.\n2022\n2021\n% change\n(Dollars in millions)\nNet Sales\n% of Total\nOperating\nIncome (Loss)\nNet Sales\n% of Total\nOperating\nIncome (Loss)\nNet Sales\nOperating Income\n(Loss)\nBusiness Segments\nSafety and Industrial\n$\n11,604\n33.9 % $\n1,199 $\n11,981\n33.9 % $\n2,466\n(3.2)%\n(51.4)%\nTransportation and Electronics\n8,902\n26.0 \n1,012\n9,262\n26.2 \n1,880\n(3.9)\n(46.2)\nHealth Care\n8,421\n24.6 \n1,815\n8,597\n24.3 \n2,037\n(2.0)\n(10.9)\nConsumer\n5,298\n15.5 \n994\n5,513\n15.6 \n1,162\n(3.9)\n(14.4)\nCorporate and Unallocated\n4\n \n1,519\n2\n \n(176)\nTotal Company\n$\n34,229 \n100.0 % $\n6,539 $\n35,355 \n100.0 % $\n7,369 \n(3.2)%\n(11.3)%\nYear ended December 31, 2022\nWorldwide Sales Change \nBy Business Segment\nOrganic sales\nAcquisitions\nDivestitures\nTranslation\nTotal sales change\nSafety and Industrial\n1.0 %\n \n %\n %\n(4.2) %\n(3.2) %\nTransportation and Electronics\n1.2 \n \n(0.5)\n(4.6)\n(3.9)\nHealth Care\n3.2 \n \n(1.4)\n(3.8)\n(2.0)\nConsumer\n(0.9)\n \n(0.4)\n(2.6)\n(3.9)\nTotal Company\n1.2 \n \n(0.5)\n(3.9)\n(3.2)\nSales by geographic area:\nPercent change information compares the years ended December 31, 2022 and 2021 with the same prior year period, unless otherwise indicated. Additional discussion of\nbusiness segment results is provided in the Performance by Business Segment section.\nYear ended December 31, 2022\nAmericas\nAsia Pacific\nEurope, Middle East\n& Africa\nOther Unallocated\nWorldwide\nNet sales (millions)\n$\n18,400 \n$\n9,901 \n$\n5,928 \n$\n \n$\n34,229 \n% of worldwide sales\n53.8 %\n28.9 %\n17.3 %\n100.0 %\nComponents of net sales change:\nOrganic sales\n2.6 \n0.3 \n(0.6)\n1.2 \nDivestitures\n(0.6)\n(0.4)\n(0.6)\n(0.5)\nTranslation\n(0.3)\n(6.5)\n(9.8)\n(3.9)\nTotal sales change\n1.7 %\n(6.6) %\n(11.0) %\n(3.2) %\nYear ended December 31, 2021\nAmericas\nAsia Pacific\nEurope, Middle East\n& Africa\nOther Unallocated\nWorldwide\nNet sales (millions)\n$\n18,097 \n$\n10,600 \n$\n6,660 \n$\n(2)\n$\n35,355 \n% of worldwide sales\n51.2 %\n30.0 %\n18.8 %\n100.0 %\nComponents of net sales change:\nOrganic sales\n9.8 \n8.5 \n6.3 \n8.8 \nDivestitures\n(0.6)\n \n(1.1)\n(0.5)\nTranslation\n0.3 \n2.3 \n3.8 \n1.6 \nTotal sales change\n9.5 %\n10.8 %\n9.0 %\n9.9 %\n25\n [END OF FILING]",
    "gt": "The consumer segment shrunk by 0.9% organically.",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: Does Verizon have a reasonably healthy liquidity profile based on its quick ratio for FY 2022? If the quick ratio is not relevant to measure liquidity, please state that and explain why. \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Consolidated Balance Sheets \nVerizon Communications Inc. and Subsidiaries \n(dollars in millions, except per share amounts) \nAt December 31,\n2022\n2021 \nAssets \nCurrent assets \nCash and cash equivalents\n$ \n2,605 \n$ \n2,921 \nAccounts receivable\n \n25,332 \n \n24,742 \nLess Allowance for credit losses\n \n826 \n \n896 \nAccounts receivable, net \n \n24,506 \n \n23,846 \nInventories\n \n2,388 \n \n3,055 \nPrepaid expenses and other\n \n8,358 \n \n6,906 \nTotal current assets\n \n37,857 \n \n36,728 \nProperty, plant and equipment\n \n307,689 \n \n289,897 \nLess Accumulated depreciation\n \n200,255 \n \n190,201 \nProperty, plant and equipment, net\n \n107,434 \n \n99,696 \nInvestments in unconsolidated businesses\n \n1,071 \n \n1,061 \nWireless licenses\n \n149,796 \n \n147,619 \nGoodwill\n \n28,671 \n \n28,603 \nOther intangible assets, net\n \n11,461 \n \n11,677 \nOperating lease right-of-use assets\n \n26,130 \n \n27,883 \nOther assets\n \n17,260 \n \n13,329 \nTotal assets\n$ \n379,680 \n$ \n366,596 \nLiabilities and Equity \nCurrent liabilities \nDebt maturing within one year\n$ \n9,963 \n$ \n7,443 \nAccounts payable and accrued liabilities\n \n23,977 \n \n24,833 \nCurrent operating lease liabilities\n \n4,134 \n \n3,859 \nOther current liabilities\n \n12,097 \n \n11,025 \nTotal current liabilities\n \n \n \n \n \n \n50,171 \n \n \n \n \n \n \n \n47,160 \nLong-term debt\n140,676 \n143,425 \nEmployee benefit obligations\n12,974 \n15,410 \nDeferred income taxes\n43,441 \n40,685 \nNon-current operating lease liabilities\n21,558 \n23,203 \nOther liabilities\n18,397 \n13,513 \nTotal long-term liabilities\n \n237,046 \n236,236 \nCommitments and Contingencies (Note 16) \nEquity \nSeries preferred stock ($0.10 par value; 250,000,000 shares authorized; none issued)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nCommon stock ($0.10 par value; 6,250,000,000 shares authorized in each period; \n4,291,433,646 shares issued in each period)\n429 \n429 \nAdditional paid in capital\n13,420 \n13,861 \nRetained earnings\n82,380 \n71,993 \nAccumulated other comprehensive loss\n(1,865) \n(927) \nCommon stock in treasury, at cost (91,572,258 and 93,634,725 shares outstanding)\n(4,013) \n(4,104) \nDeferred compensation employee stock ownership plans (ESOPs) and other\n793 \n538 \nNoncontrolling interests\n1,319 \n1,410 \nTotal equity\n92,463 \n83,200 \nTotal liabilities and equity\n$ \n379,680 \n$ \n366,596 \nSee Notes to Consolidated Financial Statements\nVerizon 2022 Annual Report on Form 10-K 56 \n [END OF FILING]",
    "gt": "No. The quick ratio was approximately 0.54 for Verizon. It indicated that Verizon does not have a healthy liquidity profile.",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: What is Coca Cola's FY2021 COGS % margin? Calculate what was asked by utilizing the line items clearly shown in the income statement. \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] THE COCA-COLA COMPANY AND SUBSIDIARIES\nCONSOLIDATED STATEMENTS OF INCOME\n(In millions except per share data)\nYear Ended December 31,\n2021\n2020\n2019\nNet Operating Revenues\n$\n38,655 $\n33,014 $\n37,266 \nCost of goods sold\n15,357 \n13,433 \n14,619 \nGross Profit\n23,298 \n19,581 \n22,647 \nSelling, general and administrative expenses\n12,144 \n9,731 \n12,103 \nOther operating charges\n846 \n853 \n458 \nOperating Income\n10,308 \n8,997 \n10,086 \nInterest income\n276 \n370 \n563 \nInterest expense\n1,597 \n1,437 \n946 \nEquity income (loss) net\n1,438 \n978 \n1,049 \nOther income (loss) net\n2,000 \n841 \n34 \nIncome Before Income Taxes\n12,425 \n9,749 \n10,786 \nIncome taxes\n2,621 \n1,981 \n1,801 \nConsolidated Net Income\n9,804 \n7,768 \n8,985 \nLess: Net income (loss) attributable to noncontrolling interests\n33 \n21 \n65 \nNet Income Attributable to Shareowners of The Coca-Cola Company\n$\n9,771 $\n7,747 $\n8,920 \nBasic Net Income Per Share\n$\n2.26 $\n1.80 $\n2.09 \nDiluted Net Income Per Share\n$\n2.25 $\n1.79 $\n2.07 \nAverage Shares Outstanding Basic\n4,315 \n4,295 \n4,276 \nEffect of dilutive securities\n25 \n28 \n38 \nAverage Shares Outstanding Diluted\n4,340 \n4,323 \n4,314 \nCalculated based on net income attributable to shareowners of The Coca-Cola Company.\nRefer to Notes to Consolidated Financial Statements.\n1\n1\n1 \n60\n [END OF FILING]",
    "gt": "39.7%",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: What is Coca Cola's FY2022 dividend payout ratio (using total cash dividends paid and net income attributable to shareholders)? Round answer to two decimal places. Answer the question asked by assuming you only have access to information clearly displayed in the cash flow statement and the income statement. \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] THE COCA-COLA COMPANY AND SUBSIDIARIES\nCONSOLIDATED STATEMENTS OF INCOME\n(In millions except per share data)\nYear Ended December 31,\n2022\n2021\n2020\nNet Operating Revenues\n$\n43,004 $\n38,655 $\n33,014 \nCost of goods sold\n18,000 \n15,357 \n13,433 \nGross Profit\n25,004 \n23,298 \n19,581 \nSelling, general and administrative expenses\n12,880 \n12,144 \n9,731 \nOther operating charges\n1,215 \n846 \n853 \nOperating Income\n10,909 \n10,308 \n8,997 \nInterest income\n449 \n276 \n370 \nInterest expense\n882 \n1,597 \n1,437 \nEquity income (loss) net\n1,472 \n1,438 \n978 \nOther income (loss) net\n(262)\n2,000 \n841 \nIncome Before Income Taxes\n11,686 \n12,425 \n9,749 \nIncome taxes\n2,115 \n2,621 \n1,981 \nConsolidated Net Income\n9,571 \n9,804 \n7,768 \nLess: Net income (loss) attributable to noncontrolling interests\n29 \n33 \n21 \nNet Income Attributable to Shareowners of The Coca-Cola Company\n$\n9,542 $\n9,771 $\n7,747 \nBasic Net Income Per Share\n$\n2.20 $\n2.26 $\n1.80 \nDiluted Net Income Per Share\n$\n2.19 $\n2.25 $\n1.79 \nAverage Shares Outstanding Basic\n4,328 \n4,315 \n4,295 \nEffect of dilutive securities\n22 \n25 \n28 \nAverage Shares Outstanding Diluted\n4,350 \n4,340 \n4,323 \nCalculated based on net income attributable to shareowners of The Coca-Cola Company.\nRefer to Notes to Consolidated Financial Statements.\n1\n1\n1 \n61\n\n\nTHE COCA-COLA COMPANY AND SUBSIDIARIES\nCONSOLIDATED STATEMENTS OF CASH FLOWS\n(In millions)\nYear Ended December 31,\n2022\n2021\n2020\nOperating Activities\n \n \nConsolidated net income\n$\n9,571 $\n9,804 $\n7,768 \nDepreciation and amortization\n1,260 \n1,452 \n1,536 \nStock-based compensation expense\n356 \n337 \n126 \nDeferred income taxes\n(122)\n894 \n(18)\nEquity (income) loss net of dividends\n(838)\n(615)\n(511)\nForeign currency adjustments\n203 \n86 \n(88)\nSignificant (gains) losses net\n(129)\n(1,365)\n(914)\nOther operating charges\n1,086 \n506 \n556 \nOther items\n236 \n201 \n699 \nNet change in operating assets and liabilities\n(605)\n1,325 \n690 \nNet Cash Provided by Operating Activities\n11,018 \n12,625 \n9,844 \nInvesting Activities\n \n \nPurchases of investments\n(3,751)\n(6,030)\n(13,583)\nProceeds from disposals of investments\n4,771 \n7,059 \n13,835 \nAcquisitions of businesses, equity method investments and nonmarketable securities\n(73)\n(4,766)\n(1,052)\nProceeds from disposals of businesses, equity method investments and nonmarketable securities\n458 \n2,180 \n189 \nPurchases of property, plant and equipment\n(1,484)\n(1,367)\n(1,177)\nProceeds from disposals of property, plant and equipment\n75 \n108 \n189 \nCollateral (paid) received associated with hedging activities net\n(1,465)\n \n \nOther investing activities\n706 \n51 \n122 \nNet Cash Provided by (Used in) Investing Activities\n(763)\n(2,765)\n(1,477)\nFinancing Activities\n \n \nIssuances of debt\n3,972 \n13,094 \n26,934 \nPayments of debt\n(4,930)\n(12,866)\n(28,796)\nIssuances of stock\n837 \n702 \n647 \nPurchases of stock for treasury\n(1,418)\n(111)\n(118)\nDividends\n(7,616)\n(7,252)\n(7,047)\nOther financing activities\n(1,095)\n(353)\n310 \nNet Cash Provided by (Used in) Financing Activities\n(10,250)\n(6,786)\n(8,070)\nEffect of Exchange Rate Changes on Cash, Cash Equivalents, Restricted Cash and\n Restricted Cash Equivalents\n(205)\n(159)\n76 \nCash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents\n \n \nNet increase (decrease) in cash, cash equivalents, restricted cash and restricted cash\n equivalents during the year\n(200)\n2,915 \n373 \nCash, cash equivalents, restricted cash and restricted cash equivalents at beginning of year\n10,025 \n7,110 \n6,737 \nCash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents at End of Year\n9,825 \n10,025 \n7,110 \nLess: Restricted cash and restricted cash equivalents at end of year\n306 \n341 \n315 \nCash and Cash Equivalents at End of Year\n$\n9,519 $\n9,684 $\n6,795 \nRefer to Notes to Consolidated Financial Statements.\n64\n [END OF FILING]",
    "gt": "0.8",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: Which debt securities are registered to trade on a national securities exchange under American Express' name as of 2022? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] UNITED STATES\nSECURITIES AND EXCHANGE COMMISSION\nWashington, D.C. 20549\nForm 10-K\n\nANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\nFor the fiscal year ended December 31, 2022\nOR\n\nTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\nFor the transition period from to \n Commission File No. 1-7657\nAmerican Express Company\n(Exact name of registrant as specified in its charter)\nNew York\n13-4922250\n(State or other jurisdiction of incorporation or organization)\n(I.R.S. Employer Identification No.)\n200 Vesey Street\nNew York, New York\n10285\n(Address of principal executive offices)\n(Zip Code)\nRegistrants telephone number, including area code: (212) 640-2000\nSecurities registered pursuant to Section 12(b) of the Act:\nTitle of each class\nTrading Symbol(s)\nName of each exchange on which registered\nCommon Shares (par value $0.20 per Share)\nAXP\nNew York Stock Exchange\nSecurities registered pursuant to section 12(g) of the Act: None\nIndicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No o\nIndicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o No \nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or\nfor such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes No o\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T ( 232.405 of this\nchapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No o\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the\ndefinitions of large accelerated filer, accelerated filer, smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act.\nLarge accelerated filer \nAccelerated filer o\nNon-accelerated filer o\nSmaller reporting company \nEmerging growth company \nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting\nstandards provided pursuant to Section 13(a) of the Exchange Act. o\nIndicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under\nsection 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. \nIf securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an\nerror to previously issued financial statements. o\nIndicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's\nexecutive officers during the relevant recovery period pursuant to 240.10D-1(b). o\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No \nAs of June 30, 2022, the aggregate market value of the registrants voting shares held by non-affiliates of the registrant was approximately $104.0 billion based on the closing sale price as\nreported on the New York Stock Exchange.\nAs of February 2, 2023, there were 744,192,702 common shares of the registrant outstanding.\nDOCUMENTS INCORPORATED BY REFERENCE\nPart III: Portions of Registrants Proxy Statement to be filed with the Securities and Exchange Commission in connection with the Annual Meeting of Shareholders to be held on May 2,\n2023.\n [END OF FILING]",
    "gt": "There are none",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: Are JnJ's FY2022 financials that of a high growth company? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Results of Operations\nAnalysis of Consolidated Sales\nFor discussion on results of operations and financial condition pertaining to the fiscal years 2021 and 2020 see the Companys Annual Report on Form 10-\nK for the fiscal year ended January 2, 2022, Item 7. Management's Discussion and Analysis of Results of Operations and Financial Condition.\nIn 2022, worldwide sales increased 1.3% to $94.9 billion as compared to an increase of 13.6% in 2021. These sales changes consisted of the following:\nSales increase/(decrease) due to:\n2022\n2021\nVolume\n6.9 %\n12.9 %\nPrice\n(0.8)\n(0.7)\nCurrency\n(4.8)\n1.4 \nTotal\n1.3 %\n13.6 %\nThe net impact of acquisitions and divestitures on the worldwide sales growth was a negative impact of 0.1% in 2022 and a negative impact of 0.6% in\n2021.\nSales by U.S. companies were $48.6 billion in 2022 and $47.2 billion in 2021. This represents increases of 3.0% in 2022 and 9.3% in 2021. Sales by\ninternational companies were $46.4 billion in 2022 and $46.6 billion in 2021. This represents a decrease of 0.6% in 2022 and an increase of 18.2% in 2021.\nThe five-year compound annual growth rates for worldwide, U.S. and international sales were 4.4%, 4.0% and 4.9%, respectively. The ten-year\ncompound annual growth rates for worldwide, U.S. and international sales were 3.5%, 5.0% and 2.2%, respectively.\nIn 2022, sales by companies in Europe experienced a decline of 0.6% as compared to the prior year, which included operational growth of 11.0% and a\nnegative currency impact of 11.6%. Sales by companies in the Western Hemisphere, excluding the U.S., achieved growth of 6.5% as compared to the prior\nyear, which included operational growth of 10.2%, and a negative currency impact of 3.7%. Sales by companies in the Asia-Pacific, Africa region\nexperienced a decline of 2.8% as compared to the prior year, including operational growth of 6.2% and a negative currency impact of 9.0%.\nIn 2022, the Company utilized three wholesalers distributing products for all three segments that represented approximately 16.5%, 13.0% and 12.0%\nof the total consolidated revenues. In 2021, the Company had three wholesalers distributing products for all three segments that represented approximately\n14.0%, 11.0% and 11.0% of the total consolidated revenues.\nNote: values may have been rounded\n22\n [END OF FILING]",
    "gt": "No, JnJ's FY2022 financials are not of a high growth company as sales grew by 1.3% in FY2022.",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: What is Netflix's year end FY2017 total current liabilities (in USD millions)? Base your judgments on the information provided primarily in the balance sheet. \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Table of Contents\nNETFLIX, INC.\nCONSOLIDATED BALANCE SHEETS\n(in thousands, except share and per share data)\n \n \n \nAs of December 31,\n \n \n2017\n \n2016\nAssets\n \n \nCurrent assets:\n \n \nCash and cash equivalents\n $\n2,822,795 $\n1,467,576\nShort-term investments\n \n \n266,206\nCurrent content assets, net\n \n4,310,934 \n3,726,307\nOther current assets\n \n536,245 \n260,202\nTotal current assets\n \n7,669,974 \n5,720,291\nNon-current content assets, net\n \n10,371,055 \n7,274,501\nProperty and equipment, net\n \n319,404 \n250,395\nOther non-current assets\n \n652,309 \n341,423\nTotal assets\n $\n19,012,742 $\n13,586,610\nLiabilities and Stockholders Equity\n \n \nCurrent liabilities:\n \n \nCurrent content liabilities\n $\n4,173,041 $\n3,632,711\nAccounts payable\n \n359,555 \n312,842\nAccrued expenses\n \n315,094 \n197,632\nDeferred revenue\n \n618,622 \n443,472\nTotal current liabilities\n \n5,466,312 \n4,586,657\nNon-current content liabilities\n \n3,329,796 \n2,894,654\nLong-term debt\n \n6,499,432 \n3,364,311\nOther non-current liabilities\n \n135,246 \n61,188\nTotal liabilities\n \n15,430,786 \n10,906,810\nCommitments and contingencies (Note 5)\n \n \nStockholders equity:\n \n \nPreferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2017 and 2016; no shares\nissued and outstanding at December 31, 2017 and 2016\n \n \n\nCommon stock, $0.001 par value; 4,990,000,000 shares authorized at December 31, 2017 and December 31,\n2016, respectively; 433,392,686 and 430,054,212 issued and outstanding at December 31, 2017 and\nDecember 31, 2016, respectively\n \n1,871,396 \n1,599,762\nAccumulated other comprehensive loss\n \n(20,557) \n(48,565)\nRetained earnings\n \n1,731,117 \n1,128,603\nTotal stockholders equity\n \n3,581,956 \n2,679,800\nTotal liabilities and stockholders equity\n $\n19,012,742 $\n13,586,610\nSee accompanying notes to consolidated financial statements.\n43\n [END OF FILING]",
    "gt": "$5466.00",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: Has Verizon increased its debt on balance sheet between 2022 and the 2021 fiscal period? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Note 7. Debt \nOutstanding long-term debt obligations as of December 31, 2022 and 2021 are as follows: \n(dollars in millions) \nAt December 31,\nMaturities \nInterest \nRates %\n2022\n2021 \nVerizon Communications\n< 5 Years\n0.75 - 5.82\n$ \n23,929 \n$ \n18,406 \n5-10 Years\n1.50 - 7.88\n42,637 \n43,225 \n> 10 Years\n1.13 - 8.95\n60,134 \n73,520 \n< 5 Years\nFloating\n(1) \n2,992 \n4,086 \n5-10 Years\nFloating\n(1) \n3,029 \n824 \nAlltel Corporation\n5-10 Years\n6.80 - 7.88\n94 \n38 \n> 10 Years\nN/A\nN/A \n58 \nOperating telephone company subsidiariesdebentures\n< 5 Years\nN/A\nN/A \n141 \n5-10 Years\n6.00 - 8.75\n475 \n375 \n> 10 Years\n5.13 - 7.38\n139 \n250 \nOther subsidiariesasset-backed debt\n< 5 Years\n0.41 - 5.72\n9,767 \n9,620 \n< 5 Years\nFloating\n(2) \n10,271 \n4,610 \nFinance lease obligations (average rate of 2.5% and 2.2% in \n2022 and 2021, respectively)\n1,732 \n1,325 \nUnamortized discount, net of premium\n(4,039) \n(4,922) \nUnamortized debt issuance costs\n(671) \n(688) \nTotal long-term debt, including current maturities\n150,489 \n150,868 \nLess long-term debt maturing within one year\n9,813 \n7,443 \nTotal long-term debt\n$ \n140,676 \n$ \n143,425 \nLong-term debt maturing within one year\n$ \n9,813 \n$ \n7,443 \nAdd commercial paper\n150 \n \nDebt maturing within one year\n9,963 \n7,443 \nAdd long-term debt\n140,676 \n143,425 \nTotal debt\n$ \n150,639 \n$ \n150,868 \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n(1) The debt obligations bore interest at a floating rate based on the Compounded Secured Overnight Financing Rate (SOFR) for \nthe interest period or the London Interbank Offered Rate (LIBOR) plus an applicable interest margin per annum, as applicable. \nCompounded SOFR is calculated using the SOFR Index published by the Federal Reserve Bank of New York in accordance \nwith the formula set forth in the terms of the notes. The Compounded SOFR for the interest period ending in December 2022 \nwas 3.450%. The one-month and three-month LIBOR at December 31, 2022 was 4.392% and 4.767%, respectively. \n(2) The debt obligations bore interest at floating rates, including floating rates associated with SOFR for the interest period, or \nLIBOR plus an applicable interest margin per annum, as applicable. Floating rates associated with SOFR for the interest \nperiod ending in December 2022 ranged from 3.807% to 4.372%. \n \nMaturities of long-term debt (secured and unsecured) outstanding, including current maturities, excluding unamortized debt \nissuance costs, at December 31, 2022 are as follows: \nYears\n(dollars in millions) \n2023\n$ \n9,279 \n2024\n16,252 \n2025\n8,706 \n2026\n8,304 \n2027\n6,962 \nThereafter\n99,925 \n \n \n \n \n \nDuring 2022, we received $17.8 billion of proceeds from long-term borrowings, which included $10.7 billion of proceeds from \nasset-backed debt transactions. The net proceeds were primarily used for general corporate purposes including the repayment \nof debt and the funding of certain renewable energy projects. We used $13.6 billion of cash to repay, redeem and repurchase \nlong-term borrowings and finance lease obligations, including $4.9 billion to prepay and repay asset-backed, long-term \nborrowings. The net proceeds of approximately $1.0 billion from the green bond issued in 2022 are expected to be used to fund \ncertain renewable energy projects. \nDuring 2021, we received $41.4 billion of proceeds from long-term borrowings, which included $8.4 billion of proceeds from \nasset-backed debt transactions. The net proceeds were primarily used to finance the purchase of wireless licenses won in \nconnection with the FCC's auction for C-Band wireless spectrum, Auction 107, and fund certain renewable energy projects. We \n 77 \n \n Verizon 2022 Annual Report on Form 10-K\n [END OF FILING]",
    "gt": "No. Verizon's debt decreased by $229 million.",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: What production rate changes is Boeing forecasting for FY2023? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Table of Contents\nAirlines also are experiencing increased fuel and other costs, and the global economy is experiencing high inflation.\nOur Commercial Airplanes business depends on our ability to maintain a healthy production system, ensure every airplane in our\nproduction system conforms to our exacting specifications, achieve planned production rate targets, successfully develop and certify\nnew aircraft or new derivative aircraft, and meet or exceed stringent performance and reliability standards.\nThe commercial aircraft business is extremely complex, involving extensive coordination and integration with U.S and non-U.S. suppliers, highly-\nskilled labor performed by thousands of employees of ours and other partners, and stringent and evolving regulatory requirements and\nperformance and reliability standards. The FAA has been working to implement safety reforms such as the 2018 FAA Reauthorization Act and\nthe 2020 Aircraft Certification, Safety and Accountability Act (ACSAA). One of these, section 116 of the ACSAA prohibited the FAA from issuing a\ntype certificate to aircraft after December 27, 2022 unless the aircrafts flight crew alerting system met certain specifications. The Consolidated\nAppropriations Act, 2023 amended Section 116 of the ACSAA, such that applications for original or amended type certifications that were\nsubmitted to the FAA prior to December 27, 2020, including those of the 737-7 and 737-10, are no longer subject to the crew alerting\nspecifications of Section 116. Additionally, beginning one year after the FAA issues the type certificate for the 737-10, any new 737 MAX aircraft\nmust include certain safety enhancements to be issued an original airworthiness certification by the FAA. These enhancements are included in\nBoeings application for the certification for the 737-10, and the sufficiency of these enhancements will be determined by the FAA. Beginning\nthree years after the issuance of a type certificate for the 737-10, all previously delivered 737 MAX aircraft must be retrofitted with these safety\nenhancements. As the holder of the type certificate, Boeing is required to bear any costs of these safety enhancement retrofits. We have\nprovisioned for the estimated costs associated with the safety enhancements and do not expect those costs to be material. If we experience\ndelays in achieving certification and/or incorporating safety enhancements, future revenues, cash flows and results of operations could be\nadversely impacted. Comparable agencies in other countries may adopt similar changes. To the extent the FAA or similar regulatory agencies\noutside the U.S. implement more stringent regulations, we may incur additional compliance costs. In addition, the introduction of new aircraft\nprograms and/or derivatives, such as the 777X, 737-7 and 737-10, involves increased risks associated with meeting development, testing,\ncertification and production schedules.\nIn addition, we have experienced production quality issues, including in our supply chain, which have contributed to lower 787 deliveries,\nincluding a suspension of 787 deliveries from May 2021 to August 2022. We continue to conduct inspections and rework on built and stored 787\naircraft. A number of our customers have contractual remedies, including compensation for late deliveries or rights to reject individual airplane\ndeliveries based on delivery delays. Delays on the 737, 777X and 787 programs have resulted in, and may continue to result in, customers\nhaving the right to terminate orders, be compensated for late deliveries and/or substitute orders for other Boeing aircraft.\nWe must minimize disruption caused by production changes, achieve operational stability and implement productivity improvements in order to\nmeet customer demand and maintain our profitability. We have previously announced plans to adjust production rates on several of our\ncommercial aircraft programs. The 787 program is currently producing at low rates and we expect to gradually increase to 5 per month in 2023.\nProduction of the 777X is currently paused and is expected to resume in 2023. The 737 program has experienced operational and supply chain\nchallenges stabilizing production at 31 per month. We plan to gradually increase 737 production rates based on market demand and supply\nchain capacity. In addition, we continue to seek opportunities to reduce the costs of building our aircraft, including working with our suppliers to\nreduce supplier costs, identifying and implementing productivity improvements and optimizing how we manage inventory. If production rate\nchanges at any of our\n7\n [END OF FILING]",
    "gt": "Boeing forecasts an increase in the production rates for the 737, 777X and 787 aircrafts in 2023.",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: We want to calculate a financial metric. Please help us compute it by basing your answers off of the statement of income and the statement of cash flows. Here's the question: what is the FY2015 unadjusted EBITDA % margin for Netflix? Calculate unadjusted EBITDA using unadjusted operating income and D&A (from cash flow statement). \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Table of Contents\nNETFLIX, INC.\nCONSOLIDATED STATEMENTS OF OPERATIONS\n(in thousands, except per share data)\n \n \n \nYear ended December 31,\n \n \n2015\n \n2014\n \n2013\nRevenues\n $\n6,779,511 $\n5,504,656 $\n4,374,562\nCost of revenues\n \n4,591,476 \n3,752,760 \n3,117,203\nMarketing\n \n824,092 \n607,186 \n469,942\nTechnology and development\n \n650,788 \n472,321 \n378,769\nGeneral and administrative\n \n407,329 \n269,741 \n180,301\nOperating income\n \n305,826 \n402,648 \n228,347\nOther income (expense):\n \n \n \nInterest expense\n \n(132,716) \n(50,219) \n(29,142)\nInterest and other income (expense)\n \n(31,225) \n(3,060) \n(3,002)\nLoss on extinguishment of debt\n \n \n \n(25,129)\nIncome before income taxes\n \n141,885 \n349,369 \n171,074\nProvision for income taxes\n \n19,244 \n82,570 \n58,671\nNet income\n $\n122,641 $\n266,799 $\n112,403\nEarnings per share:\n \n \n \nBasic\n $\n0.29 $\n0.63 $\n0.28\nDiluted\n $\n0.28 $\n0.62 $\n0.26\nWeighted-average common shares outstanding:\n \n \n \nBasic\n \n425,889 \n420,544 \n407,385\nDiluted\n \n436,456 \n431,894 \n425,327\nSee accompanying notes to consolidated financial statements.\n38\n\n\nTable of Contents\nNETFLIX, INC.\nCONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n \n \nYear Ended December 31,\n \n \n2015\n \n2014\n \n2013\nCash flows from operating activities:\n \n \n \nNet income\n $\n122,641 $\n266,799 $\n112,403\nAdjustments to reconcile net income to net cash (used in) provided by operating activities:\n \n \n \nAdditions to streaming content assets\n \n(5,771,652) \n(3,773,019) \n(3,030,701)\nChange in streaming content liabilities\n \n1,162,413 \n593,125 \n673,785\nAmortization of streaming content assets\n \n3,405,382 \n2,656,279 \n2,121,981\nAmortization of DVD content assets\n \n79,380 \n71,491 \n71,325\nDepreciation and amortization of property, equipment and intangibles\n \n62,283 \n54,028 \n48,374\nStock-based compensation expense\n \n124,725 \n115,239 \n73,100\nExcess tax benefits from stock-based compensation\n \n(80,471) \n(89,341) \n(81,663)\nOther non-cash items\n \n31,628 \n15,282 \n5,332\nLoss on extinguishment of debt\n \n \n \n25,129\nDeferred taxes\n \n(58,655) \n(30,063) \n(22,044)\nChanges in operating assets and liabilities:\n \n \n \nOther current assets\n \n18,693 \n(9,198) \n43,177\nAccounts payable\n \n51,615 \n83,812 \n18,374\nAccrued expenses\n \n48,810 \n55,636 \n1,941\nDeferred revenue\n \n72,135 \n58,819 \n46,295\nOther non-current assets and liabilities\n \n(18,366) \n(52,406) \n(8,977)\nNet cash (used in) provided by operating activities\n \n(749,439) \n16,483 \n97,831\nCash flows from investing activities:\n \n \n \nAcquisition of DVD content assets\n \n(77,958) \n(74,790) \n(65,927)\nPurchases of property and equipment\n \n(91,248) \n(69,726) \n(54,143)\nOther assets\n \n(1,912) \n1,334 \n5,939\nPurchases of short-term investments\n \n(371,915) \n(426,934) \n(550,264)\nProceeds from sale of short-term investments\n \n259,079 \n385,300 \n347,502\nProceeds from maturities of short-term investments\n \n104,762 \n141,950 \n60,925\nNet cash used in investing activities\n \n(179,192) \n(42,866) \n(255,968)\nCash flows from financing activities:\n \n \n \nProceeds from issuance of common stock\n \n77,980 \n60,544 \n124,557\nProceeds from issuance of debt\n \n1,500,000 \n400,000 \n500,000\nIssuance costs\n \n(17,629) \n(7,080) \n(9,414)\nRedemption of debt\n \n \n \n(219,362)\nExcess tax benefits from stock-based compensation\n \n80,471 \n89,341 \n81,663\nPrincipal payments of lease financing obligations\n \n(545) \n(1,093) \n(1,180)\nNet cash provided by financing activities\n \n1,640,277 \n541,712 \n476,264\nEffect of exchange rate changes on cash and cash equivalents\n \n(15,924) \n(6,686) \n(3,453)\nNet increase in cash and cash equivalents\n \n695,722 \n508,643 \n314,674\nCash and cash equivalents, beginning of year\n \n1,113,608 \n604,965 \n290,291\nCash and cash equivalents, end of year\n $\n1,809,330 $\n1,113,608 $\n604,965\nSupplemental disclosure:\n \n \n \nIncome taxes paid\n $\n27,658 $\n50,573 $\n7,465\nInterest paid\n \n111,761 \n41,085 \n19,114\nInvesting activities included in liabilities\n \n18,824 \n23,802 \n11,508\nSee accompanying notes to consolidated financial statements.\n40\n [END OF FILING]",
    "gt": "5.4%",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: We need to calculate a reasonable approximation (or exact number if possible) of a financial metric. Basing your judgment by information plainly provided in the balance sheet and the P&L statement, what is Lockheed Martin's FY2020 asset turnover ratio? Asset turnover ratio is defined as: FY2020 revenue / (average total assets between FY2019 and FY2020). Round your answer to two decimal places. \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Table of Contents\nLockheed Martin Corporation\nConsolidated Statements of Earnings\n(in millions, except per share data)\n \n \nYears Ended December 31,\n2020\n2019\n2018\nNet sales\nProducts\n$\n54,928 \n$\n50,053 \n$\n45,005 \nServices\n10,470 \n9,759 \n8,757 \nTotal net sales\n65,398 \n59,812 \n53,762 \nCost of sales\nProducts\n(48,996)\n(44,589)\n(40,293)\nServices\n(9,371)\n(8,731)\n(7,738)\nSeverance charges\n(27)\n \n(96)\nOther unallocated, net\n1,650 \n1,875 \n1,639 \nTotal cost of sales\n(56,744)\n(51,445)\n(46,488)\nGross profit\n8,654 \n8,367 \n7,274 \nOther (expense) income, net\n(10)\n178 \n60 \nOperating profit\n8,644 \n8,545 \n7,334 \nInterest expense\n(591)\n(653)\n(668)\nOther non-operating income (expense), net\n182 \n(651)\n(828)\nEarnings from continuing operations before income taxes\n8,235 \n7,241 \n5,838 \nIncome tax expense\n(1,347)\n(1,011)\n(792)\nNet earnings from continuing operations\n6,888 \n6,230 \n5,046 \nNet loss from discontinued operations\n(55)\n \n \nNet earnings\n$\n6,833 \n$\n6,230 \n$\n5,046 \n \nEarnings (loss) per common share\nBasic\nContinuing operations\n$\n24.60 \n$\n22.09 \n$\n17.74 \nDiscontinued operations\n(0.20)\n \n \nBasic earnings per common share\n$\n24.40 \n$\n22.09 \n$\n17.74 \nDiluted\nContinuing operations\n$\n24.50 \n$\n21.95 \n$\n17.59 \nDiscontinued operations\n(0.20)\n \n \nDiluted earnings per common share\n$\n24.30 \n$\n21.95 \n$\n17.59 \nThe accompanying notes are an integral part of these consolidated financial statements.\n67\n\n\nTable of Contents\nLockheed Martin Corporation\nConsolidated Balance Sheets\n(in millions, except par value)\n \n \nDecember 31,\n2020\n2019\nAssets\nCurrent assets\nCash and cash equivalents\n$\n3,160 \n$\n1,514 \nReceivables, net\n1,978 \n2,337 \nContract assets\n9,545 \n9,094 \nInventories\n3,545 \n3,619 \nOther current assets\n1,150 \n531 \nTotal current assets\n19,378 \n17,095 \nProperty, plant and equipment, net\n7,213 \n6,591 \nGoodwill\n10,806 \n10,604 \nIntangible assets, net\n3,012 \n3,213 \nDeferred income taxes\n3,475 \n3,319 \nOther noncurrent assets\n6,826 \n6,706 \nTotal assets\n$\n50,710 \n$\n47,528 \nLiabilities and equity\nCurrent liabilities\nAccounts payable\n$\n880 \n$\n1,281 \nContract liabilities\n7,545 \n7,054 \nSalaries, benefits and payroll taxes\n3,163 \n2,466 \nCurrent maturities of long-term debt\n500 \n1,250 \nOther current liabilities\n1,845 \n1,921 \nTotal current liabilities\n13,933 \n13,972 \nLong-term debt, net\n11,669 \n11,404 \nAccrued pension liabilities\n12,874 \n13,234 \nOther noncurrent liabilities\n6,196 \n5,747 \nTotal liabilities\n44,672 \n44,357 \nStockholders equity\nCommon stock, $1 par value per share\n279 \n280 \nAdditional paid-in capital\n221 \n \nRetained earnings\n21,636 \n18,401 \nAccumulated other comprehensive loss\n(16,121)\n(15,554)\nTotal stockholders equity\n6,015 \n3,127 \nNoncontrolling interests in subsidiary\n23 \n44 \nTotal equity\n6,038 \n3,171 \nTotal liabilities and equity\n$\n50,710 \n$\n47,528 \nThe accompanying notes are an integral part of these consolidated financial statements.\n69\n [END OF FILING]",
    "gt": "1.33",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: What is the FY2017 - FY2019 3 year average of capex as a % of revenue for Activision Blizzard? Answer in units of percents and round to one decimal place. Calculate (or extract) the answer from the statement of income and the cash flow statement. \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Table of Contents\nACTIVISION BLIZZARD, INC. AND SUBSIDIARIES\nCONSOLIDATED STATEMENTS OF OPERATIONS\n(Amounts in millions, except per share data)\n \nFor the Years Ended December 31,\n \n2019\n \n2018\n \n2017\nNet revenues\n \n \n \n \nProduct sales\n$\n1,975\n $\n2,255 $\n2,110\nSubscription, licensing, and other revenues\n4,514\n \n5,245 \n4,907\nTotal net revenues\n6,489\n \n7,500 \n7,017\n \n \n \n \nCosts and expenses\n \n \n \n \nCost of revenuesproduct sales:\n \n \n \nProduct costs\n656\n \n719 \n733\nSoftware royalties, amortization, and intellectual property licenses\n240\n \n371 \n300\nCost of revenuessubscription, licensing, and other revenues:\n \n \n \nGame operations and distribution costs\n965\n \n1,028 \n984\nSoftware royalties, amortization, and intellectual property licenses\n233\n \n399 \n484\nProduct development\n998\n \n1,101 \n1,069\nSales and marketing\n926\n \n1,062 \n1,378\nGeneral and administrative\n732\n \n822 \n745\nRestructuring and related costs\n132\n \n10 \n15\nTotal costs and expenses\n4,882\n \n5,512 \n5,708\n \n \n \n \nOperating income\n1,607\n \n1,988 \n1,309\nInterest and other expense (income), net (Note 18)\n(26) \n71 \n146\nLoss on extinguishment of debt\n\n \n40 \n12\nIncome before income tax expense\n1,633\n \n1,877 \n1,151\nIncome tax expense\n130\n \n29 \n878\nNet income\n$\n1,503\n $\n1,848 $\n273\n \n \n \n \nEarnings per common share\n \n \n \n \nBasic\n$\n1.96\n $\n2.43 $\n0.36\nDiluted\n$\n1.95\n $\n2.40 $\n0.36\n \n \n \n \nWeighted-average number of shares outstanding\n \n \n \n \nBasic\n767\n \n762 \n754\nDiluted\n771\n \n771 \n766\nThe accompanying notes are an integral part of these Consolidated Financial Statements.\nF-5\n\n\nTable of Contents\nACTIVISION BLIZZARD, INC. AND SUBSIDIARIES\nCONSOLIDATED STATEMENTS OF CASH FLOWS\n(Amounts in millions)\n \nFor the Years Ended December 31,\n \n2019\n \n2018\n \n2017\nCash flows from operating activities:\n \n \n \n \n \nNet income\n$\n1,503\n $\n1,848\n $\n273\nAdjustments to reconcile net income to net cash provided by operating activities:\n \n \n \n \n \nDeferred income taxes\n(352) \n(35) \n(181)\nProvision for inventories\n6\n \n6\n \n33\nNon-cash operating lease cost\n64\n \n\n \n\nDepreciation and amortization\n328\n \n509\n \n888\nAmortization of capitalized software development costs and intellectual property licenses (1)\n225\n \n489\n \n311\nLoss on extinguishment of debt\n\n \n40\n \n12\nShare-based compensation expense (2)\n166\n \n209\n \n176\nUnrealized gain on equity investment (Note 10)\n(38) \n\n \n\nOther\n51\n \n7\n \n40\nChanges in operating assets and liabilities, net of effect from business acquisitions:\n \n \n \n \n \nAccounts receivable, net\n182\n \n(114) \n(165)\nInventories\n7\n \n(5) \n(26)\nSoftware development and intellectual property licenses\n(275) \n(372) \n(301)\nOther assets\n164\n \n(51) \n(97)\nDeferred revenues\n(154) \n(122) \n220\nAccounts payable\n31\n \n(65) \n85\nAccrued expenses and other liabilities\n(77) \n(554) \n945\nNet cash provided by operating activities\n1,831\n \n1,790\n \n2,213\nCash flows from investing activities:\n \n \n \n \n \nProceeds from maturities of available-for-sale investments\n153\n \n116\n \n80\nPurchases of available-for-sale investments\n(65) \n(209) \n(135)\nCapital expenditures\n(116) \n(131) \n(155)\nOther investing activities\n6\n \n(6) \n3\nNet cash used in investing activities\n(22) \n(230) \n(207)\nCash flows from financing activities:\n \n \n \n \n \nProceeds from issuance of common stock to employees\n105\n \n99\n \n178\nTax payment related to net share settlements on restricted stock units\n(59) \n(94) \n(56)\nDividends paid\n(283) \n(259) \n(226)\nProceeds from debt issuances, net of discounts\n\n \n\n \n3,741\nRepayment of long-term debt\n\n \n(1,740) \n(4,251)\nPremium payment for early redemption of note\n\n \n(25) \n\nOther financing activities\n\n \n(1) \n(10)\nNet cash used in financing activities\n(237) \n(2,020) \n(624)\nEffect of foreign exchange rate changes on cash and cash equivalents\n(3) \n(31) \n76\nNet increase (decrease) in cash and cash equivalents and restricted cash\n1,569\n \n(491) \n1,458\nCash and cash equivalents and restricted cash at beginning of period\n4,229\n \n4,720\n \n3,262\nCash and cash equivalents and restricted cash at end of period\n$\n5,798\n $\n4,229\n $\n4,720\n(1)\nExcludes deferral and amortization of share-based compensation expense.\n(2)\nIncludes the net effects of capitalization, deferral, and amortization of share-based compensation expense.\nThe accompanying notes are an integral part of these Consolidated Financial Statements.\nF-8\n [END OF FILING]",
    "gt": "1.9%",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: What is the FY2019 - FY2020 total revenue growth rate for Block (formerly known as Square)? Answer in units of percents and round to one decimal place. Approach the question asked by assuming the standpoint of an investment banking analyst who only has access to the statement of income. \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] SQUARE, INC.\nCONSOLIDATED STATEMENTS OF OPERATIONS\n(In thousands, except per share data)\nYear Ended December 31,\n2020\n2019\n2018\nRevenue:\nTransaction-basedrevenue\n$\n3,294,978\n$\n3,081,074\n$\n2,471,451\nSubscriptionandservices-basedrevenue\n1,539,403\n1,031,456\n591,706\nHardwarerevenue\n91,654\n84,505\n68,503\nBitcoinrevenue\n4,571,543\n516,465\n166,517\nTotalnetrevenue\n9,497,578\n4,713,500\n3,298,177\nCostofrevenue:\nTransaction-basedcosts\n1,911,848\n1,937,971\n1,558,562\nSubscriptionandservices-basedcosts\n222,712\n234,270\n169,884\nHardwarecosts\n143,901\n136,385\n94,114\nBitcoincosts\n4,474,534\n508,239\n164,827\nAmortizationofacquiredtechnology\n11,174\n6,950\n7,090\nTotalcostofrevenue\n6,764,169\n2,823,815\n1,994,477\nGrossprofit\n2,733,409\n1,889,685\n1,303,700\nOperatingexpenses:\nProductdevelopment\n881,826\n670,606\n497,479\nSalesandmarketing\n1,109,670\n624,832\n411,151\nGeneralandadministrative\n579,203\n436,250\n339,245\nTransactionandloanlosses\n177,670\n126,959\n88,077\nAmortizationofacquiredcustomerassets\n3,855\n4,481\n4,362\nTotaloperatingexpenses\n2,752,224\n1,863,128\n1,340,314\nOperatingincome(loss)\n(18,815)\n26,557\n(36,614)\nGainonsaleofassetgroup\n\n(373,445)\n\nInterestexpense,net\n56,943\n21,516\n17,982\nOtherexpense(income),net\n(291,725)\n273\n(18,469)\nIncome(loss)beforeincometax\n215,967\n378,213\n(36,127)\nProvisionforincometaxes\n2,862\n2,767\n2,326\nNetincome(loss)\n$\n213,105\n$\n375,446\n$\n(38,453)\nNetincome(loss)pershare:\nBasic\n$\n0.48\n$\n0.88\n$\n(0.09)\nDiluted\n$\n0.44\n$\n0.81\n$\n(0.09)\nWeighted-averagesharesusedtocomputenetincome(loss)pershare:\nBasic\n443,126\n424,999\n405,731\nDiluted\n482,167\n466,076\n405,731\nSeeaccompanyingnotestoconsolidatedfinancialstatements.\n85\n [END OF FILING]",
    "gt": "101.5%",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: What was the key agenda of the AMCOR's 8k filing dated 1st July 2022? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING]  \n \nItem 8.01\nOther Events.\n \nOn June 30, 2022, Amcor Finance (USA), Inc. (the Former Issuer) and Amcor Flexibles North America, Inc. (the Substitute Issuer),\neach a wholly-owned subsidiary of Amcor plc (the Company), entered into a (i) Second Supplemental Indenture (the Second Supplemental\nIndenture) with the Trustee (as defined below) with respect to the Indenture, dated as of April 28, 2016 (as amended and/or supplemented to\ndate, the 2016 Indenture and, together with the Second Supplemental Indenture, the 2016 Indenture), among the Former Issuer, the\nguarantors party thereto and Deutsche Bank Trust Company Americas, as trustee (the Trustee), governing the Former Issuers (a) 3.625%\nGuaranteed Senior Notes due 2026 (the 2026 Notes) and (b) 4.500% Guaranteed Senior Notes due 2028 (the 2028 Notes and, together with\nthe 2026 Notes, the Existing Notes) and (ii) First Supplemental Indenture (the First Supplemental Indenture and, together with the Second\nSupplemental Indenture, the Supplemental Indentures) with the Trustee with respect to the Indenture, dated as of June 13, 2019 (as amended\nand/or supplemented to date, the 2019 Indenture and, together with the First Supplemental Indenture, the 2019 Indenture and, together with\nthe 2016 Indenture, the Indentures), among the Former Issuer, the guarantors party thereto and the Trustee, governing the Former Issuers\n(a) 3.625% Guaranteed Senior Notes due 2026 (the New 2026 Notes) and (b) 4.500% Guaranteed Senior Notes due 2028 (the New 2028\nNotes and, together with the New 2026 Notes, the New Notes), in each case, relating to the substitution of the Substitute Issuer for the Former\nIssuer and the assumption by the Substitute Issuer of the covenants of the Former Issuer under the Indentures. As disclosed in the Companys\nCurrent Report on Form 8-K, filed with the Securities and Exchange Commission (the SEC) on June 17, 2019, the New Notes were issued in\nJune 2019 following the completion of the Former Issuers exchange offer to certain eligible holders of the Existing Notes.\n \nThe foregoing description of the Supplemental Indentures does not purport to be complete and is subject to, and qualified in its entirety\nby, the full text of the (i) 2016 Indenture, which was included as Exhibit 4.7 to the Companys Registration Statement on Form S-4 (File No. 333-\n230217), filed with the SEC on March 12, 2019 (the Registration Statement), including the supplemental indenture thereto, which was included\nas Exhibit 10.2 to the Companys Current Report on Form 8-K, filed with the SEC on June 17, 2019, (ii) form of 2026 Notes, which was included\nas Exhibit 4.8 to the Registration Statement, (iii) form of 2028 Notes, which was included as Exhibit 4.9 to the Registration Statement, (iv) 2019\nIndenture, which was included as Exhibit 10.4 to the Companys Current Report on Form 8-K, filed with the SEC on June 17, 2019, (v) Second\nSupplemental Indenture, which is included as Exhibit 4.6 hereto and incorporated herein by reference and (vi) First Supplemental Indenture,\nwhich is included as Exhibit 4.7 hereto and incorporated herein by reference.\n \nItem 9.01\nFinancial Statements and Exhibits.\n \nExhibit No. \nDescription\n4.1\n \nIndenture, dated as of April 28, 2016, among Amcor Finance (USA), Inc., Amcor Limited, Amcor UK Finance PLC and\nDeutsche Bank Trust Company Americas (incorporated by reference to Exhibit 4.7 to Amcor plcs Registration Statement on\nForm S-4 (File No. 333-230217), filed on March 12, 2019).\n4.2\n \nSupplemental Indenture, dated as of June 13, 2019, among Amcor Finance (USA), Inc., Amcor Limited, Amcor UK\nFinance PLC and Deutsche Bank Trust Company Americas (incorporated by reference to Exhibit 10.2 to Amcor plcs Current\nReport on Form 8-K, filed on June 17, 2019).\n4.3\n \nForm of 3.625% Guaranteed Senior Notes due 2026 (incorporated by reference to Exhibit 4.8 to Amcor plcs Registration\nStatement on Form S-4 (File No. 333-230217), filed on March 12, 2019).\n4.4\n \nForm of 4.500% Guaranteed Senior Notes due 2028 (incorporated by reference to Exhibit 4.9 to Amcor plcs Registration\nStatement on Form S-4 (File No. 333-230217), filed on March 12, 2019).\n4.5\n \nIndenture, dated as of June 13, 2019, among Amcor Finance (USA), Inc., Amcor plc, Amcor Limited, Amcor Flexibles North\nAmerica, Inc. (formerly known as Bemis Company, Inc.) and Amcor UK Finance PLC and Deutsche Bank Trust Company\nAmericas (incorporated by reference to Exhibit 10.4 to Amcor plcs Current Report on Form 8-K, filed on June 17, 2019).\n4.6\n \nSecond Supplemental Indenture, dated as of June 30, 2022, among Amcor Finance (USA), Inc., Amcor Flexibles North\nAmerica, Inc. and Deutsche Bank Trust Company Americas.\n4.7\n \nFirst Supplemental Indenture, dated as of June 30, 2022, among Amcor Finance (USA), Inc., Amcor Flexibles North\nAmerica, Inc. and Deutsche Bank Trust Company Americas.\n104\n \nCover Page Interactive Data File. The cover page XBRL tags are embedded within the inline XBRL document (contained in\nExhibit 101).\n \n \n [END OF FILING]",
    "gt": "Amcor Finance (USA), Inc. and Amcor Flexibles North America, Inc., entered into supplemental indentures relating to Guaranteed Senior Notes due 2026 and 2028. This involved the substitution of the Substitute Issuer (Amcor Flexibles North America) for the Former Issuer (Amcor Finance) and the assumption of covenants under the indentures. (In essence a novation agreement)",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: What is Lockheed Martin's 2 year total revenue CAGR from FY2020 to FY2022 (in units of percents and round to one decimal place)? Provide a response to the question by primarily using the statement of income. \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Lockheed Martin Corporation\nConsolidated Statements of Earnings\n(in millions, except per share data)\n \n \nYears Ended December 31,\n2022\n2021\n2020\nNet sales\nProducts\n$ \n55,466 $ \n56,435 $ \n54,928 \nServices\n \n10,518 \n10,609 \n10,470 \nTotal net sales\n \n65,984 \n67,044 \n65,398 \nCost of sales\nProducts\n \n(49,577) \n(50,273) \n(48,996) \nServices\n \n(9,280) \n(9,463) \n(9,371) \nSeverance and other charges\n \n(100) \n(36) \n(27) \nOther unallocated, net\n \n1,260 \n1,789 \n1,650 \nTotal cost of sales\n \n(57,697) \n(57,983) \n(56,744) \nGross profit\n \n8,287 \n9,061 \n8,654 \nOther income (expense), net\n \n61 \n62 \n(10) \nOperating profit\n \n8,348 \n9,123 \n8,644 \nInterest expense\n \n(623) \n(569) \n(591) \nNon-service FAS pension (expense) income\n \n(971) \n(1,292) \n219 \nOther non-operating (expense) income, net\n \n(74) \n288 \n(37) \nEarnings from continuing operations before income taxes\n \n6,680 \n7,550 \n8,235 \nIncome tax expense\n \n(948) \n(1,235) \n(1,347) \nNet earnings from continuing operations\n \n5,732 \n6,315 \n6,888 \nNet loss from discontinued operations\n \n \n \n(55) \nNet earnings\n$ \n5,732 $ \n6,315 $ \n6,833 \n \nEarnings (loss) per common share\nBasic\nContinuing operations\n$ \n21.74 $ \n22.85 $ \n24.60 \nDiscontinued operations\n \n \n \n(0.20) \nBasic earnings per common share\n$ \n21.74 $ \n22.85 $ \n24.40 \nDiluted\nContinuing operations\n$ \n21.66 $ \n22.76 $ \n24.50 \nDiscontinued operations\n \n \n \n(0.20) \nDiluted earnings per common share\n$ \n21.66 $ \n22.76 $ \n24.30 \nThe accompanying notes are an integral part of these consolidated financial statements.\nTable of Contents \n63\n [END OF FILING]",
    "gt": "0.4%",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: What was the largest liability in American Express's Balance Sheet in 2022? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Table of Contents\nCONSOLIDATED BALANCE SHEETS\nDecember 31 (Millions, except share data)\n2022\n2021\nAssets\nCash and cash equivalents\nCash and due from banks (includes restricted cash of consolidated variable interest entities: 2022, $5; 2021, $11)\n$\n5,510 \n$\n1,292 \nInterest-bearing deposits in other banks (includes securities purchased under resale agreements: 2022, $318; 2021, $463)\n28,097 \n20,548 \nShort-term investment securities (includes restricted investments of consolidated variable interest entities: 2022, $54; 2021, $32)\n307 \n188 \nTotal cash and cash equivalents\n33,914 \n22,028 \nCard Member receivables (includes gross receivables available to settle obligations of a consolidated variable interest entity: 2022, $5,193; 2021,\n$5,175), less reserves for credit losses: 2022, $229; 2021, $64\n57,384 \n53,581 \nCard Member loans (includes gross loans available to settle obligations of a consolidated variable interest entity: 2022, $28,461; 2021, $26,587),\nless reserves for credit losses: 2022, $3,747; 2021, $3,305\n104,217 \n85,257 \nOther loans, less reserves for credit losses: 2022, $59; 2021, $52\n5,357 \n2,859 \nInvestment securities\n4,578 \n2,591 \nPremises and equipment, less accumulated depreciation and amortization: 2022, $9,850; 2021, $8,602\n5,215 \n4,988 \nOther assets, less reserves for credit losses: 2022, $22; 2021, $25\n17,689 \n17,244 \nTotal assets\n$\n228,354 \n$\n188,548 \nLiabilities and Shareholders Equity\nLiabilities\nCustomer deposits\n$\n110,239 \n$\n84,382 \nAccounts payable\n12,133 \n10,574 \nShort-term borrowings\n1,348 \n2,243 \nLong-term debt (includes debt issued by consolidated variable interest entities: 2022, $12,662; 2021, $13,803)\n42,573 \n38,675 \nOther liabilities\n37,350 \n30,497 \nTotal liabilities\n$\n203,643 \n$\n166,371 \nContingencies and Commitments (Note 12)\nShareholders Equity\nPreferred shares, $1.66\n par value, authorized 20 million shares; issued and outstanding 1,600 shares as of December 31, 2022 and 2021 (Note\n16)\n \n \nCommon shares, $0.20 par value, authorized 3.6 billion shares; issued and outstanding 743 million shares as of December 31, 2022 and 761\nmillion shares as of December 31, 2021\n149 \n153 \nAdditional paid-in capital\n11,493 \n11,495 \nRetained earnings\n16,279 \n13,474 \nAccumulated other comprehensive income (loss)\n(3,210)\n(2,945)\nTotal shareholders equity\n24,711 \n22,177 \nTotal liabilities and shareholders equity\n$\n228,354 \n$\n188,548 \nSee Notes to Consolidated Financial Statements.\n2/3\n95\n [END OF FILING]",
    "gt": "Customer deposits",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: What is Amazon's FY2017 days payable outstanding (DPO)? DPO is defined as: 365 * (average accounts payable between FY2016 and FY2017) / (FY2017 COGS + change in inventory between FY2016 and FY2017). Round your answer to two decimal places. Address the question by using the line items and information shown within the balance sheet and the P&L statement. \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Table of Contents\nAMAZON.COM, INC.\nCONSOLIDATED STATEMENTS OF OPERATIONS\n(in millions, except per share data)\n \n \nYear Ended December 31,\n \n2015\n \n2016\n \n2017\nNet product sales\n$\n79,268 $\n94,665 $\n118,573\nNet service sales\n27,738 \n41,322 \n59,293\nTotal net sales\n107,006 \n135,987 \n177,866\nOperating expenses:\n \n \n \nCost of sales\n71,651 \n88,265 \n111,934\nFulfillment\n13,410 \n17,619 \n25,249\nMarketing\n5,254 \n7,233 \n10,069\nTechnology and content\n12,540 \n16,085 \n22,620\nGeneral and administrative\n1,747 \n2,432 \n3,674\nOther operating expense, net\n171 \n167 \n214\nTotal operating expenses\n104,773 \n131,801 \n173,760\nOperating income\n2,233 \n4,186 \n4,106\nInterest income\n50 \n100 \n202\nInterest expense\n(459) \n(484) \n(848)\nOther income (expense), net\n(256) \n90 \n346\nTotal non-operating income (expense)\n(665) \n(294) \n(300)\nIncome before income taxes\n1,568 \n3,892 \n3,806\nProvision for income taxes\n(950) \n(1,425) \n(769)\nEquity-method investment activity, net of tax\n(22) \n(96) \n(4)\nNet income\n$\n596 $\n2,371 $\n3,033\nBasic earnings per share\n$\n1.28 $\n5.01 $\n6.32\nDiluted earnings per share\n$\n1.25 $\n4.90 $\n6.15\nWeighted-average shares used in computation of earnings per share:\n \n \n \nBasic\n467 \n474 \n480\nDiluted\n477 \n484 \n493\nSee accompanying notes to consolidated financial statements.\n38\n\n\nTable of Contents\nAMAZON.COM, INC.\nCONSOLIDATED BALANCE SHEETS\n(in millions, except per share data)\n \n \nDecember 31,\n \n2016\n \n2017\nASSETS\n \n \nCurrent assets:\n \n \nCash and cash equivalents\n$\n19,334 $\n20,522\nMarketable securities\n6,647 \n10,464\nInventories\n11,461 \n16,047\nAccounts receivable, net and other\n8,339 \n13,164\nTotal current assets\n45,781 \n60,197\nProperty and equipment, net\n29,114 \n48,866\nGoodwill\n3,784 \n13,350\nOther assets\n4,723 \n8,897\nTotal assets\n$\n83,402 $\n131,310\nLIABILITIES AND STOCKHOLDERS EQUITY\n \n \nCurrent liabilities:\n \n \nAccounts payable\n$\n25,309 $\n34,616\nAccrued expenses and other\n13,739 \n18,170\nUnearned revenue\n4,768 \n5,097\nTotal current liabilities\n43,816 \n57,883\nLong-term debt\n7,694 \n24,743\nOther long-term liabilities\n12,607 \n20,975\nCommitments and contingencies (Note 7)\n \nStockholders equity:\n \n \nPreferred stock, $0.01 par value:\n \n \nAuthorized shares 500\n \n \nIssued and outstanding shares none\n \n\nCommon stock, $0.01 par value:\n \n \nAuthorized shares 5,000\n \n \nIssued shares 500 and 507\n \n \nOutstanding shares 477 and 484\n5 \n5\nTreasury stock, at cost\n(1,837) \n(1,837)\nAdditional paid-in capital\n17,186 \n21,389\nAccumulated other comprehensive loss\n(985) \n(484)\nRetained earnings\n4,916 \n8,636\nTotal stockholders equity\n19,285 \n27,709\nTotal liabilities and stockholders equity\n$\n83,402 $\n131,310\nSee accompanying notes to consolidated financial statements.\n40\n [END OF FILING]",
    "gt": "93.86",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: Is CVS Health a capital-intensive business based on FY2022 data? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Index to Consolidated Financial Statements\nConsolidated Statements of Operations\nFor the Years Ended December 31,\nIn millions, except per share amounts\n2022\n2021\n2020\nRevenues:\n \n \n \nProducts\n$\n226,616 $\n203,738 $\n190,688 \nPremiums\n85,330 \n76,132 \n69,364 \nServices\n9,683 \n11,042 \n7,856 \nNet investment income\n838 \n1,199 \n798 \nTotal revenues\n322,467 \n292,111 \n268,706 \nOperating costs:\nCost of products sold\n196,892 \n175,803 \n163,981 \nBenefit costs\n71,281 \n64,260 \n55,679 \nOpioid litigation charges\n5,803 \n \n \nLoss on assets held for sale\n2,533 \n \n \nStore impairments\n \n1,358 \n \nGoodwill impairment\n \n431 \n \nOperating expenses\n38,212 \n37,066 \n35,135 \nTotal operating costs\n314,721 \n278,918 \n254,795 \nOperating income\n7,746 \n13,193 \n13,911 \nInterest expense\n2,287 \n2,503 \n2,907 \nLoss on early extinguishment of debt\n \n452 \n1,440 \nOther income\n(169)\n(182)\n(206)\nIncome before income tax provision\n5,628 \n10,420 \n9,770 \nIncome tax provision\n1,463 \n2,522 \n2,569 \nIncome from continuing operations\n4,165 \n7,898 \n7,201 \nLoss from discontinued operations, net of tax\n \n \n(9)\nNet income\n4,165 \n7,898 \n7,192 \nNet (income) loss attributable to noncontrolling interests\n(16)\n12 \n(13)\nNet income attributable to CVS Health\n$\n4,149 $\n7,910 $\n7,179 \nBasic earnings per share:\nIncome from continuing operations attributable to CVS Health\n$\n3.16 $\n6.00 $\n5.49 \nLoss from discontinued operations attributable to CVS Health\n$\n $\n $\n(0.01)\nNet income attributable to CVS Health\n$\n3.16 $\n6.00 $\n5.48 \nWeighted average basic shares outstanding\n1,312 \n1,319 \n1,309 \nDiluted earnings per share:\nIncome from continuing operations attributable to CVS Health\n$\n3.14 $\n5.95 $\n5.47 \nLoss from discontinued operations attributable to CVS Health\n$\n $\n $\n(0.01)\nNet income attributable to CVS Health\n$\n3.14 $\n5.95 $\n5.46 \nWeighted average diluted shares outstanding\n1,323 \n1,329 \n1,314 \nDividends declared per share\n$\n2.20 $\n2.00 $\n2.00 \nSee accompanying notes to consolidated financial statements.\n106\n\n\nIndex to Consolidated Financial Statements\nConsolidated Balance Sheets\nAt December 31,\nIn millions, except per share amounts\n2022\n2021\nAssets:\n \nCash and cash equivalents\n$\n12,945 $\n9,408 \nInvestments\n2,778 \n3,117 \nAccounts receivable, net\n27,276 \n24,431 \nInventories\n19,090 \n17,760 \nAssets held for sale\n908 \n \nOther current assets\n2,685 \n5,292 \nTotal current assets\n65,682 \n60,008 \nLong-term investments\n21,096 \n23,025 \nProperty and equipment, net\n12,873 \n12,896 \nOperating lease right-of-use assets\n17,872 \n19,122 \nGoodwill\n78,150 \n79,121 \nIntangible assets, net\n24,754 \n29,026 \nSeparate accounts assets\n3,228 \n5,087 \nOther assets\n4,620 \n4,714 \nTotal assets\n$\n228,275 $\n232,999 \nLiabilities:\nAccounts payable\n$\n14,838 $\n12,544 \nPharmacy claims and discounts payable\n19,423 \n17,330 \nHealth care costs payable\n10,406 \n8,808 \nPolicyholders funds\n1,500 \n4,301 \nAccrued expenses\n18,745 \n17,670 \nOther insurance liabilities\n1,140 \n1,303 \nCurrent portion of operating lease liabilities\n1,678 \n1,646 \nCurrent portion of long-term debt\n1,778 \n4,205 \nLiabilities held for sale\n228 \n \nTotal current liabilities\n69,736 \n67,807 \nLong-term operating lease liabilities\n16,800 \n18,177 \nLong-term debt\n50,476 \n51,971 \nDeferred income taxes\n3,880 \n6,270 \nSeparate accounts liabilities\n3,228 \n5,087 \nOther long-term insurance liabilities\n6,108 \n6,402 \nOther long-term liabilities\n6,732 \n1,904 \nTotal liabilities\n156,960 \n157,618 \nCommitments and contingencies (Note 16)\nShareholders equity:\nPreferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding\n \n \nCommon stock, par value $0.01: 3,200 shares authorized; 1,758 shares issued and 1,300 shares outstanding at\nDecember 31, 2022 and 1,744 shares issued and 1,322 shares outstanding at December 31, 2021 and capital\nsurplus\n48,193 \n47,377 \nTreasury stock, at cost: 458 and 422 shares at December 31, 2022 and 2021\n(31,858)\n(28,173)\nRetained earnings\n56,145 \n54,906 \nAccumulated other comprehensive income (loss)\n(1,465)\n965 \nTotal CVS Health shareholders equity\n71,015 \n75,075 \nNoncontrolling interests\n300 \n306 \nTotal shareholders equity\n71,315 \n75,381 \nTotal liabilities and shareholders equity\n$\n228,275 $\n232,999 \nSee accompanying notes to consolidated financial statements.\n108\n [END OF FILING]",
    "gt": "Yes, CVS Health requires an extensive asset base to operate, which is evident from its ROA of only 1.82% in 2022 and 3.39% in 2021, though it should be noted that a significant portion of this asset base is goodwill, and CVS's fixed assets/total assets ratio is on the lower side of 5.6%.",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: Who are the primary customers of Boeing as of FY2022? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Table of Contents\nForward-looking statements are based on expectations and assumptions that we believe to be reasonable when made, but that may not prove to\nbe accurate. These statements are not guarantees and are subject to risks, uncertainties and changes in circumstances that are difficult to\npredict. Many factors, including those set forth in the Risk Factors section below and other important factors disclosed in this report and from\ntime to time in our other filings with the SEC, could cause actual results to differ materially and adversely from these forward-looking statements.\nAny forward-looking statement speaks only as of the date on which it is made, and we assume no obligation to update or revise any forward-\nlooking statement whether as a result of new information, future events or otherwise, except as required by law.\nItem 1A. Risk Factors\nAn investment in our common stock or debt securities involves risks and uncertainties and our actual results and future trends may differ\nmaterially from our past or projected future performance. We urge investors to consider carefully the risk factors described below in evaluating\nthe information contained in this report.\nRisks Related to Our Business and Operations\nWe depend heavily on commercial airlines, subjecting us to unique risks.\nMarket conditions have a significant impact on demand for our commercial aircraft and related services. The commercial aircraft market is\npredominantly driven by long-term trends in airline passenger and cargo traffic. The principal factors underlying long-term traffic growth are\nsustained economic growth and political stability both in developed and emerging markets. Demand for our commercial aircraft is further\ninfluenced by airline profitability, availability of aircraft financing, world trade policies, government-to-government relations, technological\nadvances, price and other competitive factors, fuel prices, terrorism, pandemics, epidemics and environmental regulations. Historically, the\nairline industry has been cyclical and very competitive and has experienced significant profit swings and constant challenges to be more cost\ncompetitive. Significant deterioration in the global economic environment, the airline industry generally or the financial stability of one or more of\nour major customers could result in fewer new orders for aircraft or services, or could cause customers to seek to postpone or cancel contractual\norders and/or payments to us, which could result in lower revenues, profitability and cash flows and a reduction in our contractual backlog. In\naddition, because our commercial aircraft backlog consists of aircraft scheduled for delivery over a period of several years, any of these\nmacroeconomic, industry or customer impacts could unexpectedly affect deliveries over a long period.\nWe enter into firm fixed-price aircraft sales contracts with indexed price escalation clauses, which could subject us to losses if we have cost\noverruns or if increases in our costs exceed the applicable escalation rate. Commercial aircraft sales contracts are often entered into years\nbefore the aircraft are delivered. In order to help account for economic fluctuations between the contract date and delivery date, aircraft pricing\ngenerally consists of a fixed amount as modified by price escalation formulas derived from labor, commodity and other price indices. Our\nrevenue estimates are based on current expectations with respect to these escalation formulas, but the actual escalation amounts are outside of\nour control. Escalation factors can fluctuate significantly from period to period. Changes in escalation amounts can significantly impact revenues\nand operating margins in our Commercial Airplanes business.\nWe derive a significant portion of our revenues from a limited number of commercial airlines. We can make no assurance that any customer will\nexercise purchase options, fulfill existing purchase commitments or purchase additional products or services from us. In addition, fleet decisions,\nairline consolidations or financial challenges involving any of our major commercial airline customers could significantly reduce our revenues and\nlimit our opportunity to generate profits from those customers.\n6\n\n\nTable of Contents\ncommercial aircraft assembly facilities are delayed or create significant disruption to our production system, or if our suppliers cannot timely\ndeliver components to us at the cost and rates necessary to achieve our targets, we may be unable to meet delivery schedules and/or the\nfinancial performance of one or more of our programs may suffer.\nOperational challenges impacting the production system for one or more of our commercial aircraft programs could result in additional production\ndelays and/or failure to meet customer demand for new aircraft, either of which would negatively impact our revenues and operating margins.\nOur commercial aircraft production system is extremely complex. Operational issues, including delays or defects in supplier components, failure\nto meet internal performance plans, or delays or failures to achieve required regulatory approval, could result in additional out-of-sequence work\nand increased production costs, as well as delayed deliveries to customers, impacts to aircraft performance and/or increased warranty or fleet\nsupport costs. We and our suppliers are experiencing supply chain disruptions as a result of the lingering impacts of COVID-19, global supply\nchain constraints, and labor instability. We and our suppliers are also experiencing inflationary pressures. We continue to monitor the health and\nstability of the supply chain as we ramp up production. These factors have reduced overall productivity and adversely impacted our financial\nposition, results of operations and cash flows.\nIf our commercial aircraft fail to satisfy performance and reliability requirements and/or potentially required sustainability standards, we could\nface additional costs and/or lower revenues. Developing and manufacturing commercial aircraft that meet or exceed our performance and\nreliability standards and/or potentially required sustainability standards, as well as those of customers and regulatory agencies, can be costly\nand technologically challenging. These challenges are particularly significant with newer aircraft programs. Any failure of any Boeing aircraft to\nsatisfy performance or reliability requirements could result in disruption to our operations, higher costs and/or lower revenues.\nChanges in levels of U.S. government defense spending or acquisition priorities could negatively impact our financial position and\nresults of operations.\nWe derive a substantial portion of our revenue from the U.S. government, primarily from defense related programs with the United States\nDepartment of Defense (U.S. DoD). Levels of U.S. defense spending are very difficult to predict and may be impacted by numerous factors such\nas the evolving nature of the national security threat environment, U.S. national security strategy, U.S. foreign policy, the domestic political\nenvironment, macroeconomic conditions and the ability of the U.S. government to enact relevant legislation such as authorization and\nappropriations bills.\nThe timeliness of FY24 and future appropriations for government departments and agencies remains a recurrent risk. A lapse in appropriations\nfor government departments or agencies would result in a full or partial government shutdown, which could impact the Companys operations.\nAlternatively, Congress may fund government departments and agencies with one or more Continuing Resolutions; however, this would restrict\nthe execution of certain program activities and delay new programs or competitions. In addition, long-term uncertainty remains with respect to\noverall levels of defense spending in FY24 and beyond. U.S. government discretionary spending, including defense spending, is likely to\ncontinue to be subject to pressure.\nThere continues to be uncertainty with respect to future acquisition priorities and program-level appropriations for the U.S. DoD and other\ngovernment agencies (including NASA), including changes to national security and defense priorities, and tension between modernization\ninvestments, sustainment investments, and investments in new technologies or emergent capabilities. Future investment priority changes or\nbudget cuts, including changes associated with the authorizations and appropriations process, could result in reductions, cancellations, and/or\ndelays of existing contracts or programs, or future program opportunities. Any of these impacts could have a material effect on the results of the\nCompanys financial position, results of operations and/or cash flows.\n8\n\n\nTable of Contents\nguarantees, partner performance and indemnifications. Consolidations of joint ventures could also impact our reported results of operations or\nfinancial position. While we believe that we have established appropriate and adequate procedures and processes to mitigate these risks, there\nis no assurance that these transactions will be successful. We also may make strategic divestitures from time to time. These transactions may\nresult in continued financial involvement in the divested businesses, such as through guarantees or other financial arrangements, following the\ntransaction. Nonperformance by those divested businesses could affect our future financial results through additional payment obligations,\nhigher costs or asset write-downs.\nRisks Related to Our Contracts\nWe conduct a significant portion of our business pursuant to U.S. government contracts, which are subject to unique risks.\nIn 2022, 40% of our revenues were earned pursuant to U.S. government contracts, which include FMS through the U.S. government. Business\nconducted pursuant to such contracts is subject to extensive procurement regulations and other unique risks.\nOur sales to the U.S. government are subject to extensive procurement regulations, and changes to those regulations could increase our costs.\nNew procurement regulations or climate or cyber-related contractual disclosures, or changes to existing requirements, could increase our\ncompliance costs or otherwise have a material impact on the operating margins of our BDS and BGS businesses. These requirements may also\nresult in withheld payments and/or reduced future business if we fail to comply. For example, proposals to raise domestic content thresholds for\nour U.S. government contracts could have negative impacts on our business. Compliance costs attributable to current and potential future\nprocurement regulations such as these could negatively impact our financial position, results of operations and/or cash flows.\nThe U.S. government may modify, curtail or terminate one or more of our contracts. The U.S. government contracting party may modify, curtail or\nterminate its contracts and subcontracts with us, without prior notice and either at its convenience or for default based on performance. In\naddition, funding pursuant to our U.S. government contracts may be reduced or withheld as part of the U.S. Congressional appropriations\nprocess due to fiscal constraints, changes in U.S. national security strategy and/or priorities or other reasons. Further uncertainty with respect to\nongoing programs could also result in the event that the U.S. government finances its operations through temporary funding measures such as\ncontinuing resolutions rather than full-year appropriations. Any loss or anticipated loss or reduction of expected funding and/or modification,\ncurtailment or termination of one or more large programs could have a material adverse effect on our financial position, results of operations\nand/or cash flows.\nWe are subject to U.S. government inquiries and investigations, including periodic audits of costs that we determine are reimbursable under U.S.\ngovernment contracts. U.S. government agencies, including the Defense Contract Audit Agency and the Defense Contract Management Agency,\nroutinely audit government contractors. These agencies review our performance under contracts, cost structure and compliance with applicable\nlaws, regulations and standards, as well as the adequacy of and our compliance with our internal control systems and policies. Any costs found\nto be misclassified or inaccurately allocated to a specific contract will be deemed non-reimbursable, and to the extent already reimbursed, must\nbe refunded. Any inadequacies in our systems and policies could result in withholds on billed receivables, penalties and reduced future business.\nFurthermore, if any audit, inquiry or investigation uncovers improper or illegal activities, we could be subject to civil and criminal penalties and\nadministrative sanctions, including termination of contracts, forfeiture of profits, suspension of payments, fines and suspension or debarment\nfrom doing business with the U.S. government. We also\n12\n [END OF FILING]",
    "gt": "Boeing's primary customers as of FY2022 are a limited number of commercial airlines and the US government. The US government accounted for 40% of Boeing's total revenues in FY2022.",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: Does American Water Works have positive working capital based on FY2022 data? If working capital is not a useful or relevant metric for this company, then please state that and explain why. \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Table of Contents\nAmerican Water Works Company, Inc. and Subsidiary Companies\nConsolidated Balance Sheets\n(In millions, except share and per share data)\nDecember 31, 2022\nDecember 31, 2021\nASSETS\nProperty, plant and equipment\n$\n29,736 \n$\n27,413 \nAccumulated depreciation\n(6,513)\n(6,329)\nProperty, plant and equipment, net\n23,223 \n21,084 \nCurrent assets:\n \n \nCash and cash equivalents\n85 \n116 \nRestricted funds\n32 \n20 \nAccounts receivable, net of allowance for uncollectible accounts of $60 and $75, respectively\n334 \n271 \nIncome tax receivable\n114 \n4 \nUnbilled revenues\n275 \n248 \nMaterials and supplies\n98 \n57 \nAssets held for sale\n \n683 \nOther\n312 \n155 \nTotal current assets\n1,250 \n1,554 \nRegulatory and other long-term assets:\n \n \nRegulatory assets\n990 \n1,051 \nSeller promissory note from the sale of the Homeowner Services Group\n720 \n720 \nOperating lease right-of-use assets\n82 \n92 \nGoodwill\n1,143 \n1,139 \nPostretirement benefit assets\n \n193 \nOther\n379 \n242 \nTotal regulatory and other long-term assets\n3,314 \n3,437 \nTotal assets\n$\n27,787 \n$\n26,075 \nThe accompanying notes are an integral part of these Consolidated Financial Statements.\n79\n\n\nTable of Contents\nAmerican Water Works Company, Inc. and Subsidiary Companies\nConsolidated Balance Sheets\n(In millions, except share and per share data)\nDecember 31, 2022\nDecember 31, 2021\nCAPITALIZATION AND LIABILITIES\nCapitalization:\n \n \nCommon stock ($0.01 par value; 500,000,000 shares authorized; 187,200,539 and 186,880,413 shares\nissued, respectively)\n$\n2 \n$\n2 \nPaid-in-capital\n6,824 \n6,781 \nRetained earnings\n1,267 \n925 \nAccumulated other comprehensive loss\n(23)\n(45)\nTreasury stock, at cost (5,342,477 and 5,269,324 shares, respectively)\n(377)\n(365)\nTotal common shareholders' equity\n7,693 \n7,298 \nLong-term debt\n10,926 \n10,341 \nRedeemable preferred stock at redemption value\n3 \n3 \nTotal long-term debt\n10,929 \n10,344 \nTotal capitalization\n18,622 \n17,642 \nCurrent liabilities:\n \n \nShort-term debt\n1,175 \n584 \nCurrent portion of long-term debt\n281 \n57 \nAccounts payable\n254 \n235 \nAccrued liabilities\n706 \n701 \nAccrued taxes\n49 \n176 \nAccrued interest\n91 \n88 \nLiabilities related to assets held for sale\n \n83 \nOther\n255 \n217 \nTotal current liabilities\n2,811 \n2,141 \nRegulatory and other long-term liabilities:\n \n \nAdvances for construction\n316 \n284 \nDeferred income taxes and investment tax credits\n2,437 \n2,421 \nRegulatory liabilities\n1,590 \n1,600 \nOperating lease liabilities\n70 \n80 \nAccrued pension expense\n235 \n285 \nOther\n202 \n180 \nTotal regulatory and other long-term liabilities\n4,850 \n4,850 \nContributions in aid of construction\n1,504 \n1,442 \nCommitments and contingencies (See Note 16)\nTotal capitalization and liabilities\n$\n27,787 \n$\n26,075 \nThe accompanying notes are an integral part of these Consolidated Financial Statements. \n80\n [END OF FILING]",
    "gt": "No, American Water Works had negative working capital of -$1561M in FY 2022.",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: Has Microsoft increased its debt on balance sheet between FY2023 and the FY2022 period? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] PART II\nItem 8\n \nBALANCE SHEETS \n \n(In millions)\n \n \n \n \n \n \n \n \n \nJune 30,\n \n2023 \n2022 \n \n \n \nAssets\n \n \n \nCurrent assets:\n \n \n \nCash and cash equivalents\n $\n34,704 $\n13,931 \nShort-term investments\n \n76,558 \n90,826 \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nTotal cash, cash equivalents, and short-term investments\n \n111,262 \n104,757 \nAccounts receivable, net of allowance for doubtful accounts of $650 and $633\n \n48,688 \n44,261 \nInventories\n \n2,500 \n3,742 \nOther current assets\n \n21,807 \n16,924 \n \n \n \n \n \n \n \n \n \n \n \n \nTotal current assets\n \n184,257 \n169,684 \nProperty and equipment, net of accumulated depreciation of $68,251 and $59,660\n \n95,641 \n74,398 \nOperating lease right-of-use assets\n \n14,346 \n13,148 \nEquity investments\n \n9,879 \n6,891 \nGoodwill\n \n67,886 \n67,524 \nIntangible assets, net\n \n9,366 \n11,298 \nOther long-term assets\n \n30,601 \n21,897 \n \n \n \n \n \n \n \n \n \n \n \n \nTotal assets\n $\n411,976 $\n364,840 \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nLiabilities and stockholders equity\n \n \n \nCurrent liabilities:\n \n \n \nAccounts payable\n $\n18,095 $\n19,000 \nCurrent portion of long-term debt\n \n5,247 \n2,749 \nAccrued compensation\n \n11,009 \n10,661 \nShort-term income taxes\n \n4,152 \n4,067 \nShort-term unearned revenue\n \n50,901 \n45,538 \nOther current liabilities\n \n14,745 \n13,067 \n \n \n \n \n \n \n \n \n \n \n \n \nTotal current liabilities\n \n104,149 \n95,082 \nLong-term debt\n \n41,990 \n47,032 \nLong-term income taxes\n \n25,560 \n26,069 \nLong-term unearned revenue\n \n2,912 \n2,870 \nDeferred income taxes\n \n433 \n230 \nOperating lease liabilities\n \n12,728 \n11,489 \nOther long-term liabilities\n \n17,981 \n15,526 \n \n \n \n \n \n \n \n \n \n \n \n \nTotal liabilities\n \n205,753 \n198,298 \n \n \n \n \n \n \n \n \n \n \n \n \nCommitments and contingencies\n \n \n \nStockholders equity:\n \n \n \nCommon stock and paid-in capital shares authorized 24,000; outstanding 7,432 and 7,464\n \n93,718 \n86,939 \nRetained earnings\n \n118,848 \n84,281 \nAccumulated other comprehensive loss\n \n(6,343) \n(4,678)\n \n \n \n \n \n \n \n \n \n \n \n \nTotal stockholders equity\n \n206,223 \n166,542 \n \n \n \n \n \n \n \n \n \n \n \n \nTotal liabilities and stockholders equity\n $\n411,976 $\n364,840 \n \n \n \n \n \n \n \n \n \n \nRefer to accompanying notes. \n60\n [END OF FILING]",
    "gt": "No. Microsoft decreased its debt by $2.5bn in FY 2023 vs FY 2022.",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: Based on the information provided primarily in the statement of income, what is the FY2018 - FY2019 change in unadjusted operating income % margin for Walmart? Answer in units of percents and round to one decimal place. \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] WalmartInc.\nConsolidatedStatementsofIncome\n \n \nFiscalYearsEndedJanuary31,\n(Amounts in millions, except per share data)\n \n2019\n \n2018\n \n2017\nRevenues:\n \n \n \nNet sales\n $\n510,329\n $\n495,761\n $\n481,317\nMembership and other income\n \n4,076\n \n4,582\n \n4,556\nTotal revenues\n \n514,405\n \n500,343\n \n485,873\nCostsandexpenses:\n \n \n \nCost of sales\n \n385,301\n \n373,396\n \n361,256\nOperating, selling, general and administrative expenses\n \n107,147\n \n106,510\n \n101,853\nOperatingincome\n \n21,957\n \n20,437\n \n22,764\nInterest:\n \n \n \nDebt\n \n1,975\n \n1,978\n \n2,044\nCapital lease and financing obligations\n \n371\n \n352\n \n323\nInterest income\n \n(217) \n(152) \n(100)\nInterest, net\n \n2,129\n \n2,178\n \n2,267\nLoss on extinguishment of debt\n \n\n \n3,136\n \n\nOther (gains) and losses\n \n8,368\n \n\n \n\nIncomebeforeincometaxes\n \n11,460\n \n15,123\n \n20,497\nProvision for income taxes\n \n4,281\n \n4,600\n \n6,204\nConsolidatednetincome\n \n7,179\n \n10,523\n \n14,293\nConsolidatednetincomeattributabletononcontrollinginterest\n \n(509) \n(661) \n(650)\nConsolidatednetincomeattributabletoWalmart\n $\n6,670\n $\n9,862\n $\n13,643\n \n \n \n \nNetincomepercommonshare:\n \n \n \nBasicnetincomepercommonshareattributabletoWalmart\n $\n2.28\n $\n3.29\n $\n4.40\nDilutednetincomepercommonshareattributabletoWalmart\n \n2.26\n \n3.28\n \n4.38\n \n \n \n \nWeighted-averagecommonsharesoutstanding:\n \n \n \nBasic\n \n2,929\n \n2,995\n \n3,101\nDiluted\n \n2,945\n \n3,010\n \n3,112\n \n \n \n \nDividendsdeclaredpercommonshare\n $\n2.08\n $\n2.04\n $\n2.00\nSee accompanying notes.\n48\n [END OF FILING]",
    "gt": "0.2%",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: Basing your judgments off of the balance sheet, what is the year end FY2018 amount of accounts payable for MGM Resorts? Answer in USD millions. \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING]  \nMGMRESORTSINTERNATIONALANDSUBSIDIARIES\nCONSOLIDATEDBALANCESHEETS\n(Inthousands,exceptsharedata)\n \n \n\nDecember31,\n\n\n\n2018\n\n\n2017\n\nASSETS\n\nCurrentassets\n \n \n \n \nCash and cash equivalents\n $\n1,526,762 \n $\n1,499,995 \nAccounts receivable, net\n \n657,206 \n \n542,273 \nInventories\n \n110,831 \n \n102,292 \nIncome tax receivable\n \n28,431 \n \n42,551 \nPrepaid expenses and other\n \n203,548 \n \n189,244 \nTotal current assets\n \n2,526,778 \n \n2,376,355 \n \n \n \n \n \nPropertyandequipment,net\n \n20,729,888 \n \n19,635,459 \n \n \n \n \n \nOtherassets\n \n \n \n \nInvestments in and advances to unconsolidated affiliates\n \n732,867 \n \n1,033,297 \nGoodwill\n \n1,821,392 \n \n1,806,531 \nOther intangible assets, net\n \n3,944,463 \n \n3,877,960 \nOther long-term assets, net\n \n455,318 \n \n430,440 \nTotal other assets\n \n6,954,040 \n \n7,148,228 \n \n $\n30,210,706 \n $\n29,160,042 \nLIABILITIESANDSTOCKHOLDERS'EQUITY\n\nCurrentliabilities\n \n \n \n \nAccounts payable\n $\n302,578 \n $\n255,028 \nConstruction payable\n \n311,793 \n \n474,807 \nCurrent portion of long-term debt\n \n43,411 \n \n158,042 \nAccrued interest on long-term debt\n \n140,046 \n \n135,785 \nOther accrued liabilities\n \n2,151,054 \n \n2,114,635 \nTotal current liabilities\n \n2,948,882 \n \n3,138,297 \n \n \n \n \n \nDeferredincometaxes,net\n \n1,342,538 \n \n1,295,375 \nLong-termdebt,net\n \n15,088,005 \n \n12,751,052 \nOtherlong-termobligations\n \n259,240 \n \n284,416 \nCommitmentsandcontingencies(Note11)\n \n \n \n \nRedeemablenoncontrollinginterests\n \n102,250 \n \n79,778 \nStockholders'equity\n \n \n \n \nCommon stock, $.01 par value: authorized 1,000,000,000 shares, issued and\n outstanding 527,479,528 and 566,275,789 shares\n \n5,275 \n \n5,663 \nCapital in excess of par value\n \n4,092,085 \n \n5,357,709 \nRetained earnings\n \n2,423,479 \n \n2,217,299 \nAccumulated other comprehensive loss\n \n(8,556)\n \n(3,610)\nTotal MGM Resorts International stockholders' equity\n \n6,512,283 \n \n7,577,061 \nNoncontrolling interests\n \n3,957,508 \n \n4,034,063 \nTotal stockholders' equity\n \n10,469,791 \n \n11,611,124 \n \n $\n30,210,706 \n $\n29,160,042\n \n \nTheaccompanyingnotesareanintegralpartoftheseconsolidatedfinancialstatements.\n \n \n55\n [END OF FILING]",
    "gt": "$303.00",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: What is FY2018 days payable outstanding (DPO) for Walmart? DPO is defined as: 365 * (average accounts payable between FY2017 and FY2018) / (FY2018 COGS + change in inventory between FY2017 and FY2018). Round your answer to two decimal places. Please base your judgments on the information provided primarily in the statement of financial position and the P&L statement. \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Walmart Inc.\nConsolidated Statements of Income\n \n \nFiscal Years Ended January 31,\n(Amounts in millions, except per share data)\n \n2018\n \n2017\n \n2016\nRevenues:\n \n \n \nNet sales\n $\n495,761\n $\n481,317 $\n478,614\nMembership and other income\n \n4,582\n \n4,556 \n3,516\nTotal revenues\n \n500,343\n \n485,873 \n482,130\nCosts and expenses:\n \n \n \nCost of sales\n \n373,396\n \n361,256 \n360,984\nOperating, selling, general and administrative expenses\n \n106,510\n \n101,853 \n97,041\nOperating income\n \n20,437\n \n22,764 \n24,105\nInterest:\n \n \n \nDebt\n \n1,978\n \n2,044 \n2,027\nCapital lease and financing obligations\n \n352\n \n323 \n521\nInterest income\n \n(152) \n(100) \n(81)\nInterest, net\n \n2,178\n \n2,267 \n2,467\nLoss on extinguishment of debt\n \n3,136\n \n \n\nIncome before income taxes\n \n15,123\n \n20,497 \n21,638\nProvision for income taxes\n \n4,600\n \n6,204 \n6,558\nConsolidated net income\n \n10,523\n \n14,293 \n15,080\nConsolidated net income attributable to noncontrolling interest\n \n(661) \n(650) \n(386)\nConsolidated net income attributable to Walmart\n $\n9,862\n $\n13,643 $\n14,694\n \n \n \n \nNet income per common share:\n \n \n \nBasic net income per common share attributable to Walmart\n $\n3.29\n $\n4.40 $\n4.58\nDiluted net income per common share attributable to Walmart\n \n3.28\n \n4.38 \n4.57\n \n \n \n \nWeighted-average common shares outstanding:\n \n \n \nBasic\n \n2,995\n \n3,101 \n3,207\nDiluted\n \n3,010\n \n3,112 \n3,217\n \n \n \n \nDividends declared per common share\n $\n2.04\n $\n2.00 $\n1.96\nSee accompanying notes.\n55\n\n\nWalmart Inc.\nConsolidated Balance Sheets\n \n \nAs of January 31,\n(Amounts in millions)\n \n2018\n \n2017\nASSETS\n \n \nCurrent assets:\n \n \nCash and cash equivalents\n $\n6,756\n $\n6,867\nReceivables, net\n \n5,614\n \n5,835\nInventories\n \n43,783\n \n43,046\nPrepaid expenses and other\n \n3,511\n \n1,941\nTotal current assets\n \n59,664\n \n57,689\nProperty and equipment:\n \n \nProperty and equipment\n \n185,154\n \n179,492\nLess accumulated depreciation\n \n(77,479) \n(71,782)\nProperty and equipment, net\n \n107,675\n \n107,710\nProperty under capital lease and financing obligations:\n \n \nProperty under capital lease and financing obligations\n \n12,703\n \n11,637\nLess accumulated amortization\n \n(5,560) \n(5,169)\nProperty under capital lease and financing obligations, net\n \n7,143\n \n6,468\n \n \n \nGoodwill\n \n18,242\n \n17,037\nOther assets and deferred charges\n \n11,798\n \n9,921\nTotal assets\n $\n204,522\n $\n198,825\n \n \n \nLIABILITIES AND EQUITY\n \n \nCurrent liabilities:\n \n \nShort-term borrowings\n $\n5,257\n $\n1,099\nAccounts payable\n \n46,092\n \n41,433\nAccrued liabilities\n \n22,122\n \n20,654\nAccrued income taxes\n \n645\n \n921\nLong-term debt due within one year\n \n3,738\n \n2,256\nCapital lease and financing obligations due within one year\n \n667\n \n565\nTotal current liabilities\n \n78,521\n \n66,928\n \n \n \nLong-term debt\n \n30,045\n \n36,015\nLong-term capital lease and financing obligations\n \n6,780\n \n6,003\nDeferred income taxes and other\n \n8,354\n \n9,344\n \n \n \nCommitments and contingencies\n \n \n \n \n \nEquity:\n \n \nCommon stock\n \n295\n \n305\nCapital in excess of par value\n \n2,648\n \n2,371\nRetained earnings\n \n85,107\n \n89,354\nAccumulated other comprehensive loss\n \n(10,181) \n(14,232)\nTotal Walmart shareholders' equity\n \n77,869\n \n77,798\nNoncontrolling interest\n \n2,953\n \n2,737\nTotal equity\n \n80,822\n \n80,535\nTotal liabilities and equity\n $\n204,522\n $\n198,825\nSee accompanying notes.\n57\n [END OF FILING]",
    "gt": "42.69",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: According to the information provided in the statement of cash flows, what is the FY2020 free cash flow (FCF) for General Mills? FCF here is defined as: (cash from operations - capex). Answer in USD millions. \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING]  \n52 \n \nConsolidated Statements of Cash Flows \nGENERAL MILLS, INC. AND SUBSIDIARIES \n(In Millions) \n \nFiscal Year \n \n2020 \n2019 \n2018 \nCash Flows - Operating Activities \n \n \n \n \nNet earnings, including earnings attributable to redeemable and noncontrolling interests $ \n2,210.8 $ \n1,786.2 $ \n2,163.0 \nAdjustments to reconcile net earnings to net cash provided by operating activities: \n \n \n \n \n \n \nDepreciation and amortization \n \n594.7 \n620.1 \n618.8 \nAfter-tax earnings from joint ventures \n \n(91.1) \n(72.0) \n(84.7)\nDistributions of earnings from joint ventures \n \n76.5 \n86.7 \n113.2 \nStock-based compensation \n \n94.9 \n84.9 \n77.0 \nDeferred income taxes \n \n(29.6) \n93.5 \n(504.3)\nPension and other postretirement benefit plan contributions \n \n(31.1) \n(28.8) \n(31.8)\nPension and other postretirement benefit plan costs \n \n(32.3) \n6.1 \n4.6 \nDivestitures loss \n \n- \n30.0 \n- \nRestructuring, impairment, and other exit costs \n \n43.6 \n235.7 \n126.0 \nChanges in current assets and liabilities, excluding the effects of acquisitions \n and divestitures \n \n793.9 \n(7.5) \n542.1 \nOther, net \n \n45.9 \n(27.9) \n(182.9)\nNet cash provided by operating activities \n \n3,676.2 \n2,807.0 \n2,841.0 \nCash Flows - Investing Activities \n \n \n \n \n \n \nPurchases of land, buildings, and equipment \n \n(460.8) \n(537.6) \n(622.7)\nAcquisition, net of cash acquired \n \n- \n- \n(8,035.8)\nInvestments in affiliates, net \n \n(48.0) \n0.1 \n(17.3)\nProceeds from disposal of land, buildings, and equipment \n \n1.7 \n14.3 \n1.4 \nProceeds from divestitures \n \n- \n26.4 \n- \nOther, net \n \n20.9 \n(59.7) \n(11.0)\nNet cash used by investing activities \n \n(486.2) \n(556.5) \n(8,685.4)\nCash Flows - Financing Activities \n \n \n \n \n \n \nChange in notes payable \n \n(1,158.6) \n(66.3) \n327.5 \nIssuance of long-term debt \n \n1,638.1 \n339.1 \n6,550.0 \nPayment of long-term debt \n \n(1,396.7) \n(1,493.8) \n(600.1)\nProceeds from common stock issued on exercised options \n \n263.4 \n241.4 \n99.3 \nProceeds from common stock issued \n \n- \n- \n969.9 \nPurchases of common stock for treasury \n \n(3.4) \n(1.1) \n(601.6)\nDividends paid \n \n(1,195.8) \n(1,181.7) \n(1,139.7)\nInvestments in redeemable interest \n \n- \n55.7 \n- \nDistributions to noncontrolling and redeemable interest holders \n \n(72.5) \n(38.5) \n(51.8)\nOther, net \n \n(16.0) \n(31.2) \n(108.0)\nNet cash (used) provided by financing activities \n \n(1,941.5) \n(2,176.4) \n5,445.5 \nEffect of exchange rate changes on cash and cash equivalents \n \n(20.7) \n(23.1) \n31.8 \nIncrease (decrease) in cash and cash equivalents \n \n1,227.8 \n \n51.0 \n \n(367.1)\nCash and cash equivalents - beginning of year \n \n450.0 \n399.0 \n766.1 \nCash and cash equivalents - end of year \n$ \n1,677.8 $ \n450.0 $ \n399.0 \nCash flow from changes in current assets and liabilities, excluding the effects of \n acquisitions and divestitures: \n \n \n \n \n \n \nReceivables \n$ \n37.9 $ \n(42.7) $ \n(122.7)\nInventories \n \n103.1 \n53.7 \n15.6 \nPrepaid expenses and other current assets \n \n94.2 \n(114.3) \n(10.7)\nAccounts payable \n \n392.5 \n162.4 \n575.3 \nOther current liabilities \n \n166.2 \n(66.6) \n84.6 \nChanges in current assets and liabilities \n$ \n793.9 $ \n(7.5) $ \n542.1 \nSee accompanying notes to consolidated financial statements. \n \n \n \n \n [END OF FILING]",
    "gt": "$3215.00",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: Did Ulta Beauty's wages expense as a percent of net sales increase or decrease in FY2023? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Comparable sales (sales for stores open at least 14 months and e-commerce sales)\nincreased 15.6% compared to an increase of 21.4% in the fourth quarter of fiscal 2021,\ndriven by a 13.6% increase in transactions and a 1.8% increase in average ticket.\nGross profit increased 18.0% to $1.2 billion compared to $1.0 billion in the fourth\nquarter of fiscal 2021. As a percentage of net sales, gross profit of 37.6% was flat\ncompared to the fourth quarter of fiscal 2021, primarily due to leverage of fixed costs,\nfavorable channel mix shifts, and strong growth in other revenue, offset by higher\ninventory shrink.\nSelling, general and administrative (SG&A) expenses increased 17.3% to $762.7\nmillion compared to $650.0 million in the fourth quarter of fiscal 2021. As a percentage\nof net sales, SG&A expenses decreased to 23.6% compared to 23.8% in the fourth\nquarter of fiscal 2021, primarily due to leverage of marketing expenses and incentive\ncompensation due to higher sales, partially offset by deleverage of store payroll and\nbenefits due to wage investments and deleverage in corporate overhead due to\nstrategic investments.\nOperating income increased 19.2% to $447.6 million, or 13.9% of net sales, compared\nto $375.6 million, or 13.8% of net sales, in the fourth quarter of fiscal 2021.\nThe tax rate increased to 24.6% compared to 22.9% in the fourth quarter of fiscal\n2021.\nNet income increased 17.8% to $340.8 million compared to $289.4 million in the fourth\nquarter of fiscal 2021.\nDiluted earnings per share increased 23.5% to $6.68, including a $0.02 benefit due to\nincome tax accounting for stock-based compensation, compared to $5.41 including a\n$0.05 benefit due to income tax accounting for stock-based compensation, in the fourth\nquarter of fiscal 2021.\nFor the Full Year of Fiscal 2022\nNet sales increased 18.3% to $10.2 billion compared to $8.6 billion in fiscal 2021,\nprimarily due to the favorable impact from the continued resilience of the beauty\ncategory, retail price increases, the impact of new brands and product innovation,\nincreased social occasions, and fewer COVID-19 limitations compared to fiscal 2021.\nComparable sales increased 15.6% compared to an increase of 37.9% in fiscal 2021,\ndriven by a 10.8% increase in transactions and a 4.3% increase in average ticket.\nGross profit increased 20.1% to $4.0 billion compared to $3.4 billion in fiscal 2021. As\na percentage of net sales, gross profit increased to 39.6% compared to 39.0% in fiscal\n2021, primarily due to leverage of fixed costs, strong growth in other revenue, and\nfavorable channel mix shifts, partially offset by higher inventory shrink and lower\nmerchandise margin.\nSG&A expenses increased 16.2% to $2.4 billion compared to $2.1 billion in fiscal\n2021. As a percentage of net sales, SG&A expenses decreased to 23.5% compared to\n23.9% in fiscal 2021, primarily due to lower marketing expenses and leverage of\nincentive compensation due to higher sales, partially offset by deleverage of corporate\noverhead due to strategic investments and deleverage of store payroll and benefits\ndue to wage investments.\nOperating income increased 26.3% to $1.6 billion, or 16.1% of net sales, compared to\n$1.3 billion, or 15.0% of net sales, in fiscal 2021.\nThe tax rate increased to 24.4% compared to 23.9% in fiscal 2021.\nNet income increased 26.0% to $1.2 billion compared to $985.8 million in fiscal 2021.\n [END OF FILING]",
    "gt": "Wages expense as a percent of net sales increased in FY2023. The answer here assumes FY2023 refers to the 12 months ended on January 28, 2023 (although the company refers to this period as its fiscal 2022.",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: Has CVS Health paid dividends to common shareholders in Q2 of FY2022? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Table of Contents\nPART II\nItem 5. Market for Registrants Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.\nMarket Information\nCVS Health Corporations common stock is listed on the New York Stock Exchange under the symbol CVS.\nDividends\nDuring 2022, 2021 and 2020, the quarterly cash dividend was $0.55, $0.50 and $0.50 per share, respectively. In December 2022, the Board authorized a 10%\nincrease in the quarterly cash dividend to $0.605 per share effective in 2023. CVS Health Corporation has paid cash dividends every quarter since becoming a\npublic company. Future dividends will depend on the Companys earnings, capital requirements, financial condition and other factors considered relevant by\nthe Board.\nSee Note 12 Shareholders Equity included in Item 8 of this 10-K for information regarding CVS Health Corporations dividends.\nHolders of Common Stock\nAs of February 1, 2023, there were 24,142 registered holders of the registrants common stock according to the records maintained by the registrants transfer\nagent.\nIssuer Purchases of Equity Securities\nThe following share repurchase programs have been authorized by the Board:\nIn billions\nAuthorization Date\nAuthorized\nRemaining as of\nDecember 31, 2022\nNovember 17, 2022 (2022 Repurchase Program)\n$\n10.0 \n$\n10.0 \nDecember 9, 2021 (2021 Repurchase Program)\n10.0 \n6.5 \nEach of the share Repurchase Programs was effective immediately and permit the Company to effect repurchases from time to time through a combination of\nopen market repurchases, privately negotiated transactions, accelerated share repurchase (ASR) transactions, and/or other derivative transactions. Both the\n2022 and 2021 Repurchase Programs can be modified or terminated by the Board at any time.\nDuring the year ended December 31, 2022, the Company repurchased an aggregate of 34.1 million shares of common stock for approximately $3.5 billion\npursuant to the 2021 Repurchase Program, including share repurchases under the $1.5 billion fixed dollar ASR transaction described below. During the years\nended December 31, 2021 and 2020, the Company did not repurchase any shares of common stock.\nPursuant to the authorization under the 2021 Repurchase Program, the Company entered into a $2.0 billion fixed dollar ASR with Citibank, N.A. (Citibank).\nUpon payment of the $2.0 billion purchase price on January 4, 2023, the Company received a number of shares of CVS Health Corporations common stock\nequal to 80% of the $2.0 billion notional amount of the ASR or approximately 17.4 million shares at a price of $92.19 per share, which were placed into\ntreasury stock in January 2023. At the conclusion of the ASR, the Company may receive additional shares representing the remaining 20% of the $2.0 billion\nnotional amount. The ultimate number of shares the Company may receive will depend on the daily volume-weighted average price of the Companys stock\nover an averaging period, less a discount. It is also possible, depending on such weighted average price, that the Company will have an obligation to Citibank\nwhich, at the Companys option, could be settled in additional cash or by issuing shares. Under the terms of the ASR, the maximum number of shares that\ncould be delivered to the Company is 43.4 million.\nPursuant to the authorization under the 2021 Repurchase Program, the Company entered into a $1.5 billion fixed dollar ASR with Barclays Bank PLC. Upon\npayment of the $1.5 billion purchase price on January 4, 2022, the Company received a number of shares of CVS Health Corporations common stock equal to\n80% of the $1.5 billion notional amount of the ASR or approximately 11.6 million shares at a price of $103.34 per share, which were placed into treasury stock\nin January 2022. The\n66\n [END OF FILING]",
    "gt": "Yes, CVS paid a $ 0.55 dividend per share every quarter in FY2022",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: What drove the increase in Ulta Beauty's merchandise inventories balance at end of FY2023? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Diluted earnings per share increased 33.5% to $24.01, including a $0.07 benefit due to\nincome tax accounting for stock-based compensation, compared to $17.98 including a\n$0.13 benefit due to income tax accounting for stock-based compensation, in fiscal\n2021.\nBalance Sheet\nCash and cash equivalents at the end of the fourth quarter of fiscal 2022 were $737.9\nmillion.\nMerchandise inventories, net at the end of the fourth quarter of fiscal 2022 totaled $1.6\nbillion compared to $1.5 billion at the end of the fourth quarter of fiscal 2021. The $104.2\nmillion increase was primarily due to the opening of 47 new stores since January 29, 2022,\ninventory to support new brand launches and brand expansions, and inventory cost\nincreases.\nShare Repurchase Program\nDuring the fourth quarter of fiscal 2022, the Company repurchased 722,457 shares of its\ncommon stock at a cost of $328.1 million. During fiscal 2022, the Company repurchased 2.2\nmillion shares of its common stock at a cost of $900.0 million. As of January 28, 2023, $1.1\nbillion remained available under the $2.0 billion share repurchase program announced in\nMarch 2022.\nStore Update\nReal estate activity in the fourth quarter of fiscal 2022 included 12 new stores located in\nGarden Grove, CA; Glendale, AZ; Hartsdale, NY; Hollister, CA; Indianapolis, IN; Liverpool,\nNY; Nanuet, NY; Oklahoma City, OK; Richmond, TX; Rock Springs, WY; Tullahoma, TN;\nand Woburn, MA. In addition, the Company relocated one store and remodeled 12 stores.\nDuring fiscal 2022, the Company opened 47 new stores, relocated 12 stores, and remodeled\n20 stores.\nAt the end of the fourth quarter of fiscal 2022, the Company operated 1,355 stores totaling\n14.2 million square feet.\nFiscal 2023 Outlook\nFor fiscal 2023, the Company plans to:\n \n \n \n \n \nFY23 Outlook\nNet sales\n \n \n$10.95 billion to $11.05 billion\nComparable sales\n \n \n4% to 5%\nNew stores, net\n \n \n25-30\nRemodel and relocation projects\n \n \n20-30\nOperating margin\n \n \n14.7% to 15.0%\nDiluted earnings per share\n \n \n$24.70 to $25.40\nShare repurchases\n \n \napproximately $900 million\nEffective tax rate\n \n \napproximately 24.6%\nCapital expenditures\n \n \n$400 million to $475 million\nDepreciation and amortization expense\n \n \n$245 million to $250 million\n [END OF FILING]",
    "gt": "Increase in Merchandise inventories balance was driven by the opening of 47 new stores. The answer here assumes FY2023 refers to the 12 months ended on January 28, 2023 (although the company refers to this period as its fiscal 2022.",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: Is 3M a capital-intensive business based on FY2022 data? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Table of Contents\n3M Company and Subsidiaries\nConsolidated Statement of Income\nYears ended December 31\n(Millions, except per share amounts)\n2022\n2021\n2020\nNet sales\n$\n34,229 $\n35,355 $\n32,184 \nOperating expenses\nCost of sales\n19,232 \n18,795 \n16,605 \nSelling, general and administrative expenses\n9,049 \n7,197 \n6,929 \nResearch, development and related expenses\n1,862 \n1,994 \n1,878 \nGain on business divestitures\n(2,724)\n \n(389)\nGoodwill impairment expense\n271 \n \n \nTotal operating expenses\n27,690 \n27,986 \n25,023 \nOperating income\n6,539 \n7,369 \n7,161 \nOther expense (income), net\n147 \n165 \n366 \nIncome before income taxes\n6,392 \n7,204 \n6,795 \nProvision for income taxes\n612 \n1,285 \n1,337 \nIncome of consolidated group\n5,780 \n5,919 \n5,458 \nIncome (loss) from unconsolidated subsidiaries, net of taxes\n11 \n10 \n(5)\nNet income including noncontrolling interest\n5,791 \n5,929 \n5,453 \nLess: Net income (loss) attributable to noncontrolling interest\n14 \n8 \n4 \nNet income attributable to 3M\n$\n5,777 $\n5,921 $\n5,449 \nWeighted average 3M common shares outstanding basic\n566.0 \n579.0 \n577.6 \nEarnings per share attributable to 3M common shareholders basic\n$\n10.21 $\n10.23 $\n9.43 \nWeighted average 3M common shares outstanding diluted\n567.6 \n585.3 \n582.2 \nEarnings per share attributable to 3M common shareholders diluted\n$\n10.18 $\n10.12 $\n9.36 \nThe accompanying Notes to Consolidated Financial Statements are an integral part of this statement.\n48\n\n\nTable of Contents\n3M Company and Subsidiaries\nConsolidated Balance Sheet\nAt December 31\n(Dollars in millions, except per share amount)\n2022\n2021\nAssets\nCurrent assets\nCash and cash equivalents\n$\n3,655 $\n4,564 \nMarketable securities current\n238 \n201 \nAccounts receivable net of allowances of $174 and $189\n4,532 \n4,660 \nInventories\nFinished goods\n2,497 \n2,196 \nWork in process\n1,606 \n1,577 \nRaw materials and supplies\n1,269 \n1,212 \nTotal inventories\n5,372 \n4,985 \nPrepaids\n435 \n654 \nOther current assets\n456 \n339 \nTotal current assets\n14,688 \n15,403 \nProperty, plant and equipment\n25,998 \n27,213 \nLess: Accumulated depreciation\n(16,820)\n(17,784)\nProperty, plant and equipment net\n9,178 \n9,429 \nOperating lease right of use assets\n829 \n858 \nGoodwill\n12,790 \n13,486 \nIntangible assets net\n4,699 \n5,288 \nOther assets\n4,271 \n2,608 \nTotal assets\n$\n46,455 $\n47,072 \nLiabilities\nCurrent liabilities\nShort-term borrowings and current portion of long-term debt\n$\n1,938 $\n1,307 \nAccounts payable\n3,183 \n2,994 \nAccrued payroll\n692 \n1,020 \nAccrued income taxes\n259 \n260 \nOperating lease liabilities current\n261 \n263 \nOther current liabilities\n3,190 \n3,191 \nTotal current liabilities\n9,523 \n9,035 \nLong-term debt\n14,001 \n16,056 \nPension and postretirement benefits\n1,966 \n2,870 \nOperating lease liabilities\n580 \n591 \nOther liabilities\n5,615 \n3,403 \nTotal liabilities\n31,685 \n31,955 \nCommitments and contingencies (Note 16)\nEquity\n3M Company shareholders equity:\nCommon stock par value, $.01 par value; 944,033,056 shares issued\n9 \n9 \nShares outstanding - December 31, 2022: 549,245,105\nShares outstanding - December 31, 2021: 571,845,478\nAdditional paid-in capital\n6,691 \n6,429 \nRetained earnings\n47,950 \n45,821 \nTreasury stock, at cost:\n(33,255)\n(30,463)\nAccumulated other comprehensive income (loss)\n(6,673)\n(6,750)\nTotal 3M Company shareholders equity\n14,722 \n15,046 \nNoncontrolling interest\n48 \n71 \nTotal equity\n14,770 \n15,117 \nTotal liabilities and equity\n$\n46,455 $\n47,072 \nThe accompanying Notes to Consolidated Financial Statements are an integral part of this statement.\n50\n\n\nTable of Contents\n3M Company and Subsidiaries\nConsolidated Statement of Cash Flows\nYears ended December 31\n(Millions)\n2022\n2021\n2020\nCash Flows from Operating Activities\nNet income including noncontrolling interest\n$\n5,791 $\n5,929 $\n5,453 \nAdjustments to reconcile net income including noncontrolling interest to net cash provided by operating\nactivities\nDepreciation and amortization\n1,831 \n1,915 \n1,911 \nLong-lived and indefinite-lived asset impairment expense\n618 \n \n6 \nGoodwill impairment expense\n271 \n \n \nCompany pension and postretirement contributions\n(158)\n(180)\n(156)\nCompany pension and postretirement expense\n178 \n206 \n322 \nStock-based compensation expense\n263 \n274 \n262 \nGain on business divestitures\n(2,724)\n \n(389)\nDeferred income taxes\n(663)\n(166)\n(165)\nChanges in assets and liabilities\nAccounts receivable\n(105)\n(122)\n165 \nInventories\n(629)\n(903)\n(91)\nAccounts payable\n111 \n518 \n252 \nAccrued income taxes (current and long-term)\n(47)\n(244)\n132 \nOther net\n854 \n227 \n411 \nNet cash provided by (used in) operating activities\n5,591 \n7,454 \n8,113 \nCash Flows from Investing Activities\nPurchases of property, plant and equipment (PP&E)\n(1,749)\n(1,603)\n(1,501)\nProceeds from sale of PP&E and other assets\n200 \n51 \n128 \nAcquisitions, net of cash acquired\n \n \n(25)\nPurchases of marketable securities and investments\n(1,250)\n(2,202)\n(1,579)\nProceeds from maturities and sale of marketable securities and investments\n1,261 \n2,406 \n1,811 \nProceeds from sale of businesses, net of cash sold\n13 \n \n576 \nCash payment from Food Safety business split-off, net of divested cash\n478 \n \n \nOther net\n1 \n31 \n10 \nNet cash provided by (used in) investing activities\n(1,046)\n(1,317)\n(580)\nCash Flows from Financing Activities\nChange in short-term debt net\n340 \n(2)\n(143)\nRepayment of debt (maturities greater than 90 days)\n(1,179)\n(1,144)\n(3,482)\nProceeds from debt (maturities greater than 90 days)\n1 \n1 \n1,750 \nPurchases of treasury stock\n(1,464)\n(2,199)\n(368)\nProceeds from issuance of treasury stock pursuant to stock option and benefit plans\n381 \n639 \n429 \nDividends paid to shareholders\n(3,369)\n(3,420)\n(3,388)\nOther net\n(60)\n(20)\n(98)\nNet cash provided by (used in) financing activities\n(5,350)\n(6,145)\n(5,300)\nEffect of exchange rate changes on cash and cash equivalents\n(104)\n(62)\n48 \nNet increase (decrease) in cash and cash equivalents\n(909)\n(70)\n2,281 \nCash and cash equivalents at beginning of year\n4,564 \n4,634 \n2,353 \nCash and cash equivalents at end of period\n$\n3,655 $\n4,564 $\n4,634 \nThe accompanying Notes to Consolidated Financial Statements are an integral part of this statement.\n52\n [END OF FILING]",
    "gt": "No, the company is managing its CAPEX and Fixed Assets pretty efficiently, which is evident from below key metrics:\nCAPEX/Revenue Ratio: 5.1%\nFixed assets/Total Assets: 20%\nReturn on Assets= 12.4%",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: Were there any potential events that are not in Pfizer's standard business operations that substantially increased net income in 2019? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Consolidated Statements of Income\nPfizer Inc. and Subsidiary Companies\n \nYear Ended December 31,\n(MILLIONS, EXCEPT PER COMMON SHARE DATA)\n2021\n2020\n2019\nRevenues\n$\n81,288 \n$\n41,651 \n$\n40,905 \nCosts and expenses:\n \n \nCost of sales\n30,821 \n8,484 \n8,054 \nSelling, informational and administrative expenses\n12,703 \n11,597 \n12,726 \nResearch and development expenses\n13,829 \n9,393 \n8,385 \nAmortization of intangible assets\n3,700 \n3,348 \n4,429 \nRestructuring charges and certain acquisition-related costs\n802 \n579 \n601 \n(Gain) on completion of Consumer Healthcare JV transaction\n \n(6)\n(8,107)\nOther (income)/deductionsnet\n(4,878)\n1,219 \n3,497 \nIncome from continuing operations before provision/(benefit) for taxes on income\n24,311 \n7,036 \n11,321 \nProvision/(benefit) for taxes on income\n1,852 \n370 \n583 \nIncome from continuing operations\n22,459 \n6,666 \n10,738 \nDiscontinued operationsnet of tax\n(434)\n2,529 \n5,318 \nNet income before allocation to noncontrolling interests\n22,025 \n9,195 \n16,056 \nLess: Net income attributable to noncontrolling interests\n45 \n36 \n29 \nNet income attributable to Pfizer Inc. common shareholders\n$\n21,979 \n$\n9,159 \n$\n16,026 \nEarnings per common sharebasic:\n \n \n \nIncome from continuing operations attributable to Pfizer Inc. common shareholders\n$\n4.00 \n$\n1.19 \n$\n1.92 \nDiscontinued operationsnet of tax\n(0.08)\n0.46 \n0.95 \nNet income attributable to Pfizer Inc. common shareholders\n$\n3.92 \n$\n1.65 \n$\n2.88 \nEarnings per common sharediluted:\n \n \nIncome from continuing operations attributable to Pfizer Inc. common shareholders\n$\n3.93 \n$\n1.18 \n$\n1.89 \nDiscontinued operationsnet of tax\n(0.08)\n0.45 \n0.94 \nNet income attributable to Pfizer Inc. common shareholders\n$\n3.85 \n$\n1.63 \n$\n2.82 \nWeighted-average sharesbasic\n5,601 \n5,555 \n5,569 \nWeighted-average sharesdiluted\n5,708 \n5,632 \n5,675 \nExclusive of amortization of intangible assets, except as disclosed in Note 1M.\nSee Accompanying Notes.\n(a)\n(a)\n(a)\n(a)\nPfizer Inc.\n2021 Form 10-K\n51\n [END OF FILING]",
    "gt": "Yes, the gain on completion of Consumer Healthcare JV Transaction",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: Does AMCOR have an improving gross margin profile as of FY2023? If gross margin is not a useful metric for a company like this, then state that and explain why. \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Amcor plc and Subsidiaries\nConsolidated Statements of Income\n($ in millions, except per share data)\nFor the years ended June 30,\n2023\n2022\n2021\nNet sales\n$\n14,694 \n$\n14,544 \n$\n12,861 \nCost of sales\n(11,969)\n(11,724)\n(10,129)\nGross profit\n2,725 \n2,820 \n2,732 \nSelling, general, and administrative expenses\n(1,246)\n(1,284)\n(1,292)\nResearch and development expenses\n(101)\n(96)\n(100)\nRestructuring, impairment, and other related activities, net\n104 \n(234)\n(94)\nOther income, net\n26 \n33 \n75 \nOperating income\n1,508 \n1,239 \n1,321 \nInterest income\n31 \n24 \n14 \nInterest expense\n(290)\n(159)\n(153)\nOther non-operating income, net\n2 \n11 \n11 \nIncome before income taxes and equity in income of affiliated companies\n1,251 \n1,115 \n1,193 \nIncome tax expense\n(193)\n(300)\n(261)\nEquity in income of affiliated companies, net of tax\n \n \n19 \nNet income\n$\n1,058 \n$\n815 \n$\n951 \nNet income attributable to non-controlling interests\n(10)\n(10)\n(12)\nNet income attributable to Amcor plc\n$\n1,048 \n$\n805 \n$\n939 \nBasic earnings per share:\nBasic earnings per share\n$\n0.709 \n$\n0.532 \n$\n0.604 \nDiluted earnings per share\n$\n0.705 \n$\n0.529 \n$\n0.602 \n See accompanying notes to consolidated financial statements.\n50\n [END OF FILING]",
    "gt": "No. For AMCOR there has been a slight decline in gross margins by 0.8%.",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: How much was the Real change in Sales for AMCOR in FY 2023 vs FY 2022, if we exclude the impact of FX movement, passthrough costs and one-off items? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Components of Fiscal 2023 Net Sales growth \nThree Months Ended June 30\nTwelve Months Ended June 30\n($ million)\nFlexibles\nRigid \nPackaging\nTotal\nFlexibles\nRigid \nPackaging\nTotal\nNet sales fiscal year 2023\n \n2,777 \n897 \n3,673 \n \n11,154 \n3,540 \n14,694 \nNet sales fiscal year 2022\n \n2,967 \n942 \n3,909 \n \n11,151 \n3,393 \n14,544 \nReported Growth %\n (6) \n (5) \n (6) \n \n 4 \n 1 \nFX %\n 1 \n (1) \n \n (4) \n (1) \n (3) \nConstant Currency Growth %\n (7) \n (4) \n (6) \n 4 \n 5 \n 4 \nRaw Material Pass Through %\n 1 \n \n 1 \n 5 \n 8 \n 5 \nItems affecting comparability %\n (3) \n \n (2) \n (2) \n \n (1) \nComparable Constant Currency \nGrowth %\n (5) \n (4) \n (5) \n 1 \n (3) \n \nVolume %\n (7) \n (6) \n (7) \n (3) \n (4) \n (3) \nPrice/Mix %\n 2 \n 2 \n 2 \n 4 \n 1 \n 3 \n10\n [END OF FILING]",
    "gt": "The Real Growth was flat in FY 2023 vs FY 2022.",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: What drove the reduction in SG&A expense as a percent of net sales in FY2023? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Comparable sales (sales for stores open at least 14 months and e-commerce sales)\nincreased 15.6% compared to an increase of 21.4% in the fourth quarter of fiscal 2021,\ndriven by a 13.6% increase in transactions and a 1.8% increase in average ticket.\nGross profit increased 18.0% to $1.2 billion compared to $1.0 billion in the fourth\nquarter of fiscal 2021. As a percentage of net sales, gross profit of 37.6% was flat\ncompared to the fourth quarter of fiscal 2021, primarily due to leverage of fixed costs,\nfavorable channel mix shifts, and strong growth in other revenue, offset by higher\ninventory shrink.\nSelling, general and administrative (SG&A) expenses increased 17.3% to $762.7\nmillion compared to $650.0 million in the fourth quarter of fiscal 2021. As a percentage\nof net sales, SG&A expenses decreased to 23.6% compared to 23.8% in the fourth\nquarter of fiscal 2021, primarily due to leverage of marketing expenses and incentive\ncompensation due to higher sales, partially offset by deleverage of store payroll and\nbenefits due to wage investments and deleverage in corporate overhead due to\nstrategic investments.\nOperating income increased 19.2% to $447.6 million, or 13.9% of net sales, compared\nto $375.6 million, or 13.8% of net sales, in the fourth quarter of fiscal 2021.\nThe tax rate increased to 24.6% compared to 22.9% in the fourth quarter of fiscal\n2021.\nNet income increased 17.8% to $340.8 million compared to $289.4 million in the fourth\nquarter of fiscal 2021.\nDiluted earnings per share increased 23.5% to $6.68, including a $0.02 benefit due to\nincome tax accounting for stock-based compensation, compared to $5.41 including a\n$0.05 benefit due to income tax accounting for stock-based compensation, in the fourth\nquarter of fiscal 2021.\nFor the Full Year of Fiscal 2022\nNet sales increased 18.3% to $10.2 billion compared to $8.6 billion in fiscal 2021,\nprimarily due to the favorable impact from the continued resilience of the beauty\ncategory, retail price increases, the impact of new brands and product innovation,\nincreased social occasions, and fewer COVID-19 limitations compared to fiscal 2021.\nComparable sales increased 15.6% compared to an increase of 37.9% in fiscal 2021,\ndriven by a 10.8% increase in transactions and a 4.3% increase in average ticket.\nGross profit increased 20.1% to $4.0 billion compared to $3.4 billion in fiscal 2021. As\na percentage of net sales, gross profit increased to 39.6% compared to 39.0% in fiscal\n2021, primarily due to leverage of fixed costs, strong growth in other revenue, and\nfavorable channel mix shifts, partially offset by higher inventory shrink and lower\nmerchandise margin.\nSG&A expenses increased 16.2% to $2.4 billion compared to $2.1 billion in fiscal\n2021. As a percentage of net sales, SG&A expenses decreased to 23.5% compared to\n23.9% in fiscal 2021, primarily due to lower marketing expenses and leverage of\nincentive compensation due to higher sales, partially offset by deleverage of corporate\noverhead due to strategic investments and deleverage of store payroll and benefits\ndue to wage investments.\nOperating income increased 26.3% to $1.6 billion, or 16.1% of net sales, compared to\n$1.3 billion, or 15.0% of net sales, in fiscal 2021.\nThe tax rate increased to 24.4% compared to 23.9% in fiscal 2021.\nNet income increased 26.0% to $1.2 billion compared to $985.8 million in fiscal 2021.\n [END OF FILING]",
    "gt": "Lower marketing expenses and leverage of incentive compensation due to higher sales. The answer here assumes FY2023 refers to the 12 months ended on January 28, 2023 (although the company refers to this period as its fiscal 2022.",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: What is the nature & purpose of AMCOR's restructuring liability as oF Q2 of FY2023 close? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Note 6 - Restructuring\n The Company's restructuring activities in the three and six months ended December 31, 2022 were primarily comprised of restructuring\nactivities related to the Russia-Ukraine conflict and the three and six months ended December 31, 2021 included expenses related to the\nCompany's 2019 plan from the integration of acquired Bemis operations which was substantially completed at the end of fiscal year 2022.\n Restructuring and related expenses, net were $2 million and $10 million during the three months ended December 31, 2022 and 2021, and $3\nmillion and $18 million in the six months ended December 31, 2022 and 2021, respectively, and primarily relate to the Flexibles reportable\nsegment. The expenses related to restructuring activities have been presented on the unaudited condensed consolidated statements of income as\nrestructuring and other related activities, net.\n An analysis of the Company's restructuring plan liability is as follows:\n($ in millions)\nEmployee Costs\nFixed Asset\nRelated Costs\nOther Costs\nTotal\nRestructuring\nCosts\nLiability balance at June 30, 2022\n$\n97 \n$\n3 \n$\n18 \n$\n118 \nNet charges to earnings\n2 \n \n \n2 \nCash paid\n(16)\n(1)\n(8)\n(25)\nReversal of unused amounts\n(2)\n \n \n(2)\nLiability balance at December 31, 2022\n$\n81 \n$\n2 \n$\n10 \n$\n93 \n The Company expects the majority of the liability for employee, fixed assets related, and other costs as of December 31, 2022 to be paid\nwithin the next twelve months. The accruals related to restructuring activities have been recorded on the unaudited condensed consolidated\nbalance sheets under other current liabilities and other non-current liabilities.\n15\n [END OF FILING]",
    "gt": "87% of the total restructuring liability is related Employee liabilities.",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: How much has the effective tax rate of Corning changed between FY2021 and FY2022? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Table of Contents\n \n2022 Results\n \nNet sales for the year ended December 31, 2022 were $14.2 billion, a net increase of $107 million, or 1%, when compared to the year ended December 31, 2021. This is\ndriven by 15% growth in segment net sales in Optical Communications of $674 million and 34% growth in Hemlock and Emerging Growth Businesses of $419 million,\nwhich helped offset a $394 million decrease in Display Technologies. In addition, movements in foreign exchange rates adversely impacted Cornings consolidated net\nsales by $616 million for the year ended December 31, 2022, when compared to the same period in 2021.\n \nFor the year ended December 31, 2022, we generated net income attributable to Corning Incorporated of $1,316 million, or $1.54 per diluted share, compared to net\nincome attributable to Corning Incorporated of $1,906 million, or $1.28 per diluted share, for the year ended December 31, 2021. When compared to 2021, the $590\nmillion decrease was primarily driven by a $238 million increase in severance, accelerated depreciation, asset write-offs and other related charges, a $50 million increase\nin litigation, regulatory and other legal matters and a $120 million adverse impact from foreign currency translation.\n \nDiluted earnings per share for the year ended December 31, 2022 increased by $0.26 per diluted share, or 20%, when compared to the year ended December 31, 2021,\nprimarily driven by the immediate repurchase and retirement of 35 million common shares which resulted in an $803 million one-time reduction to net income available\nto common shareholders in 2021, partially offset by the decrease in net income attributable to Corning Incorporated as described above. Refer to Note 16 (Shareholders\nEquity) and Note 17 (Earnings per Common Share) in the accompanying notes to the consolidated financial statements for additional information.\n \n2023 Corporate Outlook\n \nFor the first quarter 2023, we anticipate core sales in the range of $3.2 billion to $3.4 billion.\n \n \nRESULTS OF OPERATIONS\n \nThe following table presents selected highlights from our operations (in millions):\n \n \n \nYear ended December 31,\n \n% change\n \n \n \n2022\n \n2021\n \n22 vs. 21\n \n \n \n \n \n \nNet sales\n $\n14,189 $\n14,082 \n1%\n \n \n \n \n \nGross margin\n $\n4,506 $\n5,063 \n(11%)\n(gross margin %)\n \n32% \n36% \n \n \n \n \n \n \nSelling, general and administrative expenses\n $\n1,898 $\n1,827 \n4%\n(as a % of net sales)\n \n13% \n13% \n \n \n \n \n \n \nResearch, development and engineering expenses\n $\n1,047 $\n995 \n5%\n(as a % of net sales)\n \n7% \n7% \n \n \n \n \n \n \nTranslated earnings contract gain, net\n $\n351 $\n354 \n(1%)\n(as a % of net sales)\n \n2% \n3% \n \n \n \n \n \n \nIncome before income taxes\n $\n1,797 $\n2,426 \n(26%)\n(as a % of net sales)\n \n13% \n17% \n \n \n \n \n \n \nProvision for income taxes\n $\n(411) $\n(491) \n16%\nEffective tax rate\n \n23% \n20% \n \n \n \n \n \n \nNet income attributable to Corning Incorporated\n $\n1,316 $\n1,906 \n(31%)\n(as a % of net sales)\n \n9% \n14% \n \n \n \n \n \n \nComprehensive income attributable to Corning Incorporated\n $\n661 $\n1,471 \n(55%)\n \n24\n [END OF FILING]",
    "gt": "The effective tax rate of Corning has changed from 20% in FY2021 to 23% in FY 2022.",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: Does AMEX have an improving operating margin profile as of 2022? If operating margin is not a useful metric for a company like this, then state that and explain why. \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Table of Contents\nCONSOLIDATED STATEMENTS OF INCOME\nYear Ended December 31 (Millions, except per share amounts)\n2022\n2021\n2020\nRevenues\nNon-interest revenues\nDiscount revenue\n$\n30,739 \n$\n24,563 \n$\n19,435 \nNet card fees\n6,070 \n5,195 \n4,664 \nService fees and other revenue\n4,521 \n3,316 \n2,702 \nProcessed revenue\n1,637 \n1,556 \n1,301 \nTotal non-interest revenues\n42,967 \n34,630 \n28,102 \nInterest income\nInterest on loans\n11,967 \n8,850 \n9,779 \nInterest and dividends on investment securities\n96 \n83 \n127 \nDeposits with banks and other\n595 \n100 \n177 \nTotal interest income\n12,658 \n9,033 \n10,083 \nInterest expense\nDeposits\n1,527 \n458 \n943 \nLong-term debt and other\n1,236 \n825 \n1,155 \nTotal interest expense\n2,763 \n1,283 \n2,098 \nNet interest income\n9,895 \n7,750 \n7,985 \nTotal revenues net of interest expense\n52,862 \n42,380 \n36,087 \nProvisions for credit losses\nCard Member receivables\n627 \n(73)\n1,015 \nCard Member loans\n1,514 \n(1,155)\n3,453 \nOther\n41 \n(191)\n262 \nTotal provisions for credit losses\n2,182 \n(1,419)\n4,730 \nTotal revenues net of interest expense after provisions for credit losses\n50,680 \n43,799 \n31,357 \nExpenses\nCard Member rewards\n14,002 \n11,007 \n8,041 \nBusiness development\n4,943 \n3,762 \n3,051 \nCard Member services\n2,959 \n1,993 \n1,230 \nMarketing\n5,458 \n5,291 \n3,696 \nSalaries and employee benefits\n7,252 \n6,240 \n5,718 \nOther, net\n6,481 \n4,817 \n5,325 \nTotal expenses\n41,095 \n33,110 \n27,061 \nPretax income\n9,585 \n10,689 \n4,296 \nIncome tax provision\n2,071 \n2,629 \n1,161 \nNet income\n$\n7,514 \n$\n8,060 \n$\n3,135 \nEarnings per Common Share (Note 21)\nBasic\n$\n9.86 \n$\n10.04 \n$\n3.77 \nDiluted\n$\n9.85 \n$\n10.02 \n$\n3.77 \nAverage common shares outstanding for earnings per common share:\nBasic\n751 \n789 \n805 \nDiluted\n752 \n790 \n806 \n(a)\nRepresents net income less (i) earnings allocated to participating share awards of $57 million, $56 million and $20 million for the years ended December 31, 2022, 2021 and 2020, respectively,\n(ii) dividends on preferred shares of $57 million, $71 million and $79 million for the years ended December 31, 2022, 2021 and 2020, respectively, and (iii) equity-related adjustments of\n$16 million related to the redemption of preferred shares for the year ended December 31, 2021.\nSee Notes to Consolidated Financial Statements.\n(a)\n93\n [END OF FILING]",
    "gt": "Performance is not measured through operating margin",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: What is the FY2022 unadjusted EBITDA less capex for PepsiCo? Define unadjusted EBITDA as unadjusted operating income + depreciation and amortization [from cash flow statement]. Answer in USD millions. Respond to the question by assuming the perspective of an investment analyst who can only use the details shown within the statement of cash flows and the income statement. \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Table of Contents\nConsolidated Statement of Income\nPepsiCo, Inc. and Subsidiaries\nFiscal years ended December 31, 2022, December 25, 2021 and December 26, 2020\n(in millions except per share amounts)\n2022\n2021\n2020\nNet Revenue\n$\n86,392 $\n79,474 $\n70,372 \nCost of sales\n40,576 \n37,075 \n31,797 \nGross profit\n45,816 \n42,399 \n38,575 \nSelling, general and administrative expenses\n34,459 \n31,237 \n28,453 \nGain associated with the Juice Transaction (see Note 13)\n(3,321)\n \n \nImpairment of intangible assets (see Notes 1 and 4)\n3,166 \n \n42 \nOperating Profit\n11,512 \n11,162 \n10,080 \nOther pension and retiree medical benefits income\n132 \n522 \n117 \nNet interest expense and other\n(939)\n(1,863)\n(1,128)\nIncome before income taxes\n10,705 \n9,821 \n9,069 \nProvision for income taxes\n1,727 \n2,142 \n1,894 \nNet income\n8,978 \n7,679 \n7,175 \nLess: Net income attributable to noncontrolling interests\n68 \n61 \n55 \nNet Income Attributable to PepsiCo\n$\n8,910 $\n7,618 $\n7,120 \nNet Income Attributable to PepsiCo per Common Share\nBasic\n$\n6.45 $\n5.51 $\n5.14 \nDiluted\n$\n6.42 $\n5.49 $\n5.12 \nWeighted-average common shares outstanding\nBasic\n1,380 \n1,382 \n1,385 \nDiluted\n1,387 \n1,389 \n1,392 \nSee accompanying notes to the consolidated financial statements.\n60\n\n\nTable of Contents\nConsolidated Statement of Cash Flows\nPepsiCo, Inc. and Subsidiaries\nFiscal years ended December 31, 2022, December 25, 2021 and December 26, 2020\n(in millions)\n2022\n2021\n2020\nOperating Activities\nNet income\n$\n8,978 $\n7,679 $\n7,175 \nDepreciation and amortization\n2,763 \n2,710 \n2,548 \nGain associated with the Juice Transaction\n(3,321)\n \n \nImpairment and other charges\n3,618 \n \n \nOperating lease right-of-use asset amortization\n517 \n505 \n478 \nShare-based compensation expense\n343 \n301 \n264 \nRestructuring and impairment charges\n411 \n247 \n289 \nCash payments for restructuring charges\n(224)\n(256)\n(255)\nAcquisition and divestiture-related charges\n80 \n(4)\n255 \nCash payments for acquisition and divestiture-related charges\n(46)\n(176)\n(131)\nPension and retiree medical plan expenses\n419 \n123 \n408 \nPension and retiree medical plan contributions\n(384)\n(785)\n(562)\nDeferred income taxes and other tax charges and credits\n(873)\n298 \n361 \nTax expense related to the TCJ Act\n86 \n190 \n \nTax payments related to the TCJ Act\n(309)\n(309)\n(78)\nChange in assets and liabilities:\nAccounts and notes receivable\n(1,763)\n(651)\n(420)\nInventories\n(1,142)\n(582)\n(516)\nPrepaid expenses and other current assets\n118 \n159 \n26 \nAccounts payable and other current liabilities\n1,842 \n1,762 \n766 \nIncome taxes payable\n57 \n30 \n(159)\nOther, net\n(359)\n375 \n164 \nNet Cash Provided by Operating Activities\n10,811 \n11,616 \n10,613 \nInvesting Activities\nCapital spending\n(5,207)\n(4,625)\n(4,240)\nSales of property, plant and equipment\n251 \n166 \n55 \nAcquisitions, net of cash acquired, investments in noncontrolled affiliates and purchases of\nintangible and other assets\n(873)\n(61)\n(6,372)\nProceeds associated with the Juice Transaction\n3,456 \n \n \nOther divestitures, sales of investments in noncontrolled affiliates and other assets\n49 \n169 \n6 \nShort-term investments, by original maturity:\nMore than three months - purchases\n(291)\n \n(1,135)\nMore than three months - maturities\n150 \n1,135 \n \nThree months or less, net\n24 \n(58)\n27 \nOther investing, net\n11 \n5 \n40 \nNet Cash Used for Investing Activities\n(2,430)\n(3,269)\n(11,619)\n(Continued on following page)\n62\n [END OF FILING]",
    "gt": "$9068.00",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: When primarily referencing the income statement and the statement of financial position, what is the FY2021 inventory turnover ratio for Nike? Inventory turnover ratio is defined as: (FY2021 COGS) / (average inventory between FY2020 and FY2021). Round your answer to two decimal places. \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Table of Contents\nNIKE, INC.\nCONSOLIDATED STATEMENTS OF INCOME\nYEAR ENDED MAY 31,\n(In millions, except per share data)\n2021\n2020\n2019\nRevenues\n$\n44,538 $\n37,403 $\n39,117 \nCost of sales\n24,576 \n21,162 \n21,643 \nGross profit\n19,962 \n16,241 \n17,474 \nDemand creation expense\n3,114 \n3,592 \n3,753 \nOperating overhead expense\n9,911 \n9,534 \n8,949 \nTotal selling and administrative expense\n13,025 \n13,126 \n12,702 \nInterest expense (income), net\n262 \n89 \n49 \nOther (income) expense, net\n14 \n139 \n(78)\nIncome before income taxes\n6,661 \n2,887 \n4,801 \nIncome tax expense\n934 \n348 \n772 \nNET INCOME\n$\n5,727 $\n2,539 $\n4,029 \nEarnings per common share:\nBasic\n$\n3.64 $\n1.63 $\n2.55 \nDiluted\n$\n3.56 $\n1.60 $\n2.49 \nWeighted average common shares outstanding:\nBasic\n1,573.0 \n1,558.8 \n1,579.7 \nDiluted\n1,609.4 \n1,591.6 \n1,618.4 \nThe accompanying Notes to the Consolidated Financial Statements are an integral part of this statement.\n2021 FORM 10-K 57\n\n\nTable of Contents\nNIKE, INC.\nCONSOLIDATED BALANCE SHEETS\nMAY 31,\n(In millions)\n2021\n2020\nASSETS\nCurrent assets:\nCash and equivalents\n$\n9,889 $\n8,348 \nShort-term investments\n3,587 \n439 \nAccounts receivable, net\n4,463 \n2,749 \nInventories\n6,854 \n7,367 \nPrepaid expenses and other current assets\n1,498 \n1,653 \nTotal current assets\n26,291 \n20,556 \nProperty, plant and equipment, net\n4,904 \n4,866 \nOperating lease right-of-use assets, net\n3,113 \n3,097 \nIdentifiable intangible assets, net\n269 \n274 \nGoodwill\n242 \n223 \nDeferred income taxes and other assets\n2,921 \n2,326 \nTOTAL ASSETS\n$\n37,740 $\n31,342 \nLIABILITIES AND SHAREHOLDERS' EQUITY\nCurrent liabilities:\nCurrent portion of long-term debt\n$\n $\n3 \nNotes payable\n2 \n248 \nAccounts payable\n2,836 \n2,248 \nCurrent portion of operating lease liabilities\n467 \n445 \nAccrued liabilities\n6,063 \n5,184 \nIncome taxes payable\n306 \n156 \nTotal current liabilities\n9,674 \n8,284 \nLong-term debt\n9,413 \n9,406 \nOperating lease liabilities\n2,931 \n2,913 \nDeferred income taxes and other liabilities\n2,955 \n2,684 \nCommitments and contingencies (Note 18)\nRedeemable preferred stock\n \n \nShareholders' equity:\nCommon stock at stated value:\nClass A convertible 305 and 315 shares outstanding\n \n \nClass B 1,273 and 1,243 shares outstanding\n3 \n3 \nCapital in excess of stated value\n9,965 \n8,299 \nAccumulated other comprehensive income (loss)\n(380)\n(56)\nRetained earnings (deficit)\n3,179 \n(191)\nTotal shareholders' equity\n12,767 \n8,055 \nTOTAL LIABILITIES AND SHAREHOLDERS' EQUITY\n$\n37,740 $\n31,342 \nThe accompanying Notes to the Consolidated Financial Statements are an integral part of this statement.\n2021 FORM 10-K 59\n [END OF FILING]",
    "gt": "3.46",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: What is Lockheed Martin's FY2021 net working capital? Define net working capital as total current assets less total current liabilities. Answer in USD millions. Respond to the question by assuming the perspective of an investment analyst who can only use the details shown within the balance sheet. \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Table of Contents\nLockheed Martin Corporation\nConsolidated Balance Sheets\n(in millions, except par value)\n \n \nDecember 31,\n2021\n2020\nAssets\nCurrent assets\nCash and cash equivalents\n$\n3,604 \n$\n3,160 \nReceivables, net\n1,963 \n1,978 \nContract assets\n10,579 \n9,545 \nInventories\n2,981 \n3,545 \nOther current assets\n688 \n1,150 \nTotal current assets\n19,815 \n19,378 \nProperty, plant and equipment, net\n7,597 \n7,213 \nGoodwill\n10,813 \n10,806 \nIntangible assets, net\n2,706 \n3,012 \nDeferred income taxes\n2,290 \n3,475 \nOther noncurrent assets\n7,652 \n6,826 \nTotal assets\n$\n50,873 \n$\n50,710 \nLiabilities and equity\nCurrent liabilities\nAccounts payable\n$\n780 \n$\n880 \nSalaries, benefits and payroll taxes\n3,108 \n3,163 \nContract liabilities\n8,107 \n7,545 \nCurrent maturities of long-term debt\n6 \n500 \nOther current liabilities\n1,996 \n1,845 \nTotal current liabilities\n13,997 \n13,933 \nLong-term debt, net\n11,670 \n11,669 \nAccrued pension liabilities\n8,319 \n12,874 \nOther noncurrent liabilities\n5,928 \n6,196 \nTotal liabilities\n39,914 \n44,672 \nStockholders equity\nCommon stock, $1 par value per share\n271 \n279 \nAdditional paid-in capital\n94 \n221 \nRetained earnings\n21,600 \n21,636 \nAccumulated other comprehensive loss\n(11,006)\n(16,121)\nTotal stockholders equity\n10,959 \n6,015 \nNoncontrolling interests in subsidiary\n \n23 \nTotal equity\n10,959 \n6,038 \nTotal liabilities and equity\n$\n50,873 \n$\n50,710 \nThe accompanying notes are an integral part of these consolidated financial statements.\n68\n [END OF FILING]",
    "gt": "$5818.00",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: At the Pepsico AGM held on May 3, 2023, what was the outcome of the shareholder vote on the shareholder proposal for a congruency report by Pepsico on net-zero emissions policies? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] (4) The shareholders approved, on an advisory basis, the holding of an advisory vote on the compensation of PepsiCos named executive officers every\nyear:\nOne Year\n994,856,204\nTwo Years\n4,331,004\nThree Years\n17,603,165\nAbstain\n3,357,516\nBroker Non-Votes\n172,969,325\nIn light of the voting results on this advisory vote, and consistent with its recommendation to shareholders, PepsiCos Board of Directors has decided that\nPepsiCo will hold an advisory vote on the compensation of PepsiCos named executive officers every year.\n(5) The shareholder proposal regarding independent Board Chair was defeated:\nFor\n250,838,697\nAgainst\n746,982,272\nAbstain\n22,326,920\nBroker Non-Votes\n172,969,325\n(6) The shareholder proposal regarding a global transparency report was defeated:\nFor\n185,034,699\nAgainst\n814,416,953\nAbstain\n20,696,237\nBroker Non-Votes\n172,969,325\n(7) The shareholder proposal regarding a report on impacts of reproductive healthcare legislation was defeated:\nFor\n158,917,578\nAgainst\n830,627,354\nAbstain\n30,602,957\nBroker Non-Votes\n172,969,325\n(8) The shareholder proposal regarding a congruency report on net-zero emissions policies was defeated:\nFor\n19,718,780\nAgainst\n977,228,788\nAbstain\n23,200,321\nBroker Non-Votes\n172,969,325\n [END OF FILING]",
    "gt": "The shareholder proposal for a congruency report by Pepsico on net-zero emissions policies was defeated.",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: How much has the effective tax rate of American Express changed between FY2021 and FY2022? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Table of Contents\nTABLE 1: SUMMARY OF FINANCIAL PERFORMANCE\nYears Ended December 31,\nChange\nChange\n(Millions, except percentages, per share amounts and where indicated)\n2022\n2021\n2020\n2022 vs. 2021\n2021 vs. 2020\nSelected Income Statement Data\nTotal revenues net of interest expense\n$\n52,862\n$\n42,380\n$\n36,087\n$\n10,482 \n25 %\n$\n6,293 \n17 %\nProvisions for credit losses\n2,182\n(1,419)\n4,730\n3,601 \n#\n(6,149)\n#\nExpenses\n41,095\n33,110\n27,061\n7,985 \n24 \n6,049 \n22 \nPretax income\n9,585\n10,689\n4,296\n(1,104)\n(10)\n6,393 \n#\nIncome tax provision\n2,071\n2,629\n1,161\n(558)\n(21)\n1,468 \n#\nNet income\n7,514\n8,060\n3,135\n(546)\n(7)\n4,925 \n#\nEarnings per common share diluted \n$\n9.85\n$\n10.02\n$\n3.77\n$\n(0.17)\n(2)%\n$\n6.25 \n# %\nCommon Share Statistics \nCash dividends declared per common share\n$\n2.08\n$\n1.72\n$\n1.72\n$\n0.36 \n21 %\n$\n \n %\nAverage common shares outstanding:\nBasic\n751\n789\n805\n(38)\n(5)%\n(16)\n(2)%\nDiluted\n752\n790\n806\n(38)\n(5)%\n(16)\n(2)%\nSelected Metrics and Ratios\nNetwork volumes (Billions)\n$\n1,552.8\n$\n1,284.2\n$\n1,037.8\n$\n269 \n21 %\n$\n246 \n24 %\nReturn on average equity \n32.3 %\n33.7 %\n14.2 %\nNet interest income divided by average Card Member loans\n10.4 %\n10.2 %\n10.7 %\nNet interest yield on average Card Member loans\n10.6 %\n10.7 %\n11.5 %\nEffective tax rate\n21.6 %\n24.6 %\n27.0 %\nCommon Equity Tier 1\n10.3 %\n10.5 %\n13.5 %\nSelected Balance Sheet Data\nCash and cash equivalents\n$\n33,914\n$\n22,028\n$\n32,965\n$\n11,886 \n54 %\n$\n(10,937)\n(33)%\nCard Member receivables\n57,613\n53,645\n43,701\n3,968 \n7 \n9,944 \n23 \nCard Member loans\n107,964\n88,562\n73,373\n19,402 \n22 \n15,189 \n21 \nCustomer deposits\n110,239\n84,382\n86,875\n25,857 \n31 \n(2,493)\n(3)\nLong-term debt\n$\n42,573\n$\n38,675\n$\n42,952\n$\n3,898 \n10 %\n$\n(4,277)\n(10)%\n# Denotes a variance of 100 percent or more\n(a)\nRepresents net income, less (i) earnings allocated to participating share awards of $57 million, $56 million and $20 million for the years ended December 31, 2022, 2021 and 2020, respectively,\n(ii) dividends on preferred shares of $57 million, $71 million and $79 million for the years ended December 31, 2022, 2021 and 2020, respectively, and (iii) equity-related adjustments of $16\nmillion related to the redemption of preferred shares for the year ended December 31, 2021. Refer to Note 16 and Note 21 to the Consolidated Financial Statements for further details on\npreferred shares and earnings per common share (EPS), respectively.\n(b)\nOur common stock trades principally on The New York Stock Exchange under the trading symbol AXP.\n(c)\nReturn on average equity (ROE) is calculated by dividing (i) net income for the period by (ii) average shareholders' equity for the period.\n(d)\nNet interest yield on average Card Member loans reflects adjusted net interest income divided by average Card Member loans, computed on an annualized basis. Adjusted net interest income and\nnet interest yield on average Card Member loans are non-GAAP measures. Refer to Table 8 for a reconciliation to Net interest income divided by average Card Member loans.\n(a)\n(b)\n(c)\n (d)\n41\n [END OF FILING]",
    "gt": "The effective tax rate for American Express has changed/dropped from 24.6% in FY 2021 to 21.6% in FY 2022.",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: In 2022 Q2, which of JPM's business segments had the highest net income? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Segment results managed basis\nThe following tables summarize the Firms results by segment for the periods indicated.\nThree months ended June 30,\nConsumer & Community Banking\nCorporate & Investment Bank\nCommercial Banking\n(in millions, except ratios)\n2022\n2021\nChange\n2022\n2021\nChange\n2022\n2021\nChange\nTotal net revenue\n$ \n12,614 $ \n12,760 \n (1) %\n$ 11,947 \n$ \n13,214 \n (10) %\n$ \n2,683 \n$ \n2,483 \n 8 %\nTotal noninterest expense\n \n7,723 \n7,062 \n 9 \n \n6,745 \n \n6,523 \n 3 \n \n1,156 \n \n981 \n 18 \nPre-provision profit/(loss)\n \n4,891 \n5,698 \n (14) \n \n5,202 \n \n6,691 \n (22) \n \n1,527 \n \n1,502 \n 2 \nProvision for credit losses\n \n761 \n(1,868) \nNM\n \n59 \n \n(79) \nNM\n \n209 \n \n(377) \nNM\nNet income/(loss)\n \n3,100 \n5,645 \n(a)\n (45) \n \n3,725 \n \n5,020 \n(a)\n (26) \n \n994 \n \n1,422 \n(a)\n (30) \nReturn on equity (ROE)\n 24 %\n 44 %\n 14 %\n 23 %\n 15 %\n 23 %\nThree months ended June 30,\nAsset & Wealth Management\nCorporate\nTotal\n(in millions, except ratios)\n2022\n2021\nChange\n2022\n2021\nChange\n2022\n2021\nChange\nTotal net revenue\n$ \n4,306 \n$ \n4,107 \n 5 %\n$ \n80 $ (1,169) \nNM\n$ 31,630 \n$ \n31,395 \n 1 %\nTotal noninterest expense\n \n2,919 \n \n2,586 \n 13 \n \n206 \n515 \n (60) \n \n18,749 \n \n17,667 \n 6 \nPre-provision profit/(loss)\n \n1,387 \n \n1,521 \n (9) \n \n(126) \n(1,684) \n 93 \n \n12,881 \n \n13,728 \n (6) \nProvision for credit losses\n \n44 \n \n(10) \nNM\n \n28 \n49 \n (43) \n \n1,101 \n \n(2,285) \nNM\nNet income/(loss)\n \n1,004 \n \n1,156 \n(a)\n (13) \n \n(174) \n(1,295) \n(a)\n 87 \n \n8,649 \n \n11,948 \n (28) \nROE\n \n23 % \n32 %\nNM\nNM\n 13 %\n 18 %\nSix months ended June 30,\nConsumer & Community Banking\nCorporate & Investment Bank\nCommercial Banking\n(in millions, except ratios)\n2022\n2021\nChange\n2022\n2021\nChange\n2022\n2021\nChange\nTotal net revenue\n$ \n24,843 $ \n25,277 \n (2) %\n$ 25,476 \n$ \n27,819 \n (8) %\n$ \n5,081 \n$ \n4,876 \n 4 %\nTotal noninterest expense\n \n15,443 \n14,264 \n 8 \n \n14,043 \n \n13,627 \n 3 \n \n2,285 \n \n1,950 \n 17 \nPre-provision profit/(loss)\n \n9,400 \n11,013 \n (15) \n \n11,433 \n \n14,192 \n (19) \n \n2,796 \n \n2,926 \n (4) \nProvision for credit losses\n \n1,439 \n(5,470) \nNM\n \n504 \n \n(410) \nNM\n \n366 \n \n(495) \nNM\nNet income/(loss)\n \n5,995 \n12,432 \n(a)\n (52) \n \n8,110 \n \n10,944 \n(a)\n (26) \n \n1,844 \n \n2,603 \n(a)\n (29) \nROE\n 23 %\n 49 %\n 15 %\n 26 %\n(a)\n 14 %\n 21 %\nSix months ended June 30,\nAsset & Wealth Management\nCorporate\nTotal\n(in millions, except ratios)\n2022\n2021\nChange\n2022\n2021\nChange\n2022\n2021\nChange\nTotal net revenue\n$ \n8,621 \n$ \n8,184 \n 5 %\n$ \n(801) $ (1,642) \n 51 %\n$ 63,220 \n$ \n64,514 \n (2) %\nTotal noninterest expense\n \n5,779 \n \n5,160 \n 12 \n \n390 \n1,391 \n (72) \n \n37,940 \n \n36,392 \n 4 \nPre-provision profit/(loss)\n \n2,842 \n \n3,024 \n (6) \n \n(1,191) \n(3,033) \n 61 \n \n25,280 \n \n28,122 \n (10) \nProvision for credit losses\n \n198 \n \n(131) \nNM\n \n57 \n65 \n (12) \n \n2,564 \n \n(6,441) \nNM\nNet income/(loss)\n \n2,012 \n \n2,416 \n(a)\n (17) \n \n(1,030) \n(2,147) \n(a)\n 52 \n \n16,931 \n \n26,248 \n (35) \nROE\n \n23 % \n34 %\nNM\nNM\n 13 %\n 21 %\n(a) In the first quarter of 2022, the Firm changed its methodology for allocating income taxes to the LOBs, with no impact to Firmwide net income. Prior-\nperiod amounts have been revised to conform with the current presentation.\nThe following sections provide a comparative discussion of the Firms results by segment as of or for the three and six months \nended June 30, 2022 versus the corresponding period in the prior year, unless otherwise specified.\n21\n [END OF FILING]",
    "gt": "Corporate & Investment Bank. Its net income was $3725 million.",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: What is the quantity of restructuring costs directly outlined in AES Corporation's income statements for FY2022? If restructuring costs are not explicitly outlined then state 0. \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] 129 \nConsolidated Statements of Operations\nYears ended December 31, 2022, 2021, and 2020\n2022\n2021\n2020\n(in millions, except per share amounts)\nRevenue:\nRegulated\n$\n3,538 \n$\n2,868 \n$\n2,661 \nNon-Regulated\n9,079 \n8,273 \n6,999 \nTotal revenue\n12,617 \n11,141 \n9,660 \nCost of Sales:\nRegulated\n(3,162)\n(2,448)\n(2,235)\nNon-Regulated\n(6,907)\n(5,982)\n(4,732)\nTotal cost of sales\n(10,069)\n(8,430)\n(6,967)\nOperating margin\n2,548 \n2,711 \n2,693 \nGeneral and administrative expenses\n(207)\n(166)\n(165)\nInterest expense\n(1,117)\n(911)\n(1,038)\nInterest income\n389 \n298 \n268 \nLoss on extinguishment of debt\n(15)\n(78)\n(186)\nOther expense\n(68)\n(60)\n(53)\nOther income\n102 \n410 \n75 \nLoss on disposal and sale of business interests\n(9)\n(1,683)\n(95)\nGoodwill impairment expense\n(777)\n \n \nAsset impairment expense\n(763)\n(1,575)\n(864)\nForeign currency transaction gains (losses)\n(77)\n(10)\n55 \nOther non-operating expense\n(175)\n \n(202)\nINCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE TAXES AND EQUITY IN EARNINGS OF AFFILIATES\n(169)\n(1,064)\n488 \nIncome tax benefit (expense)\n(265)\n133 \n(216)\nNet equity in losses of affiliates\n(71)\n(24)\n(123)\nINCOME (LOSS) FROM CONTINUING OPERATIONS\n(505)\n(955)\n149 \nGain from disposal of discontinued businesses, net of income tax expense of $0, $1, and $0, respectively\n \n4 \n3 \nNET INCOME (LOSS)\n(505)\n(951)\n152 \nLess: Net loss (income) attributable to noncontrolling interests and redeemable stock of subsidiaries\n(41)\n542 \n(106)\nNET INCOME (LOSS) ATTRIBUTABLE TO THE AES CORPORATION\n$\n(546)\n$\n(409)\n$\n46 \nAMOUNTS ATTRIBUTABLE TO THE AES CORPORATION COMMON STOCKHOLDERS:\nIncome (loss) from continuing operations, net of tax\n$\n(546)\n$\n(413)\n$\n43 \nIncome from discontinued operations, net of tax\n \n4 \n3 \nNET INCOME (LOSS) ATTRIBUTABLE TO THE AES CORPORATION\n$\n(546)\n$\n(409)\n$\n46 \nBASIC EARNINGS PER SHARE:\nIncome (loss) from continuing operations attributable to The AES Corporation common stockholders, net of tax\n$\n(0.82)\n$\n(0.62)\n$\n0.06 \nIncome from discontinued operations attributable to The AES Corporation common stockholders, net of tax\n \n0.01 \n0.01 \nNET INCOME (LOSS) ATTRIBUTABLE TO THE AES CORPORATION COMMON STOCKHOLDERS\n$\n(0.82)\n$\n(0.61)\n$\n0.07 \nDILUTED EARNINGS PER SHARE:\nIncome (loss) from continuing operations attributable to The AES Corporation common stockholders, net of tax\n$\n(0.82)\n$\n(0.62)\n$\n0.06 \nIncome from discontinued operations attributable to The AES Corporation common stockholders, net of tax\n \n0.01 \n0.01 \nNET INCOME (LOSS) ATTRIBUTABLE TO THE AES CORPORATION COMMON STOCKHOLDERS\n$\n(0.82)\n$\n(0.61)\n$\n0.07 \nSee Accompanying Notes to Consolidated Financial Statements.\n [END OF FILING]",
    "gt": "0",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: We need to calculate a financial metric by using information only provided within the balance sheet. Please answer the following question: what is Boeing's year end FY2018 net property, plant, and equipment (in USD millions)? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Table of Contents\nThe Boeing Company and Subsidiaries\nConsolidated Statements of Financial Position \n(Dollarsinmillions,exceptpersharedata)\n\n \nDecember 31,\n2018\n\n2017\nAssets\n\n \nCash and cash equivalents\n$7,637\n\n$8,813\nShort-term and other investments\n927\n\n1,179\nAccounts receivable, net\n3,879\n\n2,894\nUnbilled receivables, net\n10,025\n\n8,194\nCurrent portion of customer financing, net\n460\n\n309\nInventories\n62,567\n\n61,388\nOther current assets\n2,335\n\n2,417\nTotal current assets\n87,830\n\n85,194\nCustomer financing, net\n2,418\n\n2,756\nProperty, plant and equipment, net\n12,645\n\n12,672\nGoodwill\n7,840\n\n5,559\nAcquired intangible assets, net\n3,429\n\n2,573\nDeferred income taxes\n284\n\n321\nInvestments\n1,087\n\n1,260\nOther assets, net of accumulated amortization of $503 and $482\n1,826\n\n2,027\nTotal assets\n$117,359\n\n$112,362\nLiabilities and equity\n\n \nAccounts payable\n$12,916\n\n$12,202\nAccrued liabilities\n14,808\n\n13,069\nAdvances and progress billings\n50,676\n\n48,042\nShort-term debt and current portion of long-term debt\n3,190\n\n1,335\nTotal current liabilities\n81,590\n\n74,648\nDeferred income taxes\n1,736\n\n2,188\nAccrued retiree health care\n4,584\n\n5,545\nAccrued pension plan liability, net\n15,323\n\n16,471\nOther long-term liabilities\n3,059\n\n2,015\nLong-term debt\n10,657\n\n9,782\nShareholders equity:\n\n \nCommon stock, par value $5.00 1,200,000,000 shares authorized; 1,012,261,159 shares issued\n5,061\n\n5,061\nAdditional paid-in capital\n6,768\n\n6,804\nTreasury stock, at cost\n(52,348) \n(43,454)\nRetained earnings\n55,941\n\n49,618\nAccumulated other comprehensive loss\n(15,083) \n(16,373)\nTotal shareholders equity\n339\n\n1,656\nNoncontrolling interests\n71\n\n57\nTotal equity\n410\n\n1,713\nTotal liabilities and equity\n$117,359\n\n$112,362\nSee Notes to the Consolidated Financial Statements on pages 54 113 .\n50\n [END OF FILING]",
    "gt": "$12645.00",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: Looking at VaR, did the risk that JPM faced in the second fiscal quarter of 2023 decrease compared to the same period in the prior year? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] The table below shows the results of the Firms Risk Management VaR measure using a 95% confidence level. VaR can vary \nsignificantly as positions change, market volatility fluctuates, and diversification benefits change.\nTotal VaR\nThree months ended\nJune 30, 2023\nMarch 31, 2023\nJune 30, 2022\n(in millions)\n Avg.\nMin\nMax\n Avg.\nMin\nMax\n Avg.\nMin\nMax\nCIB trading VaR by risk type\nFixed income\n$ 57 \n$ 50 \n$ 66 \n$ 56 \n$ 45 \n$ 71 \n$ 60 \n$ 48 \n$ 79 \nForeign exchange\n \n12 \n \n7 \n 24 \n \n10 \n \n6 \n \n17 \n \n8 \n \n4 \n 13 \nEquities\n \n8 \n \n5 \n 11 \n \n7 \n \n5 \n \n10 \n 11 \n \n7 \n 15 \nCommodities and other\n \n12 \n \n8 \n 17 \n \n15 \n \n11 \n \n19 \n 14 \n \n12 \n 17 \nDiversification benefit to CIB trading VaR(a)\n (48) \n NM\n NM\n (44) \nNM\nNM\n (43) \nNM\nNM\nCIB trading VaR\n \n41 \n \n31 \n 50 \n \n44 \n \n34 \n \n55 \n 50 \n \n38 \n 66 \nCredit Portfolio VaR(b)\n \n14 \n \n11 \n 18 \n \n11 \n \n8 \n \n17 \n 17 \n \n6 \n 31 \n(e)\nDiversification benefit to CIB VaR(a)\n (11) \n NM\n NM\n (10) \nNM\nNM\n (15) \nNM\nNM\nCIB VaR\n \n44 \n \n34 \n 55 \n \n45 \n \n35 \n \n58 \n 52 \n \n38 \n 70 \nCCB VaR\n \n9 \n(d) \n6 \n 14 \n \n11 \n \n6 \n \n15 \n \n5 \n(d) \n4 \n \n6 \nCorporate and other LOB VaR(c)\n \n13 \n \n11 \n 15 \n \n15 \n \n13 \n \n17 \n 10 \n \n9 \n 11 \nDiversification benefit to other VaR(a)\n \n(7) \n NM\n NM\n \n(8) \nNM\nNM\n \n(3) \nNM\nNM\nOther VaR\n \n15 \n \n13 \n 19 \n \n18 \n \n14 \n \n22 \n 12 \n \n10 \n 14 \nDiversification benefit to CIB and other VaR(a)\n (12) \n NM\n NM\n (16) \nNM\nNM\n (10) \nNM\nNM\nTotal VaR\n$ 47 \n$ 36 \n$ 56 \n$ 47 \n$ 37 \n$ 57 \n$ 54 \n$ 41 \n$ 71 \n(a) Diversification benefit represents the difference between the portfolio VaR and the sum of its individual components. This reflects the non-additive nature \nof VaR due to imperfect correlation across LOBs, Corporate, and risk types. For maximum and minimum VaR, diversification benefit is not meaningful as \nthe maximum and minimum VaR for each portfolio may have occurred on different trading days than the components.\n(b) Credit portfolio VaR includes the derivative CVA, hedges of the CVA and hedges of the retained loan portfolio, which are reported in principal transactions \nrevenue. This VaR does not include the retained loan portfolio, which is not reported at fair value. In the first quarter of 2022, in line with the Firm's \ninternal model governance, the credit risk component of CVA related to certain counterparties was removed from Credit Portfolio VaR due to the widening \nof the credit spreads for those counterparties to elevated levels. The related hedges were also removed to maintain consistency. This exposure is now \nreflected in other sensitivity-based measures.\n(c) Corporate and other LOB VaR includes a legacy private equity position in Corporate which is publicly traded.\n(d) The increase in CCB VaR is driven by interest rate volatility impacting Home Lending warehouse loans, MSR, and related hedges.\n(e) For the period ended June 30, 2022, maximum Credit Portfolio VaR remained elevated due to the effects of nickel price increases and the associated \nvolatility in the nickel market which occurred during the first quarter of 2022.\nQuarter over quarter results\nAverage total VaR was flat for the three months ended \nJune 30, 2023, when compared with March 31, 2023, \nreflecting increases in fixed income offset by market volatility \nrelating to commodities rolling out of the one-year historical \nlook-back period. \nYear over year results\nAverage total VaR decreased by $7 million for the three \nmonths ended June 30, 2023, compared with the same \nperiod in the prior year predominantly driven by risk \nreductions impacting Credit Portfolio VaR as well as fixed \nincome.\nThe following graph presents daily Risk Management VaR for the five trailing quarters.\nDaily Risk Management VaR\n$ millions\n0\n50\n100\nSecond Quarter\n2022\nThird Quarter\n2022\nFourth Quarter\n2022\nFirst Quarter\n2023\nSecond Quarter\n2023\n85\n [END OF FILING]",
    "gt": "Yes. It decreased.",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: Does Adobe have an improving Free cashflow conversion as of FY2022? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] ADOBE INC.\n CONSOLIDATED STATEMENTS OF CASH FLOWS\n(In millions)\n \nYears Ended\n \nDecember 2,\n2022\nDecember 3,\n2021\nNovember 27,\n2020\nCash flows from operating activities:\n \n \nNet income\n$ \n4,756 \n$ \n4,822 \n$ \n5,260 \nAdjustments to reconcile net income to net cash provided by operating activities:\nDepreciation, amortization and accretion\n \n856 \n \n788 \n \n757 \nStock-based compensation\n \n1,440 \n \n1,069 \n \n909 \nReduction of operating lease right-of-use assets\n \n83 \n \n73 \n \n87 \nDeferred income taxes\n \n328 \n \n183 \n \n(1,501) \nUnrealized losses (gains) on investments, net\n \n29 \n \n(4) \n(11) \nOther non-cash items\n \n10 \n \n7 \n \n40 \nChanges in operating assets and liabilities, net of acquired assets and \n assumed liabilities:\nTrade receivables, net\n \n(198) \n(430) \n106 \nPrepaid expenses and other assets\n \n(94) \n(475) \n(288) \nTrade payables\n \n66 \n \n(20) \n96 \nAccrued expenses and other liabilities\n \n7 \n \n162 \n \n86 \nIncome taxes payable\n \n19 \n \n2 \n \n(72) \nDeferred revenue\n \n536 \n \n1,053 \n \n258 \nNet cash provided by operating activities\n \n7,838 \n \n7,230 \n \n5,727 \nCash flows from investing activities:\n \n \nPurchases of short-term investments\n \n(909) \n(1,533) \n(1,071) \nMaturities of short-term investments\n \n683 \n \n877 \n \n915 \nProceeds from sales of short-term investments\n \n270 \n \n191 \n \n167 \nAcquisitions, net of cash acquired\n \n(126) \n(2,682) \n \nPurchases of property and equipment\n \n(442) \n(348) \n(419) \nPurchases of long-term investments, intangibles and other assets\n \n(46) \n(42) \n(15) \nProceeds from sales of long-term investments and other assets\n \n \n \n \n \n9 \nNet cash used for investing activities\n \n(570) \n(3,537) \n(414) \nCash flows from financing activities:\n \n \nRepurchases of common stock\n \n(6,550) \n(3,950) \n(3,050) \nProceeds from re-issuance of treasury stock\n \n278 \n \n291 \n \n270 \nTaxes paid related to net share settlement of equity awards\n \n(518) \n(719) \n(681) \nProceeds from issuance of debt\n \n \n \n \n \n3,144 \nRepayment of debt\n \n \n \n \n \n(3,150) \nOther financing activities, net\n \n(35) \n77 \n \n(21) \nNet cash used for financing activities\n \n(6,825) \n(4,301) \n(3,488) \nEffect of foreign currency exchange rates on cash and cash equivalents\n \n(51) \n(26) \n3 \nNet change in cash and cash equivalents\n \n392 \n \n(634) \n1,828 \nCash and cash equivalents at beginning of year\n \n3,844 \n \n4,478 \n \n2,650 \nCash and cash equivalents at end of year\n$ \n4,236 \n$ \n3,844 \n$ \n4,478 \nSupplemental disclosures:\n \nCash paid for income taxes, net of refunds\n$ \n778 \n$ \n843 \n$ \n469 \nCash paid for interest\n$ \n103 \n$ \n100 \n$ \n88 \nSee accompanying Notes to Consolidated Financial Statements.\nTable of Contents\n57\n [END OF FILING]",
    "gt": "Yes, the FCF conversion (using net income as the denominator) for Adobe has improved by ~13% from 143% in 2021 to 156% in 2022",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: Has MGM Resorts paid dividends to common shareholders in FY2022? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] PART II\nITEM 5. MARKET FOR REGISTRANTS COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF\nEQUITY SECURITIES\nCommon Stock Information\nOur common stock is traded on the New York Stock Exchange (NYSE) under the symbol MGM.\nThere were approximately 3,143 record holders of our common stock as of February 22, 2023.\nDividend Policy\nWe implemented a dividend program in February 2017 pursuant to which it has paid regular quarterly dividends. In the second quarter of 2020, we\nreduced our annual dividend to $0.01 per share in light of the impact of the COVID-19 pandemic on our operations at that time. We maintained an annual\ndividend of $0.01 per share throughout 2022. On February 8, 2023, we announced that the Board of Directors has determined to suspend the ongoing dividends\nin light of our current preferred method of returning value to shareholders through our share repurchase plan. To the extent we determine to reinstate the\ndividend in the future, the amount, declaration and payment of any future dividends will be subject to the discretion of our Board of Directors who will\nevaluate our dividend policy from time to time based on factors it deems relevant, and the contractual limitations described below.\nPurchases of Equity Securities by the Issuer\nThe following table provides information about share repurchases of our common stock during the quarter ended December 31, 2022:\nPeriod\nTotal Number of\nShares Purchased\nAverage Price Paid\nper Share\nTotal Number of\nShares Purchased as\nPart of a Publicly\nAnnounced Program\nDollar Value of\nShares that May Yet\nbe Purchased Under\nthe Program\n(In thousands)\nOctober 1, 2022 October 31, 2022\n5,727,219 \n$\n31.74 \n5,727,219 \n$\n645,485 \nNovember 1, 2022 November 30, 2022\n1,259,233 \n$\n33.65 \n1,259,233 \n$\n603,108 \nDecember 1, 2022 December 31, 2022\n3,700,000 \n$\n34.61 \n3,700,000 \n$\n475,049 \nIn March 2022, we announced that the Board of Directors authorized a $2.0 billion stock repurchase plan and in February 2023, we announced that the\nBoard of Directors had authorized a $2.0 billion stock repurchase plan. Under the stock repurchase plans, we may repurchase shares from time to time in the\nopen market or in privately negotiated agreements. Repurchases of common stock may also be made under a Rule 10b5-1 plan, which would permit common\nstock to be purchased when we might otherwise be precluded from doing so under insider trading laws. The timing, volume and nature of stock repurchases\nwill be at the sole discretion of management, dependent on market conditions, applicable securities laws, and other factors, and may be suspended or\ndiscontinued at any time. All shares we repurchased during the quarter ended December 31, 2022 were purchased pursuant to our publicly announced stock\nrepurchase plans and have been retired.\n30\n [END OF FILING]",
    "gt": "Yes. MGM maintained 0.01$ per share annual dividend through out FY 2022.",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: What is Amazon's year-over-year change in revenue from FY2016 to FY2017 (in units of percents and round to one decimal place)? Calculate what was asked by utilizing the line items clearly shown in the statement of income. \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Table of Contents\nAMAZON.COM, INC.\nCONSOLIDATED STATEMENTS OF OPERATIONS\n(in millions, except per share data)\n \n \nYear Ended December 31,\n \n2015\n \n2016\n \n2017\nNet product sales\n$\n79,268 $\n94,665 $\n118,573\nNet service sales\n27,738 \n41,322 \n59,293\nTotal net sales\n107,006 \n135,987 \n177,866\nOperating expenses:\n \n \n \nCost of sales\n71,651 \n88,265 \n111,934\nFulfillment\n13,410 \n17,619 \n25,249\nMarketing\n5,254 \n7,233 \n10,069\nTechnology and content\n12,540 \n16,085 \n22,620\nGeneral and administrative\n1,747 \n2,432 \n3,674\nOther operating expense, net\n171 \n167 \n214\nTotal operating expenses\n104,773 \n131,801 \n173,760\nOperating income\n2,233 \n4,186 \n4,106\nInterest income\n50 \n100 \n202\nInterest expense\n(459) \n(484) \n(848)\nOther income (expense), net\n(256) \n90 \n346\nTotal non-operating income (expense)\n(665) \n(294) \n(300)\nIncome before income taxes\n1,568 \n3,892 \n3,806\nProvision for income taxes\n(950) \n(1,425) \n(769)\nEquity-method investment activity, net of tax\n(22) \n(96) \n(4)\nNet income\n$\n596 $\n2,371 $\n3,033\nBasic earnings per share\n$\n1.28 $\n5.01 $\n6.32\nDiluted earnings per share\n$\n1.25 $\n4.90 $\n6.15\nWeighted-average shares used in computation of earnings per share:\n \n \n \nBasic\n467 \n474 \n480\nDiluted\n477 \n484 \n493\nSee accompanying notes to consolidated financial statements.\n38\n [END OF FILING]",
    "gt": "30.8%",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: What are three main companies acquired by Pfizer mentioned in this 10K report? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Notes to Consolidated Financial Statements\nPfizer Inc. and Subsidiary Companies\nWe regularly monitor our position and subsequently recognize the unrecognized tax benefit: (i) if there are changes in tax law, analogous case law or there is new information that\nsufficiently raise the likelihood of prevailing on the technical merits of the position to more likely than not; (ii) if the statute of limitations expires; or (iii) if there is a completion of an\naudit resulting in a favorable settlement of that tax year with the appropriate agency. Liabilities for uncertain tax positions are classified as current only when we expect to pay cash\nwithin the next 12 months. Interest and penalties, if any, are recorded in Provision/(benefit) for taxes on income and are classified on our consolidated balance sheet with the related\ntax liability.\nOur assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax\nbenefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the\nstatutes of limitations expire, as we treat these events as discrete items in the period of resolution.\nR. Pension and Postretirement Benefit Plans\nThe majority of our employees worldwide are covered by defined benefit pension plans, defined contribution plans or both. In the U.S., we have both IRC-qualified and supplemental\n(non-qualified) defined benefit plans and defined contribution plans, as well as other postretirement benefit plans consisting primarily of medical insurance for retirees and their eligible\ndependents. We recognize the overfunded or underfunded status of each of our defined benefit plans as an asset or liability. The obligations are generally measured at the actuarial\npresent value of all benefits attributable to employee service rendered, as provided by the applicable benefit formula. Our pension and other postretirement obligations may be\ndetermined using assumptions such as discount rate, expected annual rate of return on plan assets, expected employee turnover and participant mortality. For our pension plans, the\nobligation may also include assumptions as to future compensation levels. For our other postretirement benefit plans, the obligation may include assumptions as to the expected cost\nof providing medical insurance benefits, as well as the extent to which those costs are shared with the employee or others (such as governmental programs). Plan assets are\nmeasured at fair value. Net periodic pension and postretirement benefit costs other than the service costs are recognized in Other (income)/deductionsnet.\nS. Legal and Environmental Contingencies\nWe and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, such as patent litigation, product liability and other product-related\nlitigation, commercial litigation, environmental claims and proceedings, government investigations and guarantees and indemnifications. In assessing contingencies related to legal\nand environmental proceedings that are pending against the Company, or unasserted claims that are probable of being asserted, we record accruals for these contingencies to the\nextent that we conclude that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the\nrange, we accrue that amount. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, we accrue the lowest amount in the range.\nWe record anticipated recoveries under existing insurance contracts when recovery is assured.\nT. Share-Based Payments\nOur compensation programs can include share-based payments. Generally, grants under share-based payment programs are accounted for at fair value and these fair values are\ngenerally amortized on a straight-line basis over the vesting terms with the related costs recorded in Cost of sales, Selling, informational and administrative expenses and/or Research\nand development expenses, as appropriate.\nNote 2. Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements\nA. Acquisitions\nTrillium\nOn November 17, 2021, we acquired all of the issued and outstanding common stock not already owned by Pfizer of Trillium, a clinical stage immuno-oncology company developing\ntherapies targeting cancer immune evasion pathways and specific cell targeting approaches, for a price of $18.50 per share in cash, for total consideration of $2.0 billion, net of cash\nacquired. As a result, Trillium became our wholly owned subsidiary. We previously held a 2% ownership investment in Trillium. Trilliums lead program, TTI-622, is an investigational\nfusion protein that is designed to block the inhibitory activity of CD47, a molecule that is overexpressed by a wide variety of tumors.\nWe accounted for the transaction as an asset acquisition since the lead asset, TTI-622, represented substantially all of the fair value of the gross assets acquired, which exclude cash\nacquired. At the acquisition date, we recorded a $2.1 billion charge representing an acquired IPR&D asset with no alternative future use in Research and development expenses, of\nwhich the $2.0 billion net cash consideration is presented as a cash outflow from operating activities. In connection with this acquisition, we recorded $256 million of assets acquired\nprimarily consisting of cash and investments. Liabilities assumed were approximately $81 million.\nArray\nOn July 30, 2019, we acquired Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule\nmedicines to treat cancer and other diseases of high unmet need, for $48 per share in cash. The total fair value of the consideration transferred was $11.2 billion ($10.9 billion, net of\ncash acquired). In addition, $157 million in payments to Array employees for the fair value of previously unvested stock options was recognized as post-closing compensation expense\nand recorded in Restructuring charges and certain acquisition-related costs (see Note 3). We financed the majority of the transaction with debt and the balance with existing cash.\nPfizer Inc.\n2021 Form 10-K\n64\n\n\nNotes to Consolidated Financial Statements\nPfizer Inc. and Subsidiary Companies\nArrays portfolio includes Braftovi (encorafenib) and Mektovi (binimetinib), a broad pipeline of targeted cancer medicines in different stages of R&D, as well as a portfolio of out-\nlicensed medicines, which may generate milestones and royalties over time.\nThe final allocation of the consideration transferred to the assets acquired and the liabilities assumed was completed in 2020. In connection with this acquisition, we recorded: (i) $6.3\nbillion in Identifiable intangible assets, consisting of $2.0 billion of Developed technology rights with a useful life of 16 years, $2.8 billion of IPR&D and $1.5 billion of Licensing\nagreements and other ($1.2 billion for technology in developmentindefinite-lived licensing agreements and $360 million for developed technologyfinite-lived licensing agreements\nwith a useful life of 10 years), (ii) $6.1 billion of Goodwill, (iii) $1.1 billion of net deferred tax liabilities and (iv) $451 million of assumed long-term debt, which was paid in full in 2019.\nIn 2020, we recorded measurement period adjustments to the estimated fair values initially recorded in 2019, which resulted in a reduction in Identifiable intangible assets of\napproximately $900 million with a corresponding change to Goodwill and net deferred tax liabilities. The measurement period adjustments were recorded to better reflect market\nparticipant assumptions about facts and circumstances existing as of the acquisition date and did not have a material impact on our consolidated statement of income for the year\nended December 31, 2020.\nTherachon\nOn July 1, 2019, we acquired all the remaining shares of Therachon, a privately-held clinical-stage biotechnology company focused on rare diseases, with assets in development for\nthe treatment of achondroplasia, a genetic condition and the most common form of short-limb dwarfism, for $340 million upfront, plus potential milestone payments of up to $470\nmillion contingent on the achievement of key milestones in the development and commercialization of the lead asset. We accounted for the transaction as an asset acquisition since\nthe lead asset represented substantially all the fair value of the gross assets acquired. The total fair value of the consideration transferred for Therachon was $322 million, which\nconsisted of $317 million of cash and our previous $5 million investment in Therachon. In connection with this asset acquisition, we recorded a charge of $337 million in Research and\ndevelopment expenses.\nB. Divestitures\nMeridian\nOn December 31, 2021, we completed the sale of our Meridian subsidiary for approximately $51 million in cash and recognized a loss of approximately $167 million, net of tax, in\nDiscontinued operationsnet of tax. In connection with the sale, Pfizer and the purchaser of Meridian entered into various agreements to provide a framework for our relationship\nafter the sale, including interim TSAs and a manufacturing supply agreement (MSA). The TSAs primarily involve Pfizer providing services related to information technology, among\nother activities, and are generally expected to be for terms of no more than 12 to 18 months post sale. The MSA is for a term of three years post sale with a two year extension period.\nNo amounts were recorded under the above arrangements in 2021.\nUpjohn Separation and Combination with Mylan\nOn November 16, 2020, we completed the spin-off and the combination of the Upjohn Business with Mylan (the Transactions) to form Viatris.\nThe Transactions were structured as an all-stock, Reverse Morris Trust transaction. Specifically, (i) we contributed the Upjohn Business to a wholly owned subsidiary, which was\nrenamed Viatris, so that the Upjohn Business was separated from the remainder of our business (the Separation), (ii) following the Separation, we distributed, on a pro rata basis, all\nof the shares of Viatris common stock held by Pfizer to Pfizer stockholders as of the November 13, 2020 record date, such that each Pfizer stockholder as of the record date received\napproximately 0.124079 shares of Viatris common stock per share of Pfizer common stock (the Distribution); and (iii) immediately after the Distribution, the Upjohn Business combined\nwith Mylan in a series of transactions in which Mylan shareholders received one share of Viatris common stock for each Mylan ordinary share held by such shareholder, subject to any\napplicable withholding taxes (the Combination). Prior to the Distribution, Viatris made a cash payment to Pfizer equal to $12.0 billion as partial consideration for the contribution of the\nUpjohn Business to Viatris. As of the closing of the Combination, Pfizer stockholders owned approximately 57% of the outstanding shares of Viatris common stock, and Mylan\nshareholders owned approximately 43% of the outstanding shares of Viatris common stock, in each case on a fully diluted, as-converted and as-exercised basis. The Transactions are\ngenerally expected to be tax free to Pfizer and Pfizer stockholders for U.S. tax purposes. Beginning November 16, 2020, Viatris operates both the Upjohn Business and Mylan as an\nindependent publicly traded company, which is traded under the symbol VTRS on the NASDAQ.\nIn connection with the Transactions, in June 2020, Upjohn Inc. and Upjohn Finance B.V. completed privately placed debt offerings of $7.45 billion and 3.60 billion aggregate principal\namounts, respectively, (approximately $11.4 billion) of senior unsecured notes and entered into other financing arrangements, including a $600 million delayed draw term loan\nagreement and a revolving credit facility agreement for up to $4.0 billion. Proceeds from the debt offerings and other financing arrangements were used to fund the $12.0 billion cash\ndistribution Viatris made to Pfizer prior to the Distribution. We used the cash distribution proceeds to pay down commercial paper borrowings and redeem the $1.15 billion aggregate\nprincipal amount outstanding of our 1.95% senior unsecured notes that were due in June 2021 and $342 million aggregate principal amount outstanding of our 5.80% senior\nunsecured notes that were due in August 2023, before the maturity date. Interest expense for the $11.4 billion in debt securities incurred during 2020 is included in Discontinued\noperationsnet of tax. Following the Separation and Combination of the Upjohn Business with Mylan, we are no longer the obligor or guarantor of any Upjohn debt or Upjohn\nfinancing arrangements.\nAs a result of the spin-off of the Upjohn Business, we distributed net assets of $1.6 billion as of November 16, 2020, which was reflected as a reduction to Retained earnings and\nreflects the change in accounting principle in the first quarter of 2021 to MTM Accounting. See Note 1C. Of this amount, $412 million represents cash transferred to the Upjohn\nBusiness, with the remainder considered a non-cash activity in the consolidated statement of cash flows for the year ended December 31, 2020. The spin-off also resulted in a net\nincrease to Accumulated other comprehensive loss of $423 million for the derecognition of net gains on foreign currency translation adjustments of $397 million and prior service net\ncredits associated with benefit plans of $26 million, which were reclassified to Retained earnings.\nAs a result of the separation of Upjohn, we incurred separation-related costs of $434 million in 2020 and $83 million in 2019, which are included in Discontinued operationsnet of\ntax. These costs primarily relate to professional fees for regulatory filings and separation activities within finance, tax, legal and information system functions as well as investment\nbanking fees.\nPfizer Inc.\n2021 Form 10-K\n65\n [END OF FILING]",
    "gt": "Trillium, Array, and Therachon",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: For Pfizer, which geographic region had the biggest drop in Q22023 year over year revenues (on a percentage basis)? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] PFIZER INC. AND SUBSIDIARY COMPANIES.\nNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\n(UNAUDITED)\nSegment AssetsWe manage our assets on a total company basis, not by operating segment, as our operating assets are shared or commingled. Therefore, our\nchief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by\noperating segment. Total assets were $220 billion as of July 2, 2023 and $197 billion as of December 31, 2022.\nSelected Income Statement Information\nThe following provides selected income statement information by reportable segment:\nThree Months Ended\nSix Months Ended\n \nRevenues\nEarnings\nRevenues\nEarnings\n(MILLIONS)\nJuly 2,\n2023\nJuly 3,\n2022\nJuly 2,\n2023\nJuly 3,\n2022\nJuly 2,\n2023\nJuly 3,\n2022\nJuly 2,\n2023\nJuly 3,\n2022\nReportable Segment:\nBiopharma\n$\n12,418 \n$\n27,425 \n$\n7,003 \n$\n17,166 \n$\n30,389 \n$\n52,748 \n$\n17,939 \n$\n30,557 \nOther business activities\n316 \n317 \n(2,871)\n(3,384)\n626 \n655 \n(5,605)\n(5,812)\nReconciling Items:\nAmortization of intangible assets\n(1,184)\n(822)\n(2,287)\n(1,657)\nAcquisition-related items\n(387)\n(82)\n(550)\n(269)\nCertain significant items\n(293)\n(1,431)\n(958)\n(2,322)\n$\n12,734 \n$\n27,742 \n$\n2,269 \n$\n11,447 \n$\n31,015 \n$\n53,402 \n$\n8,539 \n$\n20,497 \nIncome from continuing operations before provision/(benefit) for taxes on income. Biopharmas earnings include dividend income from our investment in ViiV of $91 million in the second quarter\nof 2023 and $69 million in the second quarter of 2022, and $183 million in the first six months of 2023 and $125 million in the first six months of 2022. In connection with the organizational\nchanges effective in the third quarter of 2022, certain functions transferred between Biopharma and corporate enabling functions and certain activities were realigned within the GPD organization.\nWe have reclassified $58 million of costs in the second quarter of 2022 and $105 million in the first six months of 2022 from corporate enabling functions, which are included in Other business\nactivities, to Biopharma to conform to the current period presentation.\nOther business activities include revenues and costs associated with Business Innovation and costs that we do not allocate to our operating segments, per above, including acquired IPR&D\nexpenses in the periods presented. Earnings in the second quarter and first six months of 2023 include approximately $140 million and $260 million, respectively, of write-offs to Cost of sales of\ninventory related to COVID-19 products that exceeded or were expected to exceed their approved shelf-lives prior to being used. Earnings in the second quarter and first six months of 2022\nincluded a $450 million write-off to Cost of sales of inventory related to COVID-19 products that exceeded or were expected to exceed their approved shelf-lives prior to being used.\nCertain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above). Earnings in the second quarter and first six months of 2022 included, among other\nitems, net losses on equity securities of $539 million and $1.2 billion, respectively, recorded in Other (income)/deductionsnet. See Note 4.\nB. Geographic Information\nThe following summarizes revenues by geographic area:\n \nThree Months Ended\nSix Months Ended\n(MILLIONS)\nJuly 2,\n2023\nJuly 3,\n2022\n%\nChange\nJuly 2,\n2023\nJuly 3,\n2022\n%\nChange\nUnited States\n$\n6,185 \n$\n11,222 \n(45)\n$\n14,692 \n$\n20,140 \n(27)\nDeveloped Europe\n2,415 \n5,480 \n(56)\n5,236 \n11,569 \n(55)\nDeveloped Rest of World\n1,305 \n5,034 \n(74)\n3,778 \n8,320 \n(55)\nEmerging Markets\n2,828 \n6,006 \n(53)\n7,308 \n13,373 \n(45)\nRevenues\n$\n12,734 \n$\n27,742 \n(54)\n$\n31,015 \n$\n53,402 \n(42)\nIn May 2023, we and our collaboration partner, BioNTech, amended our contract with the EC to deliver COVID-19 vaccines to the EU. The amended\nagreement includes rephasing of delivery of doses annually through 2026 and an aggregate volume reduction, providing additional flexibility for EU member\nstates. The EC will maintain access to future adapted COVID-19 vaccines and the ability to donate doses, in alignment with the original agreement. See Note\n13C.\nC. Other Revenue Information\nSignificant CustomersFor information on our significant wholesale customers, see Note 17C in our 2022 Form 10-K. Additionally, revenues from the U.S.\ngovernment represented 1% and 9% of total revenues for the three and six months ended July 2, 2023, respectively, and 26% and 22% of total revenues for the\nthree and six months ended July 3, 2022, respectively. Accounts receivable from the U.S. government represented less than 1% and 4% of total trade accounts\nreceivable as of July 2, 2023 and December 31, 2022, respectively. Revenues and accounts receivable from the U.S. government primarily represent sales of\nPaxlovid and Comirnaty.\n(a)\n(a)\n(b)\n(c)\n(a)\n(b)\n(c)\n35\n [END OF FILING]",
    "gt": "Developed Rest of the World",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: As of May 26, 2023, what is the total amount Pepsico may borrow under its unsecured revolving credit agreements? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] \n\nItem 8.01.\nOther Events.\n\nEffective May 26, 2023, PepsiCo, Inc. (PepsiCo) terminated the $3,800,000,000 364 day unsecured revolving credit agreement, dated as of\nMay 27, 2022, among PepsiCo, as borrower, the lenders party thereto, and Citibank, N.A., as administrative agent (the 2022 364 Day Credit\nAgreement). There were no outstanding borrowings under the 2022 364 Day Credit Agreement at the time of its termination.\n\nOn May 26, 2023, PepsiCo entered into a new $4,200,000,000 364 day unsecured revolving credit agreement (the 2023 364 Day Credit\nAgreement) among PepsiCo, as borrower, the lenders party thereto, and Citibank, N.A., as administrative agent. The 2023 364 Day Credit Agreement\nenables PepsiCo and its borrowing subsidiaries to borrow up to $4,200,000,000 in U.S. Dollars and/or Euros, subject to customary terms and conditions,\nand expires on May 24, 2024. PepsiCo may also, upon the agreement of either the then existing lenders or of additional banks not currently party to the\n2023 364 Day Credit Agreement, increase the commitments under the 2023 364 Day Credit Agreement to up to $4,950,000,000 in U.S. Dollars and/or\nEuros. PepsiCo may request renewal of the 2023 364 Day Credit Agreement for an additional 364 day period or convert any amounts outstanding into a\nterm loan for a period of up to one year, which term loan would mature no later than the anniversary of the then effective termination date. Subject to\ncertain conditions stated in the 2023 364 Day Credit Agreement, PepsiCo and its borrowing subsidiaries may borrow, prepay and reborrow amounts under\nthe 2023 364 Day Credit Agreement at any time during the term of the 2023 364 Day Credit Agreement. Funds borrowed under the 2023 364 Day Credit\nAgreement may be used for general corporate purposes of PepsiCo and its subsidiaries. The 2023 364 Day Credit Agreement contains customary\nrepresentations and warranties and events of default. In the ordinary course of their respective businesses, the lenders under the 2023 364 Day Credit\nAgreement and their affiliates have engaged, and may in the future engage, in commercial banking and/or investment banking transactions with PepsiCo\nand its affiliates.\n\nEffective May 26, 2023, PepsiCo terminated the $3,800,000,000 five year unsecured revolving credit agreement, dated as of May 27, 2022, among\nPepsiCo, as borrower, the lenders party thereto, and Citibank, N.A., as administrative agent (the 2022 Five Year Credit Agreement). There were no\noutstanding borrowings under the 2022 Five Year Credit Agreement at the time of its termination.\n\nOn May 26, 2023, PepsiCo entered into a new $4,200,000,000 five year unsecured revolving credit agreement (the 2023 Five Year Credit\nAgreement) among PepsiCo, as borrower, the lenders party thereto, and Citibank, N.A., as administrative agent. The 2023 Five Year Credit Agreement\nenables PepsiCo and its borrowing subsidiaries to borrow up to $4,200,000,000 in U.S. Dollars and/or Euros, including a $750,000,000 swing line\nsubfacility for Euro-denominated borrowings permitted to be borrowed on a same day basis, subject to customary terms and conditions, and expires on\nMay 26, 2028. PepsiCo may also, upon the agreement of either the then existing lenders or of additional banks not currently party to the 2023 Five Year\nCredit Agreement, increase the commitments under the 2023 Five Year Credit Agreement to up to $4,950,000,000 in U.S. Dollars and/or Euros. PepsiCo\nmay, once a year, request renewal of the 2023 Five Year Credit Agreement for an additional one year period. Subject to certain conditions stated in the 2023\nFive Year Credit Agreement, PepsiCo and its borrowing subsidiaries may borrow, prepay and reborrow amounts under the 2023 Five Year Credit\nAgreement at any time during the term of the 2023 Five Year Credit Agreement. Funds borrowed under the 2023 Five Year Credit Agreement may be used\nfor general corporate purposes of PepsiCo and its subsidiaries. The 2023 Five Year Credit Agreement contains customary representations and warranties\nand events of default. In the ordinary course of their respective businesses, the lenders under the 2023 Five Year Credit Agreement and their affiliates have\nengaged, and may in the future engage, in commercial banking and/or investment banking transactions with PepsiCo and its affiliates.\n\nThe foregoing descriptions of the 2023 364 Day Credit Agreement and 2023 Five Year Credit Agreement do not purport to be complete and are\nqualified in their entirety by reference to the full text of the 2023 364 Day Credit Agreement and the 2023 Five Year Credit Agreement, as applicable,\nwhich are filed as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and incorporated by reference herein.\n\n1\n [END OF FILING]",
    "gt": "Total amount Pepsico may borrow under unsecured revolving credit agreements = $8,400,000,000.",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: Which debt securities are registered to trade on a national securities exchange under Ulta Beauty's name as of FY2023? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Table of Contents\nUNITED STATES\nSECURITIES AND EXCHANGE COMMISSION\nWashington, DC 20549\nFORM 10-K\n Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934\nFor the fiscal year ended January 28, 2023\nor\n Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934\nFor the transition period from _____________ to _____________\nCommission File Number: 001-33764\nULTA BEAUTY, INC.\n(Exact name of registrant as specified in its charter)\nDelaware\n(State or other jurisdiction of\nincorporation or organization)\n38-4022268\n(I.R.S. Employer\nIdentification No.)\n1000 Remington Blvd., Suite 120\nBolingbrook, Illinois\n(Address of principal executive offices)\n60440\n(Zip code)\nRegistrants telephone number, including area code: (630) 410-4800\nSecurities registered pursuant to Section 12(b) of the Act:\nTitle of each class\nTrading symbol\nName of each exchange on which registered\nCommon stock, par value $0.01 per share\nULTA\nThe NASDAQ Global Select Market\nSecurities registered pursuant to Section 12(g) of the Act: None\nIndicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No\nIndicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934\nduring the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing\nrequirements for the past 90 days. Yes No\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of\nRegulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such\nfiles). Yes No\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or\nemerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth\ncompany in Rule 12b-2 of the Exchange Act.:\nLarge accelerated filer \nAccelerated filer \nNon-accelerated filer \nSmaller reporting company \nEmerging growth company \nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new\nor revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \nIndicate by check mark whether the registrant has filed a report on and attestation to its managements assessment of the effectiveness of its internal control\nover financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or\nissued its audit report. \nIf securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the \nfiling reflect the correction of an error to previously issued financial statements. \nIndicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received\nby any of the registrants executive officers during the relevant recovery period pursuant to 240.10D-1(b). \n [END OF FILING]",
    "gt": "There are none",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: What is the FY2017 return on assets (ROA) for Coca Cola? ROA is defined as: FY2017 net income / (average total assets between FY2016 and FY2017). Round your answer to two decimal places. Give a response to the question by relying on the details shown in the balance sheet and the P&L statement. \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING]  \nTHE COCA-COLA COMPANY AND SUBSIDIARIES\nCONSOLIDATED STATEMENTS OF INCOME\nYear Ended December 31,\n2017\n \n2016\n \n2015\n(In millions except per share data)\n \n \nNET OPERATING REVENUES\n$\n35,410\n $\n41,863\n $\n44,294\nCost of goods sold\n13,256\n \n16,465\n \n17,482\nGROSS PROFIT\n22,154\n \n25,398\n \n26,812\nSelling, general and administrative expenses\n12,496\n \n15,262\n \n16,427\nOther operating charges\n2,157\n \n1,510\n \n1,657\nOPERATING INCOME\n7,501\n \n8,626\n \n8,728\nInterest income\n677\n \n642\n \n613\nInterest expense\n841\n \n733\n \n856\nEquity income (loss) net\n1,071\n \n835\n \n489\nOther income (loss) net\n(1,666) \n(1,234) \n631\nINCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES\n6,742\n \n8,136\n \n9,605\nIncome taxes from continuing operations\n5,560\n \n1,586\n \n2,239\nNET INCOME FROM CONTINUING OPERATIONS\n1,182\n \n6,550\n \n7,366\nIncome from discontinued operations (net of income taxes of $47, $0 and $0, respectively)\n101\n \n\n \n\nCONSOLIDATED NET INCOME\n1,283\n \n6,550\n \n7,366\nLess: Net income attributable to noncontrolling interests\n35\n \n23\n \n15\nNET INCOME ATTRIBUTABLE TO SHAREOWNERS OF\n THE COCA-COLA COMPANY\n$\n1,248\n $\n6,527\n $\n7,351\n \n \n \n \nBasic net income per share from continuing operations1\n$\n0.28\n $\n1.51\n $\n1.69\nBasic net income per share from discontinued operations2\n0.02\n \n\n \n\nBASIC NET INCOME PER SHARE\n$\n0.29\n3 $\n1.51\n $\n1.69\nDiluted net income per share from continuing operations1\n$\n0.27\n $\n1.49\n $\n1.67\nDiluted net income per share from discontinued operations2\n0.02\n \n\n \n\nDILUTED NET INCOME PER SHARE\n$\n0.29\n $\n1.49\n $\n1.67\nAVERAGE SHARES OUTSTANDING BASIC\n4,272\n \n4,317\n \n4,352\nEffect of dilutive securities\n52\n \n50\n \n53\nAVERAGE SHARES OUTSTANDING DILUTED\n4,324\n \n4,367\n \n4,405\n1 Calculated based on net income from continuing operations less net income from continuing operations attributable to noncontrolling\ninterests.\n2 Calculated based on net income from discontinued operations less net income from discontinued operations attributable to noncontrolling\ninterests.\n3 Per share amounts do not add due to\nrounding.\nRefer to Notes to Consolidated Financial Statements.\n72\n\n\n \nTHE COCA-COLA COMPANY AND SUBSIDIARIES\nCONSOLIDATED BALANCE SHEETS\nDecember 31,\n2017\n \n2016\n(In millions except par value)\n \n \nASSETS\n \n \nCURRENT ASSETS\n \n \nCash and cash equivalents\n$\n6,006\n $\n8,555\nShort-term investments\n9,352\n \n9,595\nTOTAL CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS\n15,358\n \n18,150\nMarketable securities\n5,317\n \n4,051\nTrade accounts receivable, less allowances of $477 and $466, respectively\n3,667\n \n3,856\nInventories\n2,655\n \n2,675\nPrepaid expenses and other assets\n2,000\n \n2,481\nAssets held for sale\n219\n \n2,797\nAssets held for sale discontinued operations\n7,329\n \n\nTOTAL CURRENT ASSETS\n36,545\n \n34,010\nEQUITY METHOD INVESTMENTS\n20,856\n \n16,260\nOTHER INVESTMENTS\n1,096\n \n989\nOTHER ASSETS\n4,560\n \n4,248\nPROPERTY, PLANT AND EQUIPMENT net\n8,203\n \n10,635\nTRADEMARKS WITH INDEFINITE LIVES\n6,729\n \n6,097\nBOTTLERS' FRANCHISE RIGHTS WITH INDEFINITE LIVES\n138\n \n3,676\nGOODWILL\n9,401\n \n10,629\nOTHER INTANGIBLE ASSETS\n368\n \n726\nTOTAL ASSETS\n$\n87,896\n $\n87,270\nLIABILITIES AND EQUITY\n \n \nCURRENT LIABILITIES\n \n \nAccounts payable and accrued expenses\n$\n8,748\n $\n9,490\nLoans and notes payable\n13,205\n \n12,498\nCurrent maturities of long-term debt\n3,298\n \n3,527\nAccrued income taxes\n410\n \n307\nLiabilities held for sale\n37\n \n710\n Liabilities held for sale discontinued operations\n1,496\n \n\nTOTAL CURRENT LIABILITIES\n27,194\n \n26,532\nLONG-TERM DEBT\n31,182\n \n29,684\nOTHER LIABILITIES\n8,021\n \n4,081\nDEFERRED INCOME TAXES\n2,522\n \n3,753\nTHE COCA-COLA COMPANY SHAREOWNERS' EQUITY\n \n \n Common stock, $0.25 par value; Authorized 11,200 shares;\n Issued 7,040 and 7,040 shares, respectively\n1,760\n \n1,760\nCapital surplus\n15,864\n \n14,993\nReinvested earnings\n60,430\n \n65,502\nAccumulated other comprehensive income (loss)\n(10,305) \n(11,205)\nTreasury stock, at cost 2,781 and 2,752 shares, respectively\n(50,677) \n(47,988)\nEQUITY ATTRIBUTABLE TO SHAREOWNERS OF THE COCA-COLA COMPANY\n17,072\n \n23,062\nEQUITY ATTRIBUTABLE TO NONCONTROLLING INTERESTS\n1,905\n \n158\nTOTAL EQUITY\n18,977\n \n23,220\nTOTAL LIABILITIES AND EQUITY\n$\n87,896\n $\n87,270\nRefer to Notes to Consolidated Financial Statements.\n74\n [END OF FILING]",
    "gt": "0.01",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: What are major acquisitions that Best Buy has done in FY2023, FY2022 and FY2021? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Vendor Allowances\n \nWe receive funds from our merchandise vendors through a variety of programs and arrangements, primarily in the form of purchases-based or sales-based \nvolumes and for product advertising and placement. We recognize allowances based on purchases and sales as a reduction of cost of sales when the associated \ninventory is sold. Allowances for advertising and placement are recognized as a reduction of cost of sales ratably over the corresponding performance period. \nFunds that are determined to be a reimbursement of specific, incremental and identifiable costs incurred to sell a vendors products are recorded as an offset to \nthe related expense within SG&A when incurred.\n \nAdvertising Costs\n \nAdvertising costs, which are included in SG&A, are expensed the first time the advertisement runs. Advertising costs consist primarily of digital advertisements. \nAdvertising expenses were $864 million, $915 million and $819 million in fiscal 2023, fiscal 2022 and fiscal 2021, respectively.\n \nStock-Based Compensation\n \nWe recognize stock-based compensation expense for the fair value of our stock-based compensation awards, which is determined based on the closing market \nprice of our stock at the date of grant for time-based and performance-based share awards, and Monte-Carlo simulation for market-based share awards. \nCompensation expense is recognized on a straight-line basis over the period in which services are required, except for performance-based share awards that \nvest on a graded basis, in which case the expense is front-loaded or recognized on a graded-attribution basis. Forfeitures are expensed as incurred or upon \ntermination.\n \nComprehensive Income (Loss)\n \nComprehensive income (loss) is computed as net earnings plus certain other items that are recorded directly to shareholders equity.\n \n2. Acquisitions\n \nCurrent Health Ltd.\n \nIn fiscal 2022, we acquired all of the outstanding shares of Current Health Ltd. (Current Health), a care-at-home technology platform, on November 2, 2021, for \nnet cash consideration of $389 million. The acquired assets included $351 million of goodwill that was assigned to our Best Buy Health reporting unit and was \ndeductible for income tax purposes. The acquisition is aligned with our focus in virtual care to enable people in their homes to connect seamlessly with their \nhealth care providers and is included in our Domestic reportable segment and Services revenue category. The acquisition was accounted for using the \nacquisition method of accounting for business combinations and was not material to the results of operations.\n \nTwo Peaks, LLC d/b/a Yardbird Furniture\n \nIn fiscal 2022, we acquired all of the outstanding shares of Two Peaks, LLC d/b/a Yardbird Furniture (Yardbird), a direct-to-consumer outdoor furniture company, \non November 4, 2021, for net cash consideration of $79 million. The acquired assets included $47 million of goodwill that was assigned to our Best Buy Domestic \nreporting unit and was deductible for income tax purposes. The acquisition expands our assortment in categories like outdoor living, as more and more \nconsumers look to make over or upgrade their outdoor living spaces. The acquisition was accounted for using the acquisition method of accounting for business \ncombinations and was not material to the results of our operations.\n \n3. Restructuring\n \n \nRestructuring charges were as follows ($ in millions):\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n2023\n \n2022\n \n2021\nFiscal 2023 Resource Optimization Initiative\n \n \n$\n 145 \n \n$\n - \n \n$\n - \nMexico Exit and Strategic Realignment(1)\n \n \n \n 2 \n \n \n (41) \n \n \n 277 \nFiscal 2020 U.S. Retail Operating Model Changes\n \n -\n \n \n 1 \n \n \n -\n \nTotal\n \n \n \n \n \n$\n 147 \n \n$\n (40) \n \n$\n 277 \n \n(1)\nIncludes ($6) million and $23 million related to inventory markdowns recorded in Cost of sales on our Consolidated Statements of Earnings in fiscal 2022 and fiscal 2021, respectively.\n \nFiscal 2023 Resource Optimization Initiative\n \nIn light of ongoing changes in business trends, during the second quarter of fiscal 2023, we commenced an enterprise-wide initiative to better align our spending \nwith critical strategies and operations, as well as to optimize our cost structure. Charges incurred relate to employee termination benefits within our Domestic and \nInternational segments of $140 million and $5 million, respectively. We currently do not expect the remaining charges in fiscal 2024 related to this initiative to be \nmaterial to the results of our operations.\n \nAll charges incurred related to this initiative were from continuing operations and were presented within Restructuring charges on our Consolidated Statements of \nEarnings. \n \n51\n [END OF FILING]",
    "gt": "Best Buy closed two acquisitions, both these companies were already partially owned by Best Buy, but Best Buy acquired all outstanding shares of these two companies during FY 2022: (1) Current Health Ltd and (2) Two Peaks, LLC d/b/a Yardbird Furniture",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: Has CVS Health reported any materially important ongoing legal battles from 2022, 2021 and 2020? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved\nfor several years. The Company also may be named from time to time in qui tam actions initiated by private third parties that could also be separately pursued\nby a governmental body. The results of legal proceedings, including government investigations, are often uncertain and difficult to predict, and the costs\nincurred in these matters can be substantial, regardless of the outcome.\nThe Company records accruals for outstanding legal matters when it believes it is probable that a loss will be incurred and the amount can be reasonably\nestimated. The Company evaluates, on a quarterly basis, developments in legal matters that could affect the amount of any accrual and developments that\nwould make a loss contingency both probable and reasonably estimable. If a loss contingency is not both probable and reasonably estimable, the Company\ndoes not establish an accrued liability. None of the Companys accruals for outstanding legal matters are material individually or in the aggregate to the\nCompanys financial condition.\nExcept as otherwise noted, the Company cannot predict with certainty the timing or outcome of the legal matters described below, and the Company is unable\nto reasonably estimate a possible loss or range of possible loss in excess of amounts already accrued for these matters. The Company believes that its defenses\nand assertions in pending legal proceedings have merit and does not believe that any of these pending matters, after consideration of applicable reserves and\nrights to indemnification, will have a material adverse effect on the Companys financial position. Substantial unanticipated verdicts, fines and rulings,\nhowever, do sometimes occur, which could result in judgments against the Company, entry into settlements or a revision to its expectations regarding the\noutcome of certain matters, and such developments could have a material adverse effect on its results of operations. In addition, as a result of governmental\ninvestigations or proceedings, the Company may be subject to damages, civil or criminal fines or penalties, or other sanctions including possible suspension or\nloss of licensure and/or exclusion from participating in government programs. The outcome of such governmental investigations of proceedings could be\nmaterial to the Company.\nUsual and Customary Pricing Litigation\nThe Company and certain current and former directors and officers are named as a defendant in a number of lawsuits that allege that the Companys retail\npharmacies overcharged for prescription drugs by not submitting the correct usual and customary price during the claims adjudication process. These actions\nare brought by a number of different types of plaintiffs, including plan members, private payors, government payors, and shareholders based on different legal\ntheories. Some of these cases are brought as putative class actions, and in some instances, classes have been certified. In October 2022, one of the litigating\nshareholders made a litigation demand to the Board related to these and other issues after his amended derivative complaint was dismissed for failing to\ndemonstrate demand futility. The Company is defending itself against these claims.\nPBM Litigation and Investigations\nThe Company is named as a defendant in a number of lawsuits and is subject to a number of investigations concerning its PBM practices.\nThe Company is facing multiple lawsuits, including by state Attorneys General, governmental subdivisions and several putative class actions, regarding drug\npricing and its rebate arrangements with drug manufacturers. These complaints, brought by a number of different types of plaintiffs under a variety of legal\ntheories, generally allege that rebate agreements between the drug manufacturers and PBMs caused inflated prices for certain drug products. The Company is\ndefending itself against these claims. The Company has also received subpoenas, civil investigative demands (CIDs), and other requests for documents and\ninformation from, and is being investigated by, the FTC and Attorneys General of several states and the District of Columbia regarding its PBM practices,\nincluding pricing and rebates. The Company has been providing documents and information in response to these subpoenas, CIDs, and requests for\ninformation.\nUnited States ex rel. Behnke v. CVS Caremark Corporation, et al. (U.S. District Court for the Eastern District of Pennsylvania). In April 2018, the Court\nunsealed a complaint filed in February 2014. The government has declined to intervene in this case. The relator alleges that the Company submitted, or caused\nto be submitted, to Part D of the Medicare program Prescription Drug Event data and/or Direct and Indirect Remuneration reports that misrepresented true\nprices paid by the Companys PBM to pharmacies for drugs dispensed to Part D beneficiaries with prescription benefits administered by the Companys PBM.\nThe Company is defending itself against these claims.\n171\n\n\nto be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved\nfor several years. The Company also may be named from time to time in qui tam actions initiated by private third parties that could also be separately pursued\nby a governmental body. The results of legal proceedings, including government investigations, are often uncertain and difficult to predict, and the costs\nincurred in these matters can be substantial, regardless of the outcome.\nThe Company records accruals for outstanding legal matters when it believes it is probable that a loss will be incurred and the amount can be reasonably\nestimated. The Company evaluates, on a quarterly basis, developments in legal matters that could affect the amount of any accrual and developments that\nwould make a loss contingency both probable and reasonably estimable. If a loss contingency is not both probable and reasonably estimable, the Company\ndoes not establish an accrued liability. None of the Companys accruals for outstanding legal matters are material individually or in the aggregate to the\nCompanys financial condition.\nExcept as otherwise noted, the Company cannot predict with certainty the timing or outcome of the legal matters described below, and the Company is unable\nto reasonably estimate a possible loss or range of possible loss in excess of amounts already accrued for these matters. The Company believes that its defenses\nand assertions in pending legal proceedings have merit and does not believe that any of these pending matters, after consideration of applicable reserves and\nrights to indemnification, will have a material adverse effect on the Companys financial position. Substantial unanticipated verdicts, fines and rulings,\nhowever, do sometimes occur, which could result in judgments against the Company, entry into settlements or a revision to its expectations regarding the\noutcome of certain matters, and such developments could have a material adverse effect on its results of operations. In addition, as a result of governmental\ninvestigations or proceedings, the Company may be subject to damages, civil or criminal fines or penalties, or other sanctions including possible suspension or\nloss of licensure and/or exclusion from participating in government programs. The outcome of such governmental investigations of proceedings could be\nmaterial to the Company.\nUsual and Customary Pricing Litigation\nThe Company and certain current and former directors and officers are named as a defendant in a number of lawsuits that allege that the Companys retail\npharmacies overcharged for prescription drugs by not submitting the correct usual and customary price during the claims adjudication process. These actions\nare brought by a number of different types of plaintiffs, including plan members, private payors, government payors, and shareholders based on different legal\ntheories. Some of these cases are brought as putative class actions, and in some instances, classes have been certified. In October 2022, one of the litigating\nshareholders made a litigation demand to the Board related to these and other issues after his amended derivative complaint was dismissed for failing to\ndemonstrate demand futility. The Company is defending itself against these claims.\nPBM Litigation and Investigations\nThe Company is named as a defendant in a number of lawsuits and is subject to a number of investigations concerning its PBM practices.\nThe Company is facing multiple lawsuits, including by state Attorneys General, governmental subdivisions and several putative class actions, regarding drug\npricing and its rebate arrangements with drug manufacturers. These complaints, brought by a number of different types of plaintiffs under a variety of legal\ntheories, generally allege that rebate agreements between the drug manufacturers and PBMs caused inflated prices for certain drug products. The Company is\ndefending itself against these claims. The Company has also received subpoenas, civil investigative demands (CIDs), and other requests for documents and\ninformation from, and is being investigated by, the FTC and Attorneys General of several states and the District of Columbia regarding its PBM practices,\nincluding pricing and rebates. The Company has been providing documents and information in response to these subpoenas, CIDs, and requests for\ninformation.\nUnited States ex rel. Behnke v. CVS Caremark Corporation, et al. (U.S. District Court for the Eastern District of Pennsylvania). In April 2018, the Court\nunsealed a complaint filed in February 2014. The government has declined to intervene in this case. The relator alleges that the Company submitted, or caused\nto be submitted, to Part D of the Medicare program Prescription Drug Event data and/or Direct and Indirect Remuneration reports that misrepresented true\nprices paid by the Companys PBM to pharmacies for drugs dispensed to Part D beneficiaries with prescription benefits administered by the Companys PBM.\nThe Company is defending itself against these claims.\n171\n\n\nControlled Substances Litigation, Audits and Subpoenas\nIn December 2017, the U.S. Judicial Panel on Multidistrict Litigation consolidated numerous cases filed against various defendants by plaintiffs such as\ncounties, cities, hospitals, Indian tribes and third-party payors, alleging claims beginning as far back as the early 2000s generally concerning the impacts of\nwidespread prescription opioid abuse. The consolidated multidistrict litigation captioned In re National Prescription Opiate Litigation (MDL No. 2804) is\npending in the U.S. District Court for the Northern District of Ohio. This multidistrict litigation presumptively includes hundreds of relevant federal court cases\nthat name the Company as a defendant. A significant number of similar cases that name the Company as a defendant in some capacity are pending in state\ncourts.\nIn addition, the Company has been named as a defendant in similar cases brought by certain state Attorneys General. The Company is defending itself against\nall such claims. Additionally, the Company has received subpoenas, CIDs, and/or other requests for information regarding opioids from state Attorneys General\nand insurance and other regulators of several U.S. jurisdictions. The Company has been cooperating with the government with respect to these subpoenas,\nCIDs, and other requests for information.\nIn November 2021, the Company was among the chain pharmacies found liable by a jury in a trial in federal court in Ohio; in August 2022, the court issued a\njudgment jointly against the three defendants in the amount of $651 million to be paid over 15 years, and also ordered certain injunctive relief. The Company is\nappealing the judgment and has not accrued a liability for this matter. In March 2022, CVS Health Corporation and CVS Pharmacy, Inc. entered into a\nsettlement agreement with the State of Florida to resolve claims related to opioid medications dating back more than a decade. Under the terms of the\nsettlement agreement, CVS Health Corporation settled all opioid claims against it and its subsidiaries by the State of Florida for $484 million, which is to be\npaid over a period of 18 years. During the three months ended March 31, 2022, the Company recorded a $484 million liability associated with this legal\nsettlement. In August 2022, CVS Pharmacy, Inc. entered into an agreement with the State of New Mexico to settle all opioid claims against it and its parents\nand subsidiaries by the State of New Mexico and participating subdivisions. In September 2022, CVS Pharmacy, Inc. entered into an agreement with the State\nof West Virginia to settle all opioid claims against it and its parents and subsidiaries by the State of West Virginia and participating subdivisions. Also in\nSeptember 2022, CVS Pharmacy, Inc. entered into an agreement with the Cherokee Nation to settle all opioid claims against it and its parents and subsidiaries\nby the Cherokee Nation.\nIn December 2022, the Company agreed to a formal settlement agreement, the financial amounts of which were agreed to in principle in October 2022, with a\nleadership group of a number of state Attorneys General and the Plaintiffs Executive Committee (PEC). The agreement would resolve substantially all\nopioid claims against Company entities by states and political subdivisions, but not private plaintiffs. The maximum amount payable by the Company under the\nsettlement would be approximately $4.3 billion in opioid remediation and $625 million in attorneys fees and costs and additional remediation. The amounts\nwould be payable over 10 years, beginning in 2023. The agreement also contains injunctive terms relating to the dispensing of opioid medications. The\nsettlement agreement is available at nationalopioidsettlement.com.\nUnder the settlement agreement, before the Company determines whether to enter into any final settlement, it will assess the number and identities of the\ngovernmental entities that will participate in any such settlement. The settlement agreement contemplates that if certain governmental entities do not agree to\nthe settlement, but the Company nonetheless concludes that there is sufficient participation to warrant going forward with the settlement, there would be a\ncorresponding reduction in the amount due from the Company to account for the governmental entities that did not agree. Those non-participating\ngovernmental entities would be entitled to pursue their claims against the Company and other defendants. Private plaintiff litigation will also continue.\nThe Company has been informed that 45 states, the District of Columbia, and all eligible United States territories have elected to join the settlement. Three\nstates were the subject of earlier settlements. The Company has elected to proceed with the settlement process based on that level of participation. The\nsettlement process will progress to the period during which subdivisions may elect to join.\nIn December 2022, the Company also agreed to a formal settlement agreement with a leadership group representing tribes throughout the United States. The\nagreement would resolve substantially all opioid claims against Company entities by such tribes. The maximum amount payable by the Company under the\nsettlement would be $113 million in opioid remediation and $18 million in attorneys fees and costs. The amounts would be payable over 10 years, beginning\nin 2023. The agreement is contingent upon sufficient participation by tribes.\n172\n [END OF FILING]",
    "gt": "Yes, CVS Health has been involved in multiple ongoing legal battles. Some notable legal dispute areas for CVS are: (1) usual and customary pricing litigation: where it's claimed that CVSs retail pharmacies overcharged for prescription drugs; (2) PBM litigation and investigations: where it's claimed that that rebate agreements between the drug manufacturers and PBMs caused inflated prices for certain drug products; and (3) controlled substances litigation: legal matters around opioids for which CVS has agreed to pay up to $4.3 billion to claimants in remediation and $625 million to attorneys and fees",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  },
  {
    "query": "Answer this question: What are the geographies that Pepsico primarily operates in as of FY2022? \nHere is the relevant evidence that you need to answer the question:\n[START OF FILING] Table of Contents\nForward-Looking Statements\nThis Annual Report on Form 10-K contains statements reflecting our views about our future performance that constitute\nforward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (Reform Act).\nStatements that constitute forward-looking statements within the meaning of the Reform Act are generally identified through the\ninclusion of words such as aim, anticipate, believe, drive, estimate, expect, expressed confidence, forecast,\nfuture, goal, guidance, intend, may, objective, outlook, plan, position, potential, project, seek,\nshould, strategy, target, will or similar statements or variations of such words and other similar expressions. All\nstatements addressing our future operating performance, and statements addressing events and developments that we expect or\nanticipate will occur in the future, are forward-looking statements within the meaning of the Reform Act. These forward-looking\nstatements are based on currently available information, operating plans and projections about future events and trends. They\ninherently involve risks and uncertainties that could cause actual results to differ materially from those predicted in any such\nforward-looking statement. These risks and uncertainties include, but are not limited to, those described in Item 1A. Risk\nFactors and Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations Our Business\n Our Business Risks. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak\nonly as of the date they are made. We undertake no obligation to update any forward-looking statement, whether as a result of\nnew information, future events or otherwise. The discussion of risks in this report is by no means all-inclusive but is designed to\nhighlight what we believe are important factors to consider when evaluating our future performance.\nPART I\nItem 1. Business.\nWhen used in this report, the terms we, us, our, PepsiCo and the Company mean PepsiCo, Inc. and its consolidated\nsubsidiaries, collectively. Certain terms used in this Annual Report on Form 10-K are defined in the Glossary included in Item 7.\nof this report.\nCompany Overview\nWe were incorporated in Delaware in 1919 and reincorporated in North Carolina in 1986. We are a leading global beverage and\nconvenient food company with a complementary portfolio of brands, including Lays, Doritos, Cheetos, Gatorade, Pepsi-Cola,\nMountain Dew, Quaker and SodaStream. Through our operations, authorized bottlers, contract manufacturers and other third\nparties, we make, market, distribute and sell a wide variety of beverages and convenient foods, serving customers and consumers\nin more than 200 countries and territories.\nOur Operations\nWe are organized into seven reportable segments (also referred to as divisions), as follows:\n1) Frito-Lay North America (FLNA), which includes our branded convenient food businesses in the United States and\nCanada;\n2) Quaker Foods North America (QFNA), which includes our branded convenient food businesses, such as cereal, rice, pasta\nand other branded food, in the United States and Canada;\n3) PepsiCo Beverages North America (PBNA), which includes our beverage businesses in the United States and Canada;\n4) Latin America (LatAm), which includes all of our beverage and convenient food businesses in Latin America;\n5) Europe, which includes all of our beverage and convenient food businesses in Europe;\n2\n\n\nTable of Contents\n6) Africa, Middle East and South Asia (AMESA), which includes all of our beverage and convenient food businesses in\nAfrica, the Middle East and South Asia; and\n7) Asia Pacific, Australia and New Zealand and China Region (APAC), which includes all of our beverage and convenient\nfood businesses in Asia Pacific, Australia and New Zealand, and China region.\nFrito-Lay North America\nEither independently or in conjunction with third parties, FLNA makes, markets, distributes and sells branded convenient\nfoods. These foods include branded dips, Cheetos cheese-flavored snacks, Doritos tortilla chips, Fritos corn chips, Lays potato\nchips, Ruffles potato chips and Tostitos tortilla chips. FLNAs branded products are sold to independent distributors and retailers.\nIn addition, FLNAs joint venture with Strauss Group makes, markets, distributes and sells Sabra refrigerated dips and spreads.\nQuaker Foods North America\nEither independently or in conjunction with third parties, QFNA makes, markets, distributes and sells branded convenient foods,\nwhich include cereals, rice, pasta and other branded products. QFNAs products include Capn Crunch cereal, Life cereal, Pearl\nMilling Company syrups and mixes, Quaker Chewy granola bars, Quaker grits, Quaker oatmeal, Quaker rice cakes, Quaker\nSimply Granola and Rice-A-Roni side dishes. QFNAs branded products are sold to independent distributors and retailers.\nPepsiCo Beverages North America\nEither independently or in conjunction with third parties, PBNA makes, markets and sells beverage concentrates, fountain syrups\nand finished goods under various beverage brands including Aquafina, Diet Mountain Dew, Diet Pepsi, Gatorade, Gatorade Zero,\nMountain Dew, Pepsi and Propel. PBNA operates its own bottling plants and distribution facilities and sells branded finished\ngoods directly to independent distributors and retailers. PBNA also sells concentrate and finished goods for our brands to\nauthorized and independent bottlers, who in turn sell our branded finished goods to independent distributors and retailers in\ncertain markets. PBNA also, either independently or in conjunction with third parties, makes, markets, distributes and sells ready-\nto-drink tea and coffee products through joint ventures with Unilever (under the Lipton brand name) and Starbucks, respectively.\nFurther, PBNA manufactures and distributes certain brands licensed from Keurig Dr Pepper Inc., including Crush, Dr Pepper and\nSchweppes, and certain juice brands licensed from Dole Food Company, Inc. and Ocean Spray Cranberries, Inc. In 2022, PBNA\nbegan to distribute Hard MTN Dew, an alcoholic beverage manufactured and owned by the Boston Beer Company. In the first\nquarter of 2022, we sold our Tropicana, Naked and other select juice brands to PAI Partners, while retaining a 39%\nnoncontrolling interest in a newly formed joint venture, Tropicana Brands Group (TBG), operating across North America and\nEurope (Juice Transaction). In the United States, PepsiCo acts as the exclusive distributor for TBGs portfolio of brands for\nsmall-format and foodservice customers with chilled direct-store-delivery (DSD). See Note 13 to our consolidated financial\nstatements for further information.\nLatin America\nEither independently or in conjunction with third parties, LatAm makes, markets, distributes and sells a number of convenient\nfood brands including Cheetos, Doritos, Emperador, Lays, Marias Gamesa, Ruffles, Sabritas, Saladitas and Tostitos, as well as\nmany Quaker-branded convenient foods. LatAm also, either independently or in conjunction with third parties, makes, markets,\ndistributes and sells beverage concentrates, fountain syrups and finished goods under various beverage brands including 7UP,\nDiet 7UP, Gatorade, H2oh!, Manzanita Sol, Mirinda, Pepsi, Pepsi Black, San Carlos and Toddy. These branded products are sold\nto authorized and independent bottlers, independent distributors and retailers. LatAm\n3\n [END OF FILING]",
    "gt": "As of FY2022, Pepsico primarily operates in the following geographies: North America, Latin America, Europe, Africa, Middle East, South Asia, Asia Pacific, Australia, New Zealand and China.",
    "tag": [
      "FinanceBench",
      "finance"
    ],
    "source": "FinanceBench"
  }
]